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1InTrOduCTIOn
Cervical cancer is the fourth most common cancer in women, with an estimated 527,600 
new cancer cases and 265,700 deaths worldwide in 2012.1 Cervical cancer is preceded 
by a premalignant stage which is estimated to progress to cervical cancer in 10-15 years. 
Premalignant lesions can therefore be detected by screening, to be treated before 
malignant potential occurs.2 Since the introduction of cytology-based cervical cancer 
screening, the incidence of cervical cancer in developed countries has substantially di-
minished.3 Nowadays, cervical cytology is used as primary screening test in the majority 
of programs.4 However, many Western countries are on the verge of replacing cytology 
as primary screening by testing for the presence of high-risk human papillomavirus 
(hrHPV). The Netherlands is among the first countries with a full hrHPV-based organized 
cervical cancer screening program in 2017.
Triage of high-risk HPV positive women
A persistent infection with an hrHPV is causally related to the development of cervical 
cancer.5 This results in a high sensitivity of hrHPV-based cervical cancer screening. Other 
advantages of primary hrHPV testing over cytology-based screening are the objectiv-
ity of the assay, high-throughput testing, and the possibility of analyzing self-sampled 
material, which may improve the efficacy of cervical cancer screening by increasing 
participation of non-responders.6-9 A limitation of hrHPV testing is its inability to dis-
tinguish transient infections from clinically relevant infections. This results in limited 
specificity, with higher numbers of unnecessary colposcopy referrals compared with 
cytology screening. Effective triage of hrHPV-positive women is therefore essential. Dif-
ferent triage options are available, which can be divided into: morphological triage tech-
niques, like Pap cytology and other immunochemistry markers; and molecular triage 
techniques, like HPV genotyping and methylation markers. These markers all have their 
own advantages and disadvantages, and knowledge on clinical value of most of these 
markers should be increased before they can be implemented in a screening program.  
Opportunities in improving colposcopic examination
When an abnormal result is detected during cervical screening and triage, women 
are generally referred to their gynecologist for a diagnostic colposcopic examination. 
Colposcopy is the visualization of the cervix using a stereoscopic binocular microscope 
of low magnification. Colposcopic examination combined with a biopsy and histologic 
evaluation is the gold standard for identifying premalignant cervical intraepithelial neo-
plasia (CIN). Low-grade CIN are usually monitored by watchful waiting, and regress to 
normal without treatment in the majority of cases. When a high-grade CIN is suspected, 
treatment is recommended in most cases. A limitation of colposcopy is the high degree 
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of inter- and intraobserver variability, with a low-to-average sensitivity of 61% with a 
specificity of 85% for CIN2 or worse. This results in missed lesions, unnecessary biopsies 
or overtreatment.10-12 Improving diagnostics and management of women referred for 
colposcopy is therefore desirable. 
Future risks of high-risk HPV infections
Because of the low specificity of hrHPV screening for young women, the Dutch screen-
ing program starts at 30 years of age. Younger women with cervical cancer or high-grade 
CIN lesions are missed with this screening strategy. The risk of sexual transmission of 
HPV generally peaks early in sexual life and declines with higher age.13 However, only 
a minority of these infections in young women eventually develop into cervical cancer. 
Most ot these hrHPV infections are transient and clear spontaneously; two thirds of all 
infections can be cleared by the host immune system within 12 months, and over 90% 
can be cleared within 24 months.14,15 It is yet unknown to which extent a transient or 
persistent hrHPV infection in young women is a risk factor for developing CIN or cervical 
cancer later in life. This knowledge may improve recommendations for women who test 
positive for hrHPV early in life. 
When an hrHPV infection is not cleared by the host immune system, it becomes a per-
sisting infection. A persisting infection may lead to the development of a high-grade CIN 
lesion. It is known that women diagnosed with high-grade CIN show an increased risk of 
developing malignancies of the anogenital region and head and neck region, probably 
as the result of an infection with an hrHPV. The extent of this risk has never been studied 
with data of Dutch women, and the extent of this risk for high-grade premalignancies 
after a diagnosis of CIN3 is also unknown. Knowledge on this risk is important to con-
sider preventing future risks of hrHPV infections by prophylactic HPV vaccination and/
or intensified screening for other HPV-related carcinomas and premalignancies when a 
high-grade CIN lesion is identified. 
AIM And OuTlIne OF THIs THesIs
In this thesis, we aim to improve cervical cancer prevention programs with studies on 
multiple dimensions of cervical cancer prevention.
Part I focuses on improving triage of hrHPV-positive women in cervical cancer screen-
ing. Triage is necessary because of the limited specificity of hrHPV-based screening. In 
chapter 2 an overview of triage strategies for hrHPV-positive women is provided, differ-
entiating between morphological and molecular triage techniques. Furthermore, future 
perspectives of promising triage-strategies are discussed. In chapter 3 the clinical value 
of HPV genotyping in triage of women with hrHPV-positive self-samples was evaluated. 
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1HPV genotyping is studied as individual triage method, and combined with Pap cytology 
at different thresholds. The clinical value of different combinations of triage-strategies 
with HPV genotyping is studied. Findings on p16/Ki-67 dual-stain as triage-technique 
for hrHPV-positive women are presented in chapter 4. This chapter evaluates the clinical 
utility of this dual-stain, either or not combined with other triage techniques, and results 
are put into perspective by comparing them with previously published studies.  
Part II focuses on opportunities in improving colposcopic assessment after an ab-
normal cervical screening and/or triage result. If a high-grade intraepithelial lesion is 
suspected, treatment is recommended in most cases. Treatment can be performed after 
histological confirmation of the lesion, which is called a two-step approach. However, 
treatment can also be performed immediately if a high-grade lesion is suspected, with-
out the need of an additional visit, which is called the see-and-treat strategy. It is im-
portant to decide under which circumstances see-and-treat management may be used 
with limited overtreatment-rates. Chapter 5 systematically reviews overtreatment-rates 
in see-and-treat management in regard to cytology results and the colposcopic as-
sessment. To further improve colposcopy, digital colposcopy techniques are upcoming 
and increasingly studied. In chapter 6 we performed a pilot-study on fluorescence and 
reflectance spectroscopy, a digital colposcopy technique that combines two types of 
spectroscopy. In this study, we assessed performance and patient acceptance of this 
technique. As a large variety of digital colposcopy techniques are showing promising 
results, all with all different perspectives in screening, an overview of this novel tech-
nique is needed. We therefore performed a meta-analysis on results of three different 
colposcopy techniques which could potentially lower colposcopy referral rates. Result 
of this systematic review and meta-analysis are shown in  chapter 7. 
Part III focuses on future risks of hrHPV infections. The risk of future CIN lesions in 
women who tested HPV positive before the age of 30 was assessed in chapter 8.  These 
women either cleared their infection or showed a persistent infection. Data on develop-
ment of high-grade CIN lesions or cervical cancer within eight years of follow-up was 
obtained from the Dutch nationwide database of pathology. In chapter 9 we take it one 
step further and look at the future risk of developing other HPV-related premalignancies 
and carcinomas when a high-grade CIN has been diagnosed. We compare this risk with 
the ‘baseline risk’ in a population without a previously diagnosed high-grade CIN of the 
cervix. An increased risk of other HPV-related premalignancies and carcinomas could 
be a reason for considering intensified screening or prophylactic HPV vaccination in 
women treated for a high-grade CIN lesion. 
The results of these previous chapters are put into perspective in a general discussion 
in chapter 10, and a summary is given in chapter 11. 
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AbsTrACT
Introduction High-risk human papillomavirus (hrHPV) testing is expected to replace 
cytology as primary screening method for cervical cancer screening in an increasing 
number of countries. The high sensitivity of hrHPV testing is combined with a limited 
specificity, which makes triaging of hrHPV-positive women necessary. As an ideal tri-
age method does not yet exist, an optimal triage strategy for hrHPV-positive women, 
based on current knowledge, should be obtained. The aim of this article is to present an 
overview of available options for triage of hrHPV-positive women, with their strengths 
and limitations and possible future opportunities. 
Areas covered Current knowledge on morphological biomarkers, molecular biomarkers 
and combined triage strategies will be discussed, to give an overview of the state-of-
the-art on triaging hrHPV-positive women. The literature search was limited to studies 
on triage strategies for hrHPV-positive women. 
expert commentary Experience with morphology-based biomarkers makes these 
biomarkers a valuable triage method. However, they lack the ability of differentiating 
productive from transforming infections. Molecular biomarkers are objective, highly 
reproducible, can be used in high throughput testing, and show promising results. With 
more extensive knowledge on these molecular markers, cervical cancer screening may 
transform to a full molecular screening in the future.
Triage of high-risk HPV positive women in cervical cancer screening
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1. InTrOduCTIOn
With an estimated 527,600 new cancer cases and 265,700 deaths in 2012, cervical can-
cer is the fourth most diagnosed cancer and fourth cause of cancer death in females 
worldwide. Developing countries account for almost 90% of all cervical cancer deaths, 
and in some countries in Melanesia, eastern, middle, and southern Africa, it even is the 
leading cause of cancer death amongst females. Cervical cancer incidence and mortality 
rates are lowest in Europe, eastern and western Asia, northern Africa, northern America, 
Australia and New Zealand.1 The availability of screening and differences in human 
papillomavirus (HPV) prevalence are the cause of these major geographic variations.2
The role of HPV in development of cervical cancer was first described by zur Hausen in 
1977, for which he received the Nobel Prize in Physiology or Medicine in 2008.3 Approxi-
mately two decades later, Walboomers described the necessity of a persistent infection 
with high-risk human papillomavirus (hrHPV) for the development of precancerous 
and cancerous lesions of the cervix.4 Since then, over 200 HPV genotypes have been 
identified and clinically relevant types are grouped by the innate risk of causing cervical 
cancer (Table 1).5 Low-risk types generally only induce benign warts, whereas high-risk 
(hr)HPV types have the ability to induce cervical premalignancies and malignancies, of 
which approximately 70% is caused by types 16 and 18. The lifetime risk of an infection 
with hrHPV is high, however, only a minority of infections develop into cervical cancer. 
After 12 months, two-thirds of all infections are already cleared by the host immune 
system, and after 24 months over 90% are cleared.6,7 Infections that are not cleared 
may develop into ‘productive’ infections, cytologically and histologically known as 
low-grade squamous intraepithelial lesion (LSIL), or histologically known as low-grade 
cervical intraepithelial neoplasia (CIN; CIN grade 1). These infections morphologically 
show dysplastic features overlapping with those in progressive precancers. However, 
such infections show no signs of cellular transformation and the majority of productive 
infections still clear quickly. Only a minority of all persistent hrHPV infections results in 
altered E6 and E7 viral gene expression, thereby becoming a ‘transforming’ infection. In 
transforming infections, the normal viral life cycle is aborted and the viral early genes 
E6 and E7 are overexpressed in proliferating cells, leading to altered expression of cell 
cycle and DNA repair regulators (Figure 1).8-10 Transforming infections are cytologically 
Table 1. Human papillomavirus types grouped by the innate risk of causing cervical cancer.
IArC group6 risk estimate HPV types
1 High-risk 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59
2A Probable high-risk 68
2B Possible high-risk 26, 53, 66, 67, 70, 73, 82
3 Low-risk 6, 11
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and histologically known as high-grade squamous intraepithelial lesion (HSIL) or his-
tologically known as high-grade CIN (CIN grade 3), which may finally result in cancer if 
left untreated (Figure 2). These premalignant stages preceding cervical cancer allow for 
detection and treatment of these lesions before they progress to cervical cancer. 
Screening has been very successful in decreasing cervical cancer incidence and 
mortality in Western countries.12 Screening programs worldwide differ regarding age, 
frequency, participation rate and screening modality.13 Nowadays, cervical cytology is 
used as primary screening test in the majority of programs.14 However, many Western 
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Figure 1. Molecular mechanisms by which the human papillomavirus induces cervical carcinogenesis.
(A) Genome organization of the human papillomavirus (HPV). HPV are DNA viruses coding for a long con-
trol region (LCR), several early functional genes (E1-E7), and two late structural genes (L1-L2). (b) The INK4A/
ARF locus at chromosome 9p21 encodes proteins p16INK4a (p16) and p14ARF (p14) that ultimately link the 
Retinoblastoma (Rb) and p53 tumor suppressor pathways. p16 is a cyclin-dependent kinase (CDK) inhibi-
tor that prohibits progression form G1 phase to S phase and slowing down the cell cycle. In a normal cell, 
p16 acts as a tumor suppressor by binding to CDK4/6 and preventing its interaction with cyclin D resulting 
in arrest of cell proliferation. p14 inhibits mdm2, therefore promotes p53, which promotes p21 activation. 
p21 binds and inactivates certain cyclin-CDK complexes which otherwise would promote transcription of 
genes that would carry the cell trough G1/S checkpoint of the cell cycle resulting in S-phase induced p16 
stimulation. When hrHPV types integrate into the host genome, loss of negative feedback control will result 
in increased expression of viral E6 and E7 oncogenes. HPV protein E6 binds tumor suppressor gene p53 and 
promotes its destruction, resulting in inhibition of apoptosis and loss of inhibition of cyclin-CDK complexes 
via loss of p21 stimulation. CDK4/6 binds cyclin D and forms an active protein complex that phosphorylates 
Rb which disassociates from transcription factor E2F1. Liberated E2F1 enters the nucleus and promotes 
transcription of target genes essential for transition from G1 to S phase. HPV protein E7 dissociates the 
E2F-Rb complex and binds and inactivates Rb. This also causes release of transcriptionally E2F1 dependent 
genes necessary for DNA replication, resulting in stop of growth arrest and therefore progression the cell 
cycle. HPV E7 oncoprotein expression also induces KDM6B histone demethylase expression, which trig-
gers the p16 promoter, also resulting in upregulation of p16 expression. Stimulation of progression of the 
cell cycle, combined with loss of apoptosis results in immortalization, genomic instability and finally in 
increased risk of transformation and malignant progression.8-11 
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countries are on the verge of replacing cytology as primary screening by testing for the 
presence of hrHPV. The Netherlands and Australia will be among the first countries to 
initiate full hrHPV-based organized screening in 2017. 
Advantages of primary hrHPV testing are the objectivity of the assay and high-
throughput testing, and its high sensitivity of 90% for CIN2 or worse (≥CIN2) and 95% for 
CIN3 or worse (≥CIN3), compared with moderate sensitivity of 30-87% for cytology.15,16 
Additionally, HPV screening holds the possibility to analyze self-sampled material of 
brush- or lavage based samples, which may improve the efficacy of cervical cancer 
screening by increasing participation of non-responders.17-20 The major limitation of 
hrHPV testing is its inability to distinguish transient infections from clinically relevant 
infections, resulting in limited specificity compared with cytology. This limited specific-
ity would result in higher numbers of unnecessary colposcopy referrals compared with 
cytology screening.21,22 Effective triage of hrHPV-positive women is therefore essential. 
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Figure 2. Cervical carcinogenesis and morphological abnormality. 
Viral persistence of hrHPV can result in productive infections with a productive CIN lesion, and a transform-
ing infection with a transforming CIN. Morphologically no clear distinction between productive and trans-
forming CIN lesions can be made so histological and cytological terminology and classification systems 
are not one-on-one linkable to this concept of productive and transforming infections. In the 3-tiered CIN 
terminology productive CIN are visible as CIN1 and transforming CIN lesions are morphologically known 
as CIN3. CIN2 is a mixture and is not comparable with a biological state. Therefore, this classification sys-
tem is arbitrary and does not correspond to our current understanding of HPV infection and precancer. 
The 4-tiered dysplasia spectrum includes mild dysplasia, moderate dysplasia, severe dysplasia and CIS. The 
most recent LAST terminology only distinguishes LSIL from HSIL histology and therefore corresponds most 
accurately with the concept of productive and transforming infections. Cytology is generally classified ac-
cording to the Bethesda system. Low-grade cytology results as ASC-US and LSIL generally represent pro-
ductive CIN lesions, and high-grade cytology as HSIL represents transforming CIN lesions. To simplify the 
figure, atypical glandular cells (AGC), and atypical squamous cell-cannot exclude high-grade squamous 
intraepithelial lesions (ASC-H) were not included. ASCCP = American Society for Colposcopy and Cervical 
Pathology; ASC-US = Atypical squamous cells of undetermined significance; CAP = College of American 
Pathologists; CIN = Cervical intraepithelial neoplasia; CIS = Carcinoma in situ; hrHPV = High-risk human 
papillomavirus; HSIL = High-grade squamous intraepithelial lesion; LAST = Lower Anogenital Squamous 
Terminology; LSIL = Low-grade squamous intraepithelial lesion; NILM = Negative for intraepithelial lesion 
or malignancy; TBS = The Bethesda System; WHO = World Health Organization.
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An ideal triage strategy meets two important requirements: 1) The strategy gives a 
highly sensitive and specific result, differentiating between cervical cancer and CIN le-
sions that need treatment, and abnormalities with a risk that is low enough for a woman 
to safely return to the next screening round. Ideally, low risk groups would need no 
follow-up. 2) No additional sample or additional visit is needed to perform the triage, 
thus minimizing the efforts for the screened women, and limit loss to follow-up. The 
ideal triage method for hrHPV-positive women is not yet available; therefore, the most 
optimal triage strategy using current knowledge should be obtained. Current triage 
methods all have advantages and disadvantages and some may possibly be improved 
or combined to measure up to an ideal strategy as far as possible. 
 This review gives an outline of current knowledge and future opportunities for triage 
of hrHPV-positive women, which is especially important in the transition from cytology-
based cervical cancer screening to primary hrHPV screening. A variety of triage options 
are discussed: morphological biomarkers such as Papanicolaou (Pap)-stained cytology 
or cytology with different types of immunochemistry, and molecular biomarkers such as 
HPV genotyping, RNA-based biomarkers, and methylation. We focus on the advantages 
and disadvantages of these strategies and their value as triage method of hrHPV-positive 
women. Finally, a five-year view on cervical cancer screening in a post-vaccination era 
will be discussed.
2. MOrPHOlOgICAl bIOMArkers
2.1 Cytology 
Cytological examination of exfoliated cervical cells stained with the multichromatic 
Pap staining was introduced by Papanicolaou in the 1940s.14 Triage of hrHPV-positive 
women with cytology is a common choice because of the worldwide experience with 
this technique. This widely evaluated triage method has shown to improve the initially 
limited specificity of hrHPV testing, and is known to reduce colposcopy referrals and 
follow-up testing.23-28 However, cytological assessment in these studies is generally 
performed without knowledge on hrHPV-positive status, which is different to primary 
hrHPV-based screening. The knowledge on positive hrHPV status is known to affect the 
interpretation of cytology. In hrHPV-based screening with knowledge on hrHPV-positive 
status, this might result in a slightly higher sensitivity and a lower specificity compared 
with these previously published results.29-31 The inability of high throughput testing and 
subjectivity of the examination are limitations of this technique as triage method for 
hrHPV-positive women. The performance of cytological examination highly depends 
on training and experience of cytotechnologists, resulting in variations in performance 
and quality. Quality management and benchmarking are therefore needed to obtain 
Triage of high-risk HPV positive women in cervical cancer screening
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and maintain high quality of cytological examination. With the introduction of primary 
hrHPV-based screening, the number of samples for cytological examination will de-
crease and maintaining highly trained cytotechnologists might become more difficult.  
For cytological examination of Pap stained cells, a slide can be obtained from a primary 
hrHPV-positive clinician-taken cervical sample. In case of an hrHPV-positive self-sample, 
an additional clinician-taken sample will be necessary as cytology cannot be reliably 
performed on self-sampled materials.32 Cytological triage has limited sensitivity, and 
therefore still needs follow-up for cases with an hrHPV-positive result combined with 
normal cytology, also additional follow-up is warranted for cytology positive cases which 
show no abnormalities during colposcopy or in a biopsy. The worldwide experience with 
cytological assessment of cervical samples makes cytology an interesting triage method 
for hrHPV-positive women; however, limitations as average sensitivity, subjectivity of 
the analysis, and inability to perform on self-sampled material are major disadvantages. 
2.2 p16 staining
Expression of the HPV E7 oncoprotein induces KDM6B histone demethylase expres-
sion and causes epigenetic reprogramming. Through KDM6B, demethylation of the 
p16INK4a (p16) promoter is triggered, with upregulation of p16 expression as a result.11 
The upregulation of p16 in transforming infections might therefore be used as bio-
marker for differentiating between productive and transforming infections. HrHPV 
testing with p16-staining triage produces a significant increase in sensitivity compared 
with conventional cytology, with no substantial increase in referral to colposcopy.33 The 
longitudinal sensitivity of p16-staining as triage method for hrHPV-positive women is 
77.8% for ≥CIN3, with a 95% confidence interval (CI) ranging from 63.9-91.6%. The rela-
tive sensitivity of p16 triage of hrHPV-positive women between 35 and 60 years of age, 
compared with primary conventional cytology is 2.08 (95% CI 1.13-3.56).34 Positive p16 
staining distinguishes hrHPV-positive women in need of immediate colposcopy referral, 
from hrHPV-positive and p16 staining negative women who can safely be managed with 
repeat screening after a 2-3 year interval.34 Expression of p16 is not limited to dysplastic 
cells but can also been found in normal cervical cells such as squamous metaplastic and 
endocervical cylindrical cells. This is not problematic in histological samples, but makes 
morphological assessment necessary in cytological samples. Assessment is therefore 
more subjective and limits reproducibility.35 This can be partially overcome by combin-
ing p16 with the proliferation marker Ki-67. 
2.3 p16 / ki-67 dual staining
In normal cells expression of proliferation marker Ki-67 can be found in the nucleus dur-
ing all proliferative cell cycle phases, and its expression is limited to basal or parabasal 
layers. In CIN lesions its expression extends above the first one-third of the epithelium. 
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Expression of both p16 and Ki-67 within the same cell is a sign of neoplastic transforma-
tion, independent from morphological criteria.36 The clinical performance of p16/Ki-67 
has been studied extensively as triage method for low-grade cytology; however, also 
studies in hrHPV-positive women were performed. In triage of hrHPV-positive women 
with a negative cytology result, sensitivity for ≥CIN2 varies between 67-92%, with a 
specificity of 73-82%.36,37 In triage of women with hrHPV-positive low-grade cytology, 
sensitivity and specificity of ≥CIN2 vary from 75-94% and 51-88% respectively.38-43 Lim-
ited studies have been performed with immediate p16/Ki-67 triage of hrHPV-positive 
women, without additional cytological interference. In a study with 1,509 hrHPV-posi-
tive women >30 years of age, dual-stain cytology shows similar sensitivity but a higher 
specificity for ≥CIN2 detection, when compared with Pap cytology with a threshold 
of atypical squamous cells of undetermined significance (ASC-US). For women with a 
positive dual-stain, immediate referral to colposcopy was justified. Dual-stain negative 
women had a risk of a high-grade lesion that was lower than the risk for hrHPV-positive 
women with normal cytology, which is considered low enough to re-examine after one 
year according to US management guidelines.44,45 In another study that performed p16/
Ki-67 dual-stained triage of 446 hrHPV-positive women, a sensitivity similar to cytology 
and cytology combined with HPV genotyping has been achieved. Specificity for ≥CIN3 
was significantly higher than with cytology, either or not combined with HPV geno-
typing.46 In a prospective population-based study in over 6,000 women, 396 women 
between 35 and 64 years of age were hrHPV-positive. Triage of these hrHPV-positive 
women by p16/Ki-67 dual-stain yielded a sensitivity of 87.6%, compared with 77.6% for 
cytology with an ASC-US threshold. Specificity and colposcopy referral rate were similar 
in both groups. Combined triage with cytology (threshold ASC-US or worse) and p16/
Ki67 yielded an increased sensitivity but at the expense of a decreased specificity. With 
an adjusted threshold of HSIL for cytology, the sensitivity and specificity were similar to 
triage with p16/Ki-67 alone.47 
Combined p16/Ki-67 dual staining shows promising results in triaging hrHPV-positive 
women, as well as in triaging hrHPV-positive women with negative or low-grade cytol-
ogy. However, the subjectivity of the examination, the inability for high-throughput 
testing and its inability to be used on self-sampled material are shortcomings. Also, a 
negative dual-stain result still needs follow-up, as well as a positive dual-stain result 
without colposcopic or histologic abnormalities.  
2.4 MCM2/TOP2A dual-stain
Minichromosome maintenance protein 2 (MCM2) and topoisomerase II-a (TOP2A) are 
both indicative for the formation of the origin recognition, and indicate an aberrant S 
phase induction when detected in suprabasal cells of the epidermis. Aberrant S phase 
induction is the premature and prolonged entry in the S-phase of the cell cycle, which 
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is induced by HPV E6 and E7 oncoproteins, resulting in G1/S cell-cycle checkpoint 
malfunction. Both MCM2 and TOP2A have shown to be overexpressed in high-grade 
CIN and cancer. The performance of the MCM2/TOP2A dual-stain has been examined 
as triage method of low-grade cytology showing varying sensitivity for the detection of 
≥CIN2, when compared with cytology. In triage of hrHPV-positive women in one study, 
this dual-stain yielded a relative sensitivity of 1.30 (95% CI 1.20-1.41) and relative positive 
predictive value (PPV) of 2.89 (95% CI 2.58-3.15), when compared with cytology alone.48 
Knowledge on clinical utility of the assay in triage of hrHPV-positive women is limited 
and further studies on this morphology-dependent assay are needed to determine and 
validate its clinical value. 
3. MOleCulAr bIOMArkers
3.1 HPV genotyping
Cervical infections with HPV16 and HPV18 have demonstrated the highest risk of devel-
oping precancer and cancer. HPV16 is found in 50-60% of all cervical cancers, and HPV18 
in 10-15% of cervical cancer cases.49 HPV18 and HPV45 are especially known for their 
association with the less prevalent adenocarcinoma of the cervix.50,51 Risk estimates for 
individual genotypes or the combination of different genotypes can be used for triage 
of hrHPV-positive women.  
In the guideline of the American Society for Colposcopy and Cervical Pathology (AS-
CCP), HPV16/18 genotyping is already recommended for hrHPV-positive women with 
normal cytology results; all HPV16 or HPV18 positive women are immediately referred 
for colposcopy, women positive for other hrHPV types without morphological changes 
are advised follow-up after one year with hrHPV and cytology co-testing.52 The additional 
value of genotyping with immediate referral of HPV16/18 positives was confirmed in the 
HPV FOCAL trial which included over 6,000 women screened by hybrid capture 2 (HC2) 
and Cobas hrHPV testing at baseline and liquid-based cytology (LBC) 24 months later. 
HrHPV-positive women were tested with HPV genotyping and reflex LBC for colposcopy 
triage. Of the ≥CIN2 lesions identified in the first round of screening, which includes 
baseline and 12 month follow-up, 55% had abnormal cytology and an additional 17% 
with normal cytology was HPV16/18 positive. Concluding that immediate referral of 
HPV16/18 positive women with normal cytology may allow for earlier detection of 
≥CIN2 lesions.53
Multiple studies have been performed on HPV16/18 genotyping triage of hrHPV-
positive women, of which the ATHENA trial is one of the largest. HrHPV testing with 
HPV genotyping was compared with LBC for cervical cancer screening in women over 
21 years old. In a subgroup analysis of women >25 years of age, the sensitivity and PPV 
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for ≥CIN3 in triaging hrHPV-positive women with HPV16 and/ or HPV18 was equivalent 
to detecting ASC-US or worse. Detection of HPV16 and/or HPV18 or cytology with LSIL 
or HSIL threshold showed increased sensitivity and similar or increased PPV for ≥CIN3 
detection than single cytology triage with an ASC-US threshold.54 Other studies have 
also shown promising results with high negative predictive values (NPV) by combining 
an ASC-US threshold with HPV16/18 or HPV16/18/31/33/45 genotyping. However, these 
strategies generally showed high colposcopy referral rates.23,24 In a recent European study, 
HPV16/18 genotyping performance was explored in a setting with prior knowledge on 
hrHPV-positive status during cytology assessment, similar to hrHPV-based screening. 
This study concludes that by adjusting the threshold of cytology and combining it with 
HPV16/18 genotyping, specificity for ≥CIN3 increases with similar sensitivity and no 
increase in colposcopy referrals. However, follow-up is still needed for hrHPV-positive 
women with low-grade cervical cytology results.31 A cost-effectiveness study on triage 
strategies of primary hrHPV screening in women over 30 years of age, with screening 
sensitivity and specificity based on the ATHENA trial, indicates that incorporating 
HPV16/18 genotyping in primary hrHPV screening with reflex cytology with an ASC-US 
threshold is cost-effective.55 
Compared with partial genotyping, extended genotyping methods are also available. 
The Onclarity HPV test offers extended genotyping of types 16, 19, 31, 45, 51 and 52, 
and identifies an additional three groups of 33/58, 56/59/66 and 35/39/68. The clinical 
and analytical performance of this test was recently assessed according to the VALGENT 
framework concluding that this assay offers applications for clinical workstreams.56 Also 
other techniques as the GP5+/6+-LMNX, MALDI-TOF, qPCR test, and PapilloCheck offer 
extended genotyping. Extended genotyping methods for immediate triage of hrHPV-
positive women have however not been studied as extensively as the previously men-
tioned partial genotyping tests. These studies might be performed in the near future. 
A variety of hrHPV tests have the ability of immediate and combined genotyping, 
which makes this triage strategy easy to use. The promising results of previous studies, 
combined with the ability of immediate triage of both clinician-taken and self-sampled 
specimens, makes hrHPV genotyping an interesting triage option for hrHPV-positive 
women. However, adding Pap cytology to HPV16/18 genotyping increases clinical value 
of the triage, with the disadvantage of the need of a clinician-taken sample for cytology. 
Current knowledge indicates that HPV16/18 genotyping may improve triage of hrHPV-
positive women; however, for management of hrHPV-positive women with infections 
other than HPV16 and HPV18, other techniques might still be necessary.
3.2 rnA-based biomarkers
RNAs can play an active role within cells by communicating responses to cellular signals, 
catalyzing biological reactions, and controlling gene expression with of small interfer-
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ing RNA (siRNA) or micro RNA (miRNA). Cellular organisms use messenger RNA (mRNA) 
to direct synthesis of specific proteins, and miRNA to regulate the function of mRNA. 
RNA-based tests are able to detect differences or changes in gene expression related to 
cancer development, while DNA-based tests detect the presence or absence of the HPV 
genome.
3.2.1	 E6/E7	messenger	RNA-based	biomarker
A limitation of the DNA-based hrHPV test is its inability to distinguish transient from 
persistent hrHPV infections resulting in low specificity. Cellular transformation of hrHPV 
infected cells begins with upregulation of E6 and E7 mRNA, and progression from hrHPV 
infection to cancer is dependable of E6/E7 integration. Overexpression of E6/E7 mRNA 
could therefore be used to detect only active infections which could result in high-
grade lesions. E6/E7 mRNA-based test are widely studied as substitute for DNA HPV-
based tests, indicating significance as diagnostic tool. Already three commercial E6/E7 
mRNA-based tests are known.57 A recent review of the clinical performance of the E6/E7 
mRNA-based Aptima HPV assay indicates stable similar sensitivities of the E6/E7mRNA 
hrHPV assay for detection of CIN2/3 or worse (≥CIN2/3), independent from study design, 
compared with the HC2 and GP5+/6+DNA tests. This stable sensitivity was combined 
with a higher specificity of the mRNA-based HPV test.58 In a second review the Aptima 
assay also showed consistently similar study-specific and pooled sensitivity and superior 
specificity for ≥CIN2 compared with HC2.  The pooled relative sensitivity for the Aptima 
assay was 0.98 (90% CI 0.95-1.01) with a pooled relative specificity of 1.04 (90% CI 1.02-
1.07).59  In a study comparing multiple triage algorithms for hrHPV-positive women, an 
E7 mRNA test with HPV16/18/31/33/45/52/58 genotyping achieved similar performance 
to HPV16/18 genotyping and cytology in ≥CIN2 detection.60 Triage of hrHPV-positive 
women with ASC-US cytology in the CLEAR HPV study was performed with the Aptima 
HPV 16 18/45 genotype assay. This study demonstrated that the assay has utility in strati-
fying low and high risk of ≥CIN2 and CIN3 among women with hrHPV-positive ASC-US.61 
These E6/E7 messenger RNA-based tests could possibly combine primary mRNA-based 
hrHPV testing with HPV genotyping. However, follow-up of hrHPV-positive women with 
genotypes other then 16, 18 or 45 would still be needed, and additional longitudinal 
studies and economic evaluations must be conducted before more solid conclusions 
regarding clinical applicability can be made. 
3.2.2	 Other	messenger	RNA-based	biomarkers
It has been previously demonstrated that HPV infection alone is insufficient for develop-
ment of cervical cancer; abnormal host genes play an important role in carcinogenesis.62 
The mRNA-based expression profile of normal cervical tissue is known to change during 
carcinogenesis, and expression of single genes or gene profiles might be used as mo-
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lecular biomarker to distinguish between different stages of carcinogenesis or indicate 
response to particular treatment. The expression status of thousands of genes can be 
studied at once to create a profile of cellular function. DNA microarray, which measures 
expression of previously identified target genes, and the newer sequence-based tech-
niques can be used to obtain gene expression profiles.62 Also bioinformatics tools can 
be used to identify key genes and potential biomarkers, by analyzing gene expression 
profiles and differentially expressed genes between cervical samples of different stages 
in carcinogenesis.63 
Previous studies compared expression profiles of cervical cancer with normal cervical 
tissue, early-stage with late-stage cervical cancer, and squamous cell carcinoma with 
adenocarcinoma of the cervix.64-66 Also studies on therapy response and resistance were 
performed.67,68 Differences between CIN lesions and cervical cancer or normal tissue 
have also been studied in a small number of studies, finally resulting in proposed genes 
for further research, with special attention to HOXC10, BPA1, HIF-1a, PTP, HME1, HNTH1 
and PHGDH.69-72  In a recent feasibility study the detection of mRNA-based biomarkers in 
cervical samples obtained by LBC was studied, showing promising results. Single mark-
ers and combinations of markers CDKN2A/p16, BIRC5, MMP9, TOP2A, MCM5 and MKI67 
were studied. TOP2a was most sensitive, with a sensitivity of 97% for detection of HSIL, 
and CDKN2A/p16 was most specific with a specificity of 78%. The combination of TOP2A 
and CDKN2A/p16 was highly sensitive 96% (95% CI 88-99) with a specificity of 71% (95% 
CI 55-82).73
Identified differences in these genomic expression profiles may in the future be 
used to distinguish productive from transforming hrHPV infections, and may be able 
to identify prognostic markers and targets for molecular therapy. Knowledge on these 
biomarkers is however still at an early stage, and at current state knowledge on these 
markers is far too limited for implementing these in clinical practice. 
3.2.3	 miRNA-based	biomarker
Micro RNA (miRNA) are more recently discovered and are noncoding parts of RNA 
that regulate messenger RNA (mRNA) function by modulating mRNA stability and the 
translation of mRNA into proteins. MiRNAs can be upregulated or downregulated and 
are thought to play an important role in processes as cell proliferation, metabolism, and 
apoptosis, with a possible role in onset or progression of cervical cancer. An important 
feature of miRNAs is that one miRNA often interacts with more than one mRNA and one 
transcript can be targeted by multiple miRNAs, indicating a variety of interactions for 
one miRNA. 
In a meta-analysis comparing 27 studies, including 1,132 cancer samples and 943 
normal samples, frequency of upregulation and downregulation of miRNAs was scored. 
Upregulation of miRNAs was most consistently reported for miR-20a and miR-21. Down-
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regulation was shown most frequently for miR-143, miR-03 and miR-145.74 In a large 
systematic study on deregulated miRNAs in cervical cancer development, 85 published 
reports with 3,922 cases and 2,099 noncancerous control tissue samples were analyzed. 
Expression of miRNAs in cervical cancer, as well as in different CIN lesions was reviewed. 
A meta signature of miRNAs reflecting the cervical carcinogenesis from CIN1, CIN2 and 
CIN3 to cervical cancer was made, reporting 42 upregulated and 21 downregulated 
miRNAs with a trend of increasing numbers of deregulated miRNAs during progres-
sion of CIN to carcinoma. The meta-analysis shows a selection of five upregulated and 
seven downregulated miRNAs in CIN1 compared with noncancerous tissue, which are 
also visible in more severe CIN lesions and cervical cancer, indicating a possible role in 
development of cervical cancer. CIN2 and CIN3 lesions showed an increased number 
of deregulated miRNAs with an additional 35 and 36 deregulated genes compared 
with CIN1. In cervical cancer, another five downregulated and ten upregulated miRNAs 
genes were reported.75 Knowledge on these miRNA expression profiles may be used for 
disease classification or monitoring. To our knowledge, this profile has however not yet 
been studied in large prospective studies or on cervical samples, therefore, its value for 
triage of hrHPV-positive women is yet unknown. 
3.3 HPV e6 protein biomarker
Expression of E6 and E7 genes is integral to hrHPV-induced malignant transformation, 
indicating that HPV E6/E7 protein markers could potentially serve as markers for identify-
ing high-grade CIN. Most diagnostic E6/E7 protein markers are, as previously described, 
based on mRNA testing and therefore susceptible to degradation. Development of the 
whole-cell enzyme-linked immunoabsorbent assay (ELISA) using an HPV16, 18 and 45 
anti E6 monoclonal antibody to detect HPV E6 protein in cervical samples could tackle 
this problem. In the first pilot-study as well as the first clinical trial and follow-up af-
ter one year, increased specificity with a considerable lower sensitivity for ≥CIN3 was 
found, compared with an hrHPV DNA test.76-78 Clinical evaluation of the assay in triage 
of HC2 hrHPV-positive clinician-taken samples showed a high specificity for ≥CIN3 of 
93.8% (95% CI 92.1-95.2), with again limited sensitivity of 54.2% (95% CI 43.7-64.4).79  An 
explanation for this limited sensitivity could be the fact that this E6 test only covers HPV 
types 16, 18 and 45. Future research to possibly increase the number of covered hrHPV 
types in this ELISA-based test should reveal if sensitivity can be improved to increase 
its value as triage marker for hrHPV-positive women. Also, this marker has not yet been 
tested on self-sampled specimens, so its value in triaging hrHPV-positive self-sampled 
specimens is yet unknown. 
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3.4 Methylation markers
Methylation of CpG islands is a normal epigenetic event where functionally relevant 
changes to the genome are made without changing the nucleotide sequence. Abnor-
mal DNA methylation in host or viral DNA promoter regions during carcinogenesis may 
result in inactivation of tumor suppressor genes and silencing of gene expression. These 
changes in the DNA sequence can be detected, and may possibly be used as biomarker 
to distinguish productive from transforming CIN lesions and cervical cancer. DNA 
methylation is easily detectable in clinician-taken, self-sampled and histological cervical 
specimens.12 Understanding the role of epigenetic events in host and viral genes is an 
important and promising area of investigation and is expected to result in novel risk 
stratifying strategies for triage of hrHPV-positive women. 
3.4.1	 Viral	gene	methylation	markers
Methylation of the HPV DNA genome shows type-specific variation within the viral life 
cycle and differs during carcinogenesis. Methylation of HPV DNA may be a host response 
to foreign intracellular agents, a method of evading immune recognition, or a signaling 
event indicating viral integration into the host genome. From studies using different 
HPV-positive cell lines it is known that methylation of the late region is indicative for 
integration of the viral genome.80,81 Viral gene methylation may also be indicative of 
the likelihood of persistence or clearance of the infection, therefore possibly holding a 
strong diagnostic or prognostic value in triaging hrHPV-positive women.82 
HPV genome sequence methylation is most widely studied in HPV16; hypermethyl-
ation of the HPV16 L1, L2, E2 and E4 regions is associated with an increased risk of CIN3 
and HPV persistence, and hypermethylation of the E6 gene is associated with a lower 
likelihood of ≥CIN2. Some of the hypermethylated CpG sites also showed significant 
higher methylation levels in pre-diagnostic ≥CIN2 specimens with a median time of 
three years before diagnosis, compared with a control group, indicating a positive pre-
dictive property for high-grade lesions of these markers.83-86 Conclusion of these studies 
is that elevated levels of methylation in the HPV16 genome may be useful in predicting 
concurrent or even future development of ≥CIN2. Methylation of other hrHPV types 
shows similar results to HPV16; hypermethylation of the L1, L2 regions of HPV18, 31, 
33 and 45 was associated with high-grade CIN lesions, and increased methylation of 
the E2 region was found in HPV18, 31 and 45 induced high-grade CIN lesions.87,88 HPV 
DNA methylation of HPV16, 18, 31, 33 and 45 may be useful in differentiating transform-
ing from productive hrHPV infections. However, validation studies in large cohorts are 
necessary before these biomarkers could be used in clinical practice. 
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3.4.2	 Host	gene	methylation	markers
Methylation markers based on host DNA methylation have been studied extensively 
and have been summarized in reviews indicating a promising role in triage of hrHPV-
positive women.8,89 Studies in this field still continue, as for most genes no highly con-
sistent result has yet been found. Combinations of markers most widely studied in 
hrHPV-positive women include the marker panels JAM3/EPB41L3/ TERT/C13ORF18 and 
JAM3/C13ORF18/ANKRD18CP, and various combinations of the markers CADM1, MAL, 
miR-124-2 and FAM19A4. Many other individual markers and marker panels have been 
studied less extensively and most of these studies did not include hrHPV status. Some 
small studies did include the hrHPV status when testing markers. Bi-marker panels, 
DLX4/SIM1,90 tri-marker panel DAPK1/RARB/MGMT,91 and single markers JAM3-M4,92 
EPB41L3,93 hsa-miR-203,94 PAX1,95 and POU4F3,96 show promising results; however, to 
our knowledge these are not yet confirmed by large prospective follow-up studies.  
Triage of hrHPV-positive clinician-taken samples by methylation panel JAM3/
EPB41L3/ TERT/C13ORF18 yielded a ≥CIN3 detection rate of 65%. The panel is also 
shown feasible to use on self-sampled lavage and brush samples.97,98 An adjusted panel 
of JAM3/C13ORF18/ ANKRD18CP has only been studied in women with positive cervical 
cytology.99 Further validation in population-based cohorts and large prospective studies 
is the next step for these panels. Methylation panels CADM1/MAL and MAL/miR-124-2 
were the first panels validated in a population-based screening setting. CADM1/MAL 
methylation levels are related to the degree of the cervical disease and the duration of 
preceding hrHPV infection and the methylation status in cervical scrapes appears to be 
representative for the worst underlying lesion.110,101 The CADM1/MAL bi-marker panel 
was equally discriminatory for ≥CIN3 as cytology at similar specificity in the triage of 
hrHPV-positive women.102,103 When combined with cytology, this panel showed a high 
sensitivity with a slight drop in specificity in triage of hrHPV-positive women.103,104 In 
triaging 79 hrHPV-positive women, the marker panel showed a sensitivity of 70% and 
specificity of 78% for ≥CIN3.105 In triaging women for colposcopy, the bi-marker panel 
MAL/miR-124-2 yielded a sensitivity of 64.9-71.6% at a specificity of 70% for ≥CIN3, which 
was significantly higher then the sensitivity for HPV16/18 genotyping in this specific 
study cohort.106 In a large prospective study with 1,038 hrHPV-positive non-responders 
who were randomized between MAL/miR-124-2 and cytology triage, the DNA meth-
ylation panel was at least as sensitive as cytology at a threshold of borderline or mild 
dyskaryosis or worse for ≥CIN2 detection. The methylation panel showed a decreased 
mean time to diagnosis; however, at the cost of more colposcopy referrals.107 In a recent 
pilot-study, FAM19A4 methylation in clinician-taken samples showed to be an attractive 
triage marker for hrHPV-positive women.108 Validation of bi-marker FAM19A4/miR124-2 
in lavage- and brush-based self-samples resulted in a ≥CIN3 sensitivity of 69.4-70.5% 
with a specificity of 67.8-76.4%.109 
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By adding HPV16/18 genotyping to the MAL/miR-124-2 methylation panel with 
an adjusted threshold, similar sensitivity with increased specificity for ≥CIN3 can be 
achieved, when compared with the methylation panel alone.110 By adding HPV16/18 
genotyping tot FAM19A4 methylation, sensitivity increased, with decreased specific-
ity, when compared with cytology alone, FAM19A4 methylation alone and HPV16/18 
genotyping alone.111 Combined FAM19A/mir124-2 and HPV16/18 genotyping showed a 
≥CIN3 sensitivity of 84.7% and specificity of 54.9%.109 This indicates that combining host 
methylation markers and HPV16/18 genotyping may increase the clinical value of both 
techniques separately in triaging hrHPV-positive women.
3.4.3	 Combined	methylation	marker	panels
Recently, also studies combining HPV viral DNA genome methylation and host DNA 
methylation have been performed. A study with methylation of DAPK, L1 and L2 of 
HPV16, 18, and 54 shows lowest methylation in asymptomatic infections and increased 
methylation in progression to cancer.112 Another combined methylation panel of L1 
and L2 regions of HPV16, 18 and 31, and human gene EPB41L3, was tested in 1,493 
hrHPV-positive exfoliated cervical specimens from a colposcopy referral cohort, and 
showed a sensitivity of 90%, combined with specificity of 36% and a PPV of 46%.113 By 
adding HPV33 to the panel, specificity increased to 49% with a stable 90% sensitivity.114 
Validation of this assay in exfoliated cervical specimens of 710 women attending routine 
screening, of which 341 hrHPV-positive, yielded a similar specificity of 65% with better 
sensitivity than HPV16/18 genotyping (47% vs. 54%) in identifying ≥CIN2.115
In summary, currently studied methylation markers show great potential as triage 
marker for hrHPV-positive women and could be the key to full molecular screening, 
possibly even with predictive value. Marker panels CADM1/MAL, MAL/mir124-2, and 
FAM19A/mir124-2, and combined HPV methylation and host methylation panels cur-
rently show the most potential. However, previously studied markers generally do not 
detect all ≥CIN3 lesions and detect less CIN2 lesions than cytology.8 Also high referral 
rates have been described with host methylation triage, resulting in an increase of un-
necessary colposcopies. Therefore, at the moment, we do not have methylation markers 
that merit clinical use yet. Future research with large population-based studies will prove 
whether methylation marker panels, either or not combined with other triage strategies, 
will eventually result in a triage strategy with high sensitivity and specificity and limited 
referral rates, to play a role in the triage of hrHPV-positive women. 
3.5 Chromosomal biomarkers
Cellular genomic alterations are needed for progression of HPV-induced premalignant 
lesions, which could make chromosomal biomarkers a valuable triage method. The 
chromosomal regions most frequently altered in cervical squamous cell carcinoma 
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are a loss at 3p and 11q, and gains at 3q, especially in HPV16-positive carcinomas.116 
The human telomerase RNA (hTERC) gene plays a role in maintenance of chromosome 
length and stability, and is located in chromosome 3q26 region. Gain of 3q26 shows a 
strong association with severity of dysplasia,117 and several small studies triaging LSIL 
and ASC-US report a high NPV, with a possible role in triage of women with low-grade 
CIN.118-120 Most of the studies on genomic alterations are small and retrospective. Before 
these markers could be considered as triage method further research with prospective 
large studies with long-term follow-up is needed. 
3.6 Other molecular biomarkers
Several other potential triage methods for hrHPV-positive women have been proposed; 
cellular proliferation-associated proteins, viral markers as HPV L1 capsid protein and 
E4 markers, the cervical microbiome and its cytokine profile, and proteomics based on 
differences in expressed proteins, all in a limited number of small studies.121-125 Further 
prospective research is needed to determine the utility of these molecular biomarkers 
in triage of hrHPV-positive women. 
4. exPerT COMMenTAry 
With the introduction of hrHPV-based screening with high sensitivity but limited specific-
ity, effective triaging of hrHPV-positive women is essential. None of the triage strategies 
discussed in this review currently meets the criteria for an ideal triage method; however, 
several strategies show great potential each with their own advantages and limitations. 
The worldwide experience with morphology-based Pap cytology makes this a com-
mon triage method for hrHPV-positive women. To improve sensitivity, different immu-
nochemistry stains, as p16 staining, or p16/Ki-67 dual-stain can be used as biomarker. 
However, these triage strategies are still more or less based on morphological criteria 
and cannot differentiate between productive and transforming infections or predict the 
development of high-grade lesions. Besides they are not applicable on self-sampled 
specimens, which may play an important future role in hrHPV-based screening. An 
additional clinician-taken sample would therefore still be needed for further triage of 
hrHPV-positive women. 
Molecular biomarkers have been extensively studied with a consistent increase of 
knowledge in this area. Molecular triage of hrHPV-positive women could in theory differ-
entiate productive from transforming infections, and some studies have already shown 
to be able to predict development of high-grade lesions. Molecular biomarkers are 
objective and highly reproducible, and can be used in high throughput testing. They do 
not need high cellularity, and some have already been shown applicable on lavage- and 
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brush based self-samples. Studies on these molecular techniques as single biomarker or 
as a combination of biomarkers show promising results. Yet, no molecular triage method 
can differentiate all women with a high risk from women with a low risk for high-grade 
CIN. However, with further increasing knowledge on these molecular markers, cervical 
cancer screening may transform to full molecular screening in the future.  
5. FIVe-yeAr VIew 
It is expected that in the next five years primary hrHPV testing, due to its high sensitivity, 
is increasingly incorporated in programs for cervical cancer screening in many Western 
countries. Results from the first years of primary hrHPV screening in some countries 
will then already be available. With the increased number of countries incorporating 
hrHPV screening, improving triage of hrHPV-positive women becomes more and more 
important. As knowledge on the molecular genesis of cervical precancer and cancer is 
expanding; triage tests other than cytology could fulfil the role of an additional triage 
test for HPV positive women. In the next five years, p16/Ki-67 dual-stain may replace or 
be added to morphology dependent Pap cytology as triage method for hrHPV-positive 
women. However, it is expected that triage of hrHPV-positive women by morphological 
biomarkers will finally be taken over by molecular triage techniques with advantages 
as objective evaluation and high-throughput triage. HPV genotyping has been widely 
studied and could be used as triage method for hrHPV-positive women on short notice. 
Methylation of host DNA is being widely studied and may also be used as triage method 
for hrHPV-positive women in the near future. The number of studies on predictive value 
of biomarkers is expected to increase and may finally result in biomarkers with predic-
tive characteristics to detect high-grade abnormalities even earlier in the process of 
carcinogenesis. To improve attendance to the screening program in the Netherlands, 
self-sampling will be offered to non-responders of the new hrHPV-based screening 
program. If this approach turns out successful, other countries may also consider 
implementing self-sampling in their screening programs in the future. Cervical cancer 
screening is expected to gradually transform into a more woman-friendly program with 
more objective screening and triage methods with higher clinical accuracy. 
Approximately ten years ago, vaccines for HPV types 16 and 18 first became avail-
able, and were followed-up by the quadrivalent and nonavalent vaccines. Vaccination 
programs based on vaccinating girls in their pre-sexarche for high-risk types 16 and 
18, and possibly also other types, are introduced. Recently published large studies 
show great promise of these vaccines with strong herd protection and no sign of type-
replacement yet.  It will however take many years before the vaccination program will 
affect the incidence of cervical cancer, and it is not yet fully known how this will affect 
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the effectiveness of screening programs. Screening will therefore remain necessary for 
the next decades. Vaccination will however decrease the prevalence of high-grade CIN 
and therefore test characteristics of screening must show high sensitivity and specificity. 
In time screening programs might need to be re-evaluated and adjusted again. 
6. key Issues
· hrHPV testing is expected to replace cytology as primary screening method for cervi-
cal cancer screening in an increasing number of countries. The high sensitivity of 
hrHPV testing combined with a limited specificity makes triaging of hrHPV-positive 
women necessary.
· An ideal triage strategy consists of a biomarker that can be used on the primary 
screening sample, resulting in a highly sensitive and specific result that differentiates 
women with cervical cancer or high-grade CIN lesions from women with a low risk 
for these lesions who can safely return to the next screening round. An ideal triage 
strategy does not yet exist. Therefore, the most optimal triage strategy should be 
obtained based on current knowledge. 
· Multiple options for triaging hrHPV-positive women are available. Previous experi-
ence with morphologically-based methods makes them a logical first choice as tri-
age method for hrHPV-positive women. However, these morphological markers lack 
properties that make molecular biomarkers more attractive as triage method such 
as: objectivity, option for using high-throughput systems, the capacity to distinguish 
productive from transforming infections, predict developing high-grade CIN lesions, 
and the option to be performed on self-sampled material.
· At the moment, most biomarkers lack sufficient evidence to introduce them as tri-
age method for hrHPV-positive women in screening programs. Improved sensitivity 
and specificity, and more evidence from large prospective studies is needed before 
introducing these biomarkers as triage test into standard of care in cervical cancer 
screening programs. Different triage techniques may also be combined to improve 
diagnostic value as triage method for hrHPV-positive women.  
· In the near future, cervical cancer screening programs are expected to be based on 
full molecular screening with primary hrHPV testing and molecular triage of hrHPV-
positive women. 
· The number of studies on predictive value of biomarkers is expected to increase and 
may finally result in biomarkers with predictive characteristics to detect high-grade 
abnormalities even earlier in the process of carcinogenesis.
· Self-sampling may attain a role in hrHPV-based screening programs, to finally result 
in a more women-friendly screening program with less loss to follow-up. 
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· It will take many years before vaccination programs will affect the incidence of cervi-
cal cancer, and it is not yet known how this will affect the effectiveness of screening 
programs. In time screening programs might need to be re-evaluated and adjusted 
again. 
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AbsTrACT
Objective Cytology alone, or combined with HPV16/18 genotyping, might be an ac-
ceptable method for triage in high-risk human papillomavirus (hrHPV)-cervical cancer 
screening. Previously studied HPV-genotype based triage algorithms are based on cytol-
ogy performed without knowledge of hrHPV status. The aim of this study was to explore 
the value of hrHPV genotyping combined with cytology as triage tool for hrHPV-positive 
women. 
Methods 520 hrHPV-positive women were included from a randomized controlled 
self-sampling trial on screening non-attendees (PROHTECT-3B). Eighteen baseline tri-
age strategies were evaluated for cytology and hrHPV genotyping (Cobas 4800, Roche) 
on physician-sampled triage material. Sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV), referral rate, and number of referrals needed to 
diagnose (NRND) were calculated for ≥CIN2 and ≥CIN3. A triage strategy was considered 
acceptable if the NPV for ≥CIN3 was ≥98%, combined with maintenance or improve-
ment of sensitivity and an increase in specificity in reference to the comparator, being 
cytology with a threshold of atypical cells of undetermined significance (ASC-US).
results Three triage strategies met the criteria: HPV16+ and/or ≥LSIL; HPV16+ and/
or ≥HSIL; (HPV16+ and/or HPV18+) and/or ≥HSIL. Combining HPV16+ and/or ≥HSIL 
yielded the highest specificity (74.9%, 95% CI 70.5–78.9), with a sensitivity (94.4%, 95% 
CI 89.0–97.7) similar to the comparator (93.5%, 95% CI 87.7–97.1), and a decrease in 
referral rate from 52.2% to 39.5%. 
Conclusion In case of prior knowledge of hrHPV presence, triage by cytology testing 
can be improved by adjusting its threshold, and combining it with HPV16 /18 genotyp-
ing. These strategies improve the referral rate and specificity for detecting ≥CIN3 lesions, 
while maintaining adequate sensitivity.
The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples
47
3
InTrOduCTIOn
A persistent cervical infection with high-risk human papillomavirus (hrHPV) is a nec-
essary cause for the development of cervical neoplasia.1 Western countries therefore 
increasingly consider implementation of primary hrHPV testing for cervical cancer 
screening, and replace primary cytology screening. The main concern surrounding the 
use of hrHPV testing for primary screening is its relatively low specificity, the direct result 
of the assay’s inability to distinguish transient from persistent HPV infection. Therefore, 
additional triage is required to identify women with the highest risk of cervical precan-
cer or cancer, in need of treatment.2 
In the Netherlands, primary hrHPV testing will soon be implemented in the organized 
screening program. The proposed strategy for hrHPV-positive women is cytology triage 
at baseline, with repeat cytology after six months for hrHPV-positive and cytology-
negative cases. However, this follow-up algorithm demonstrates limited specificity and 
requires repeat testing which in turn increases the risk of loss to follow-up. A suitable 
supplemental or alternative triage method may further reduce unnecessary colposco-
pies, invasive diagnostics such as biopsies, overtreatment, patient anxiety, and waste of 
financial sources.3-6 HrHPV genotyping, supplemental to cytology, may be a potential 
solution to this clinical dilemma in the management of hrHPV-positive women. 
Previous studies on triage strategies evaluating cytology with hrHPV genotyping show 
promising results with equal or increased sensitivity,7,8 combined with an increased posi-
tive predictive value (PPV) and specificity,9,10 resulting in higher detection of moderate 
dysplasia (cervical intraepithelial neoplasia grade 2) or worse (≥CIN2) at baseline. The 
latter studies have, however, been performed with cytology scoring without knowledge 
of hrHPV presence.  Understanding the extent to which prior knowledge of hrHPV status 
affects cytology-based triage algorithm outcomes is critical because primary hrHPV test-
ing becomes increasingly used for cervical cancer screening. 
The aim of this study was to assess the clinical value of hrHPV genotyping as a supple-
mental or alternative triage strategy for hrHPV-positive women, compared with Pap cy-
tology testing with a threshold of atypical squamous cells of undetermined significance 
(ASC-US), in a setting comparable to the future cervical cancer screening program in the 
Netherlands, based on primary hrHPV screening.
MeTHOds
We conducted a post-hoc analysis on 520 physician-taken triage cervical scrape samples 
of former non-responders who were recruited into the screening program by offering 
self-sampling for hrHPV testing in the PROHTECT-3B study (PRotection by Offering HPV 
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TEsting on self-sampled Cervicovaginal specimens Trial-3B). The PROHTECT-3B study is a 
randomized controlled trial designed to determine whether the participation rate by of-
fering a brush-based cervicovaginal self-sampling device (Evalyn Brush, Rovers Medical 
Devices) is non-inferior to that of a lavage-based device (Delphi screener, Rovers Medi-
cal devices) for self-collection of material for hrHPV testing.11 The Ministry of Health gave 
ethical approval for this study (No. 2010/WBO04). In short, 35,477 non-responders to the 
regular cervical screening program, 33 to 63 years of age, were invited to participate 
between October 2011 and September 2012. 10,027 women participated by returning 
self-sampled material to the laboratory for hrHPV testing (GP5+/6+ PCR; EIA HPV GP HR 
kit; Diassay, Rijswijk, The Netherlands). Women who tested hrHPV negative were advised 
to participate in the next screening round. HrHPV-positive women were advised to have 
an additional cervical smear taken by a physician for liquid based cytology (LBC) testing 
(ThinPrep). The latter population is the focus of this post-hoc analysis (Figure 1). The 
regional institutional review board approved the protocol for this post-hoc analysis, 
since all women provided written informed consent. 
Figure 1. Trial Profile.
* At exit evaluation, women with an initial cytology test result negative for intraepithelial lesion or malig-
nancy (NILM), and after six months a NILM result and an hrHPV-negative test are considered to have no CIN.
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All cervical cytology samples were tested in the laboratory of the Department of 
Pathology, Radboud university medical center, Nijmegen, the Netherlands. The Dutch 
CISOE-A (composition, inflammation, squamous cells, other and endometrium, endo-
cervical cylindrical epithelium, adequacy)  classification system was used to report the 
test results for the cervical smears, which can easily be translated into the Bethesda 
nomenclature.12 Cytologic results were reported as negative for intraepithelial lesion or 
malignancy (NILM), ASC-US, low-grade squamous intraepithelial lesions (LSIL), or high-
grade squamous intraepithelial lesions (HSIL). Atypical squamous cells cannot exclude 
high-grade squamous intraepithelial lesion (ASC-H) results are not scored as a separate 
group in the Dutch classification system, thus spread amongst ASC-US or LSIL. Cervical 
cytology samples were listed as ASC-US when they showed atypical squamous cells or 
squamous metaplasia, atypical repair, or atypical glandular cells (scored as S2-3, O3, or 
E3 in the CISOE-A classification), and listed as LSIL, when they showed mild dyskaryosis of 
the squamous epithelium, mildly atypical endometrium, or mildly-moderately atypical 
endocervical epithelium (scored as S4, O4, or E4-5). Cervical smears that showed moder-
ate dyskaryosis of squamous epithelium or worse, moderately atypical endometrium 
or worse, or severe atypical endocervical epithelium or worse (scored as S5-9, O5-9, or 
E6-9), were registered as HSIL.12  
Women with abnormal cytology results (determined by the ASC-US threshold) were 
referred for a colposcopy-directed biopsy, while women with NILM cytologic results 
were re-invited for an exit test (cytology and hrHPV co-testing) six months later. Women 
with a positive exit test (ASC-US or worse (≥ASC-US) cytology and/or hrHPV-positive test 
results) were referred for a colposcopy-directed biopsy. Colposcopists were aware of the 
hrHPV-positive status and colposcopy was performed according to the Dutch national 
guidelines. Women with an abnormal biopsy result, ≥CIN2, were treated according to 
the Dutch national guidelines.13,14 If no abnormalities were seen at colposcopy, the 
gynecologist was advised to take two random biopsies according to the study protocol. 
Histological results were obtained from gynecologists, and missing data were retrieved 
from the Dutch nationwide registry of histopathology and cytopathology (PALGA).15 The 
outcomes were classified as ≥CIN2 and/or severe dysplasia (CIN3) or worse (≥CIN3), mild 
dysplasia (CIN1), or no dysplasia (no CIN) based on the histological test results. When 
multiple results were registered, the most severe histological diagnosis was used for 
analysis. Women with a double-negative exit test (NILM cytology and negative hrHPV 
results) after six months were considered to have a minimal risk of ≥CIN2 lesions and 
were not referred for colposcopy; these women were classified as having no CIN. We 
included all results recorded before June 2013. At this point, the database was closed 
with a mean follow-up of 15 months (range 6–18 months). 
All physician-taken LBC samples, from women with ≥ASC-US cytology who were re-
ferred for colposcopy, and from women with NILM cytology who were invited for an exit 
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test six months later, were analyzed for the presence of different hrHPV genotypes using 
the clinically validated Cobas 4800 test (Roche) according to the manufacturer’s recom-
mendations in the laboratory of the Department of Medical Microbiology, Radboud 
University Medical Center, Nijmegen, the Netherlands.16 This test provides separate 
results for HPV16, 18, and a pool of 12 other hrHPV types (i.e., 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 66, and 68).17 
The hrHPV genotyping results were categorized: hrHPV-positive (positive for any of 14 
hrHPV types) and negative (negative for all 14 hrHPV types). The hrHPV-positive group 
was subcategorized in two groups; HPV16 and/or 18 positive (positive for HPV16 and/or 
18, regardless of the presence or absence of 12 other hrHPV types) and, positive for 12 
other hrHPV types (positive for one or more of the 12 other hrHPV types and negative 
for HPV16 and 18).
Eighteen different baseline triage strategies were evaluated, combining genotyping 
for HPV16, HPV16 and/or HPV18, and different thresholds for cytologic interpretations: 
≥ASC-US, LSIL or worse (≥LSIL), or HSIL or worse (≥HSIL). These strategies were assessed 
to identify potentially better algorithms for triage to immediate colposcopy. 
The performance of each strategy in detecting ≥CIN3, or ≥CIN2, was explored. The 
sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), 
and referral rate (REF) were estimated for each screening strategy. To analyze the extent 
of overdiagnosis, we estimated the number of referrals needed to diagnose (NRND) 
one lesion with endpoint ≥CIN2 or ≥CIN3, by dividing one by the PPV. In evaluating the 
strategies, we considered a NPV for ≥CIN3 of at least 98%, combined with maintenance 
or improvement of sensitivity and an increase in specificity relative to the comparator, 
being cytology with an ASC-US threshold, to be a minimal requirement. All strategies 
were analyzed in reference to this comparator. The threshold of 98% is based on cur-
rently used management strategies, in which a scientific risk estimation of <2% risk of 
cancer or precancer in the subsequent 2–3 years (i.e., NPV for ≥CIN3 for at least 98%) is 
considered acceptably low to dismiss further testing until the next screening round.7,18 
95% confidence intervals (CI) were calculated for sensitivity, specificity, PPV, and NPV. 
Differences between the comparator and the other strategies in sensitivity and specific-
ity were evaluated with McNemar’s χ2 test, and differences in PPV and NPV, with Kosinski 
and colleagues’ method.19 
We used SPSS version 20.0.1 to analyze the data. Differences in PPV and NPV were 
estimated with R, version 3.0.1.20,21
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resulTs
In the PROHTECT-3B study, 35,477 women who had not responded to an invitation 
for regular screening were invited to submit a self-collected sample for hrHPV testing. 
From the 10,027 women who participated in the PROHTECT-3B study, 834 had a positive 
hrHPV test.   Exclusion of women with inadequate follow-up (n=249) or no available 
sample for genotyping (n=65), resulted in a study population of 520 women (Figure 1). 
The mean age of the study group was 42 years (range 33–63). There was no difference in 
mean age between the included and excluded group of women. 
A total of 271 women (52.1%) had an ≥ASC-US result, and the remaining 249 women 
had a NILM cytologic test result. In this group of 249 women with a NILM result, 36 
women (14.5%) had an ≥ASC-US result at cytologic testing at exit exam at six months 
and were referred for colposcopy. Sixtysix women from the NILM group at exit exam, 
remained HPV positive and were therefore also referred for colposcopic examination. 
A histological diagnosis was available for 373 of the 520 women. Women who were re-
ferred for colposcopy after their first smear result (n=269), and women who underwent 
colposcopy after their exit exam at six months were combined: 122 had no CIN;CIN1 
(n=71); CIN2 (n=73); CIN3 (n=92); and invasive cervical carcinoma (n=15). The remaining 
147 women were considered to have no CIN, based on both an hrHPV-negative and 
NILM cytologic result at exit exam at six months. Seven ≥CIN3 lesions, and eight CIN2 
lesions were diagnosed during follow-up of hrHPV-positive women with an initial NILM 
cytologic result, of which one CIN3 and four CIN2 in random biopsies in hrHPV-positive 
women with an NILM cytology at exit exam. 
Of the 520 physician-taken triage samples, three were invalid for genotype testing 
and were therefore excluded. All 107 women with ≥CIN3 lesions were hrHPV-positive, 
and samples were frequently positive for more than one type of hrHPV; HPV16 was 
detected in 62.6% (67 of 107), HPV18 was detected in 16.8% (18 of 107), and the other 
12 types were detected in 58.9% (63 of 107) of women with ≥CIN3. In samples of women 
with ≥CIN2 lesions, HPV16 was positive in 55.0% (99 of 180), HPV18 in 16.7% (30 of 180), 
and other, non-HPV16/18 HPV was positive in 67.2% (121 of 180). A total of 2.2% (4 of 
180) ≥CIN2 lesions were hrHPV negative. Table 1 shows the hrHPV genotype distribution 
per outcome category. 
In this post-hoc analysis of the PROHTECT-3B study, the performance of baseline triage 
strategies by hrHPV genotyping, supplemental or alternative to baseline cytology triage 
were explored. Triage with cytology testing with an ASC-US threshold (strategy 2), was 
used as the comparator, yielding a sensitivity of 93.5% (95% CI 87.7–97.1), a specificity 
of 58.5% (95% CI 53.7–63.2), a PPV of 37.0% (95% CI 31.4–42.9), and a NPV of 97.2% (95% 
CI 94.6–98.8) for ≥CIN3. With this strategy, referral rate was 52.2%, and NRND was 2.70. 
The characteristics of all 18 strategies for detecting ≥CIN3 lesions are detailed in Table 2. 
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Table 1. Distribution of hrHPV types in relation to histology lesions.
Considered 
no CIn*
no CIn CIn1 CIn2 CIn3 Carcinoma
hrHPV negative**
78/147
(53.1%)
18/119
(15.1%)
6/71
(8.5%)
4/73
(5.5%)
0/92
(0.0%)
0/15
(0.0%)
hrHPV-positive†
   HPV16/18‡
   Other 12 hrHPV types ⱴ
69/147
(46.9%)
101/119
(84.9%)
65/71
(91.5%)
69/73
(94.5%)
92/92
(100.0%)
15/15
(100.0%)
14/147
(9.5%)
36/119
(30.3%)
21/71
(29.6%)
29/73
(39.7%)
68/92
(73.9%)
12/15
(80.0%)
55/147
(37.4%)
65/119
(54.6%)
44/71
(62.0%)
40/73
(54.8%)
24/92
(26.1%)
3/15
(20.0%)
CIN = cervical intraepithelial neoplasia; hrHPV = high-risk human papillomavirus. * Considered to be no CIN 
based on an HPV-negative result and a cytologic result within normal limits at six months of follow-up. ** 
Negative for all 14 hrHPV types. † Positive for any of 14 hrHPV types. ‡ Positive for HPV16 and/or 18, regard-
less of the presence or absence of 12 other HPV types (types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). 
ⱴ Positive for one or more of the 12 other HPV types and negative for HPV16 and 18.
Six triage strategies met the test criterion of a NPV of at least 98% for ≥CIN3, although 
some with limited power. The PPVs of these strategies ranged from 33.1% to 49.5%. 
Three triage strategies with a combination of cytologic testing and genotyping showed 
a higher specificity for ≥CIN3 than the comparator, without decreasing the sensitivity. 
Of these strategies, the one with positivity for HPV16 and/or ≥HSIL cytology (strategy 
11 in Table 2) revealed the highest specificity (74.9%, 95% CI 70.5–78.9; p<0.001) with 
a referral rate of 39.5%, and a NRND of 2.02. The sensitivity of this strategy was similar 
to the comparator. A specificity of 70.0% (95% CI 65.4–74.3) was achieved with HPV16 
and/or 18 positivity and/or ≥HSIL cytology (strategy 17), with a sensitivity of 97.2% (95% 
CI 92.9–99.3), a referral rate of 43.9% and NRND of 2.18. The sensitivity of combining 
HPV16 positivity and/or ≥LSIL cytology (strategy 9) was also similar the comparator, with 
a specificity of 65.6% (95% CI 60.9–70.1; p=0.003), a referral rate of 47.2%, and a NRND 
of 2.37. Genotyping for HPV16 alone or combined with HPV18, yielded a lower ≥CIN3 
sensitivity (62.6%, 95% CI 53.2–71.4, and 74.8%, 95% CI 66.0–82.3 respectively) than the 
comparator. 
The test characteristics of all 18 strategies for detecting ≥CIN2 lesions are given in Table 
3. Only the strategy HPV16 positivity and/or ≥LSIL cytology (strategy 9, Table 3) showed 
an improvement in specificity to 75.1% (95% CI 70.3–79.5) relative to the comparator 
(68.8% (95% CI 63.8–73.6; p=0.024) at similar sensitivity. None of the other strategies 
showed improvement in specificity without a decreased sensitivity for the detection of 
≥CIN2 lesions as compared with baseline cytology. 
The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples
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dIsCussIOn
Three of the 18 evaluated strategies for the triage of hrHPV-positive women met the 
NPV criterion of at least 98% for ≥CIN3, and showed a higher specificity for ≥CIN3 than 
the comparator being cytology with an ASC-US threshold. These three strategies were 
1) HPV16 genotyping and/or cytology at ≥LSIL threshold, 2) HPV16 genotyping and/ or 
cytology at ≥HSIL threshold, and 3) HPV16/18 genotyping and/or ≥HSIL cytology. The 
three strategies all showed high sensitivities and a significantly better PPV for ≥CIN3, 
the comparator (i.e. cytology with prior knowledge on hrHPV status), and in addition, 
the referral rates decreased by 5.0–12.7%. With a ≥CIN2 threshold only the strategy that 
combines HPV16 genotyping and/or cytology at ≥LSIL threshold showed improved 
specificity with similar sensitivity, relative to the comparator. However, in case of a CIN2 
lesion a watchful waiting policy could be considered, especially in young and fertile 
women. 
Our findings are consistent with those from the ATHENA study9, which is a large clinical 
trial that assessed hrHPV genotyping and cytology co-testing for cervical cancer screen-
ing. Strategies that included integrated HPV16/18 testing provided efficient referral to 
colposcopy. When the cytologic threshold is raised to HSIL as well as hrHPV genotyping 
added to cytologic triage, our results confirm the improvement of diagnostic accuracy. 
Our study differed from the Athena trial as we assessed hrHPV genotyping strategies in 
the physician-taken triage material of women 33 to 63 years of age after hrHPV-positive 
self-sampling, in contrast to the ATHENA trial where hrHPV genotyping was added in 
an opportunistic screening population that also included women between 29 and 32 
years of age. Rijkaart et al.7 showed a NPV of >98% in a triage strategy combining cytol-
ogy at ASC-US threshold and HPV16/18/31/33/45 genotyping in an organized cervical 
cancer screening setting. Dijkstra et al.8 showed a NPV of >98% by combining cytology 
at ASC-US threshold and HPV16/18 genotyping. However, both studies showed higher 
colposcopy referral rates. Our study adds to previous findings because genotyping 
performance was explored in a setting with prior knowledge on hrHPV-positive status, 
rather than cytology positivity, which will become the new practice in hrHPV-based 
population-screening. 
The choice for one of the three favorable strategies will depend on clinical needs. 
When the proposed cytologic triage is used in clinical practice, there may be a need to 
reduce the colposcopy rate because of risk of overdiagnosis, high costs, and high levels 
of anxiety for the women involved. In these cases, referring women with HPV16 and/or 
≥HSIL cytology test results (strategy 11) may be a good alternative since the specificity 
is significantly improved, and the sensitivity is similar to that of the comparator. As a 
result, the referral rate decreases from 52.2% to 39.5%, and instead of 2.70 women, only 
2.02 women need to be referred to diagnose one ≥CIN3. This may be considerable for 
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young women for whom overtreatment may be harmful in future pregnancies.22 How-
ever, women with low-grade abnormal cervical smear results will not be referred in this 
strategy. Lowering the cytology threshold to LSIL, combined with HPV16 genotyping 
(strategy 9) might partially resolve this issue. In women with an ASC-US cervical smear 
result, follow-up could be considered. When there is a clinical need to use a test with 
the highest possible sensitivity, strategy 13 (HPV16 and/or HPV18 positive or ≥ASC-US 
cytologic testing) with 100% sensitivity for ≥CIN3 (95% CI 96.6–100) may be an alterna-
tive. The referral rate increased to 62.5%, and the NRND to 3.02, while the specificity 
decreased to 47.3%. However, the length of follow-up in this study is too short to deter-
mine the actual consequences of their return to the next screening round. Furthermore, 
this strategy did not yield such high sensitivity in previous trials.7,9 
Previous studies have shown a 10-year cumulative incidence rate of ≥CIN3 lesions of 
about 17–20% among HPV16-positive women, 13–17% among HPV18-positive women 
and only 3% among hrHPV-positive, HPV16/18-negative women.18,23 An advantage of 
hrHPV genotyping is the possibility to objectively select women who have an increased 
risk (e.g. HPV16 positive), or a relatively low risk (e.g. positive for types other than 
HPV16/18) of developing ≥CIN3 lesions. Adequate follow-up based on individual risk 
stratification can therefore be provided.23,24 However, in the use of either of these triage 
methods there is still a group of hrHPV-positive women that will not be referred for ad-
ditional diagnostics. This may result in anxiety amongst women, even if their ≥CIN3 risk 
is statistically low enough for them to return to the next screening round. It is therefore 
important for the last triage test to be negative; a repeat visit for cytologic testing at six 
to 12 months could be used to accomplish this.7,25 A disadvantage of repeat testing is 
loss to follow-up, while existing ≥CIN3 lesions may be missed.26 
An important strength of this study is the study design, comparable with the future 
Dutch cervical cancer screening program with hrHPV testing and cytology triage. It is 
known that the performance of cytology is influenced by the cytotechnicians’ knowl-
edge of the positive hrHPV status.27 In this setting with knowledge of prior hrHPV status, 
we observed high sensitivity for cytology.2 A second strength of this study is that for 
some HPV tests it is possible to combine hrHPV screening with immediate HPV16/18 
genotyping, (e.g. the Cobas 4800 test used in this study). By combining hrHPV screening 
with HPV16/18 genotyping, the proposed strategies in this study will be easily avail-
able, without any additional costs. A limitation of this study is the lack of histology in 
the group of women who had a NILM cytologic triage result and, after six months of 
follow-up, an hrHPV-negative result and a NILM cytologic result. However, the Ministry 
of Health did not approve colposcopy with random biopsies in these women, because 
the risk of ≥CIN2 in his group of women is low.25 Furthermore, women with inadequate 
follow-up were excluded from this study, which might over-represent women with NILM 
cytology at baseline, and the current study also has a relative short duration of follow-
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up. When ruling out the need for intensified surveillance, we should wait for long-term 
follow-up for a more solid result, especially when strategies without referring HPV18 
positive women will be considered. Next, it might be difficult to distinguish between 
ASC-US and LSIL in cytology. When a LSIL threshold is used to distinguish women who 
need to visit a gynecologist for colposcopy, from women who do not, this might hold a 
risk for differences in scoring of these low-risk cervical smears. Therefore, the reproduc-
ibility of this difference still has to be confirmed. Furthermore, this study was performed 
in a non-responder population, which involves substantial numbers of underscreened 
women and women who were never screened before.28 For a responder population, 
these algorithms might show slightly different results. These factors altogether may lead 
to an under- or overestimation of the screening results.  
As knowledge about the molecular oncogenesis of cervical precancer and cancer is 
expanding, the clinical utility of a wide variety of novel biomarkers in supplementary or 
stand-alone triage tests is being studied extensively and could also fulfil a role in triage 
of hrHPV-positive women. Triage strategies, such as mRNA HPV testing, p16 staining, 
p16/Ki-67 dual staining, MSM2/TOP2A dual staining, E6/E7 protein markers, and DNA 
methylation markers, may help to reduce the number of unnecessary referrals for col-
poscopy.29-31 The clinical performance of these various triage strategies still needs further 
assessment in regular screening programs; also, these strategies are not yet combined in 
one test with HPV testing, as is hrHPV genotyping. 
In regular European screening programs, hrHPV testing is expected to replace cytol-
ogy testing as a primary screening tool in the coming years. In the Netherlands, primary 
hrHPV screening is scheduled to start in 2017, and non-responders will be able to opt in 
for HPV self-sampling. For the time being, if an HPV self-sampling result is positive, triage 
will consist of cytology on an extra physician-taken cervical smear. In such a screen-
ing program, it would be possible to combine hrHPV testing with HPV16 and HPV18 
genotyping, and have knowledge on the presence of cellular abnormalities, which offers 
opportunities for personalized risk management.
We conclude that HPV16 and/or 18 genotyping combined with raising the threshold 
of cervical cytological abnormalities from ≥ASC-US to ≥LSIL or ≥HSIL improves the 
referral rate and the specificity for detecting ≥CIN3 lesions while maintaining adequate 
sensitivity. 
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AbsTrACT
Objective The aim of this study was to evaluate the clinical utility of p16/Ki-67 dual 
staining, for the identification of cervical intraepithelial neoplasia (CIN) in high-risk hu-
man papillomavirus (hrHPV)-positive women from a non-responder screening cohort. 
Methods P16/Ki-67 dual staining, Pap cytology and HPV16/18 genotyping were per-
formed on physician-taken liquid-based cytology samples from 495 women who tested 
hrHPV-positive on self-sampled material (PROHTECT3B study). Different triage strate-
gies involving p16/Ki-67 dual staining were evaluated for sensitivity, specificity, and 
predictive value for ≥CIN2 and ≥CIN3, and compared with Pap cytology with a threshold 
of atypical cells of undetermined significance (ASC-US). Centrally revised histology or an 
adjusted endpoint with combined hrHPV negative and cytology negative follow-up at 
six months was used as gold standard.  
results Triage of hrHPV-positive samples by Pap cytology with an ASC-US-threshold 
showed a sensitivity of 93% (95% CI 85-98) with a specificity of 49% (95% CI 41-56) for 
≥CIN3. Three triage strategies with p16/Ki-67 showed a significantly increased specificity 
with similar sensitivity. P16/Ki-67 triage of all hrHPV-positive samples had a sensitivity of 
92% (95% CI 84-97) and a specificity of 61% (95% CI 54-69) for ≥CIN3. Applying p16/Ki-
67 triage to only hrHPV-positive women with low-grade Pap cytology showed a similar 
sensitivity of 92% (95% CI 84-97), with a specificity for ≥CIN3 of 64% (95% CI 56-71). For 
hrHPV-positive women with low-grade and normal Pap cytology, triage with p16/Ki-67 
showed a sensitivity of 96% (95% CI 89-99), and a specificity of 58% (95% CI 50-65). 
HPV16/18 genotyping combined with Pap cytology showed a sensitivity and specificity 
for ≥CIN3 similar to Pap cytology with an ASC-US threshold. 
Conclusion Because the quality of Pap cytology worldwide varies, and differences in 
sensitivity and specificity are limited between the three selected strategies, p16/Ki-67 
triage of all hrHPV-positive samples would be the most reliable strategy in triage of 
hrHPV-positive women with an increased specificity and similar sensitivity compared 
with Pap cytology triage. 
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InTrOduCTIOn
The introduction of cytology-based organized cervical cancer screening programs 
has contributed to decreased cervical cancer incidence and mortality in developed 
countries.1-3 Compared with cytology, human papillomavirus (HPV) DNA testing has a 
higher sensitivity with a higher negative predictive value (NPV) for detection of cervical 
intraepithelial neoplasia (CIN) and cancer. The high reassurance of a low risk of cervical 
cancer for high-risk HPV (hrHPV) negative women is one of the advantages of the HPV 
DNA test, which has resulted in a shift from cytology-based screening towards HPV DNA 
detection as primary screening method.4,5
However, the high sensitivity of HPV DNA testing is combined with a lower positive 
predictive value (PPV), due to the fact that most  hrHPV infections clear spontaneously 
and do not result in cancer.6 Additional triage of hrHPV-positive women is therefore re-
quired to limit the number of unnecessary referrals for follow-up procedures in women 
without clinically meaningful hrHPV infections.7 Currently proposed triage strategies for 
hrHPV-positive women in HPV DNA-based screening programs are repeated Pap cytol-
ogy and/or HPV16 and HPV18 genotyping. Pap cytology is a relatively subjective test for 
which high expertise is required. Owing to its limited sensitivity repeat cytology testing 
within 6-12 months is needed before returning hrHPV-positive women with normal 
cytology back to regular screening. This bears the risk of losing them during follow-up.8 
HPV16/18 genotyping is an objective test to triage hrHPV-positive women, however, this 
strategy alone yields limited sensitivity as it only identifies cervical lesions associated 
with these two hrHPV types. Sensitivity of HPV16/18 genotyping can be improved by 
combining it with Pap cytology at the cost of a lower specificity.9-11
Another biomarker widely studied for triage is the p16/Ki-67 dual staining. P16 INK4a (p16) 
is a cell-cycle regulatory protein that induces cell-cycle arrest under normal physiologi-
cal conditions, and Ki-67 is a marker expressed during cell proliferation.12,13 The simulta-
neous detection of p16 and Ki-67 within the same cervical epithelial cell will not occur 
under physiological conditions and may be used as a surrogate marker of cell-cycle 
deregulation mediated by transforming hrHPV infections. P16/Ki-67 dual-stain has been 
previously studied as a potential primary screening test, as triage test for women with 
atypical cells of undetermined significance (ASC-US), for surveillance of women treated 
for high-grade CIN, and also in a limited number of studies as triage test in women with 
a positive hrHPV test.14-22 
The aim of the current study was to evaluate the overall clinical performance of the 
p16/Ki-67 dual-stain test as triage method for hrHPV-positive women from a non-
responder screening cohort.
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MeTHOds
This study is a post-hoc analysis on physician-taken triage cervical scrapes of former 
non-responder women who were recruited into the screening program by offering 
self-sampling for hrHPV testing in the PROHTECT-3B study in 2011 and 2012. (PRotec-
tion by Offering HPV TEsting on self-sampled Cervicovaginal specimens Trial-3B).23 In 
this trial, non-responders to the regular cervical screening program, between 30 and 
60 years of age, were invited to participate by returning self-sampled material (Evalyn 
Brush, or Delphi Screener, Rovers Medical Devices) to the laboratory for hrHPV testing 
(GP5+/6+ polymerase chain reaction; EIA HPV GP HR kit; Diassay, Rijswijk, The Nether-
lands). Women who tested hrHPV-positive on their self-sample were advised to have an 
additional cervical smear taken by a physician for Pap cytology testing. Women with an 
abnormal cervical smear result were referred to a gynecologist for colposcopic examina-
tion, and for women with a normal cervical smear result a 6-month follow-up smear was 
performed for both hrHPV testing and Pap cytology. Further details of the PROHTECT-3B 
study design are reported elsewhere.23 All women provided written informed consent. 
The Ministry of Health gave ethical approval for this study (No.2010/WBO04), and the 
regional institutional review board approved the protocol for this post-hoc analysis. 
From 495 of the total of 834 hrHPV-positive women in the PROHTECT-3B study, a 
study-endpoint was known, and a physician-taken triage liquid-based cytology cervi-
cal scrape was available. Women with abnormal cytology results (defined as ≥ASC-US) 
were referred for a colposcopy-directed biopsy, whereas women with normal cytology 
results (defined by negative for intraepithelial lesion or malignancy (NILM) cytology 
result) were re-invited for an exit test with Pap cytology and hrHPV co-testing six months 
later. Women with a positive exit test, defined as ASC-US or worse (≥ ASC-US) cytol-
ogy and/or hrHPV-positive test results, were referred for a colposcopy-directed biopsy. 
Colposcopists were aware of the hrHPV-positive status, and colposcopy was performed 
according to the Dutch national guidelines. If no abnormalities were seen at colposcopy, 
it was advised to take two random biopsies according to the study protocol. Women 
with a double-negative exit test (NILM cytology and negative hrHPV results) after six 
months were considered to have a minimal risk of ≥CIN2 lesions and were not referred 
for colposcopy; these women were classified as not having CIN2 (<CIN2). We included all 
results recorded before June 2013. At this point, the database was closed with a mean 
follow-up of 15 months (range 6–18 months).
All liquid-based cytology samples were processed and reported in the laboratory of 
the department of Pathology, Radboud university medical center, Nijmegen, the Neth-
erlands. The ThinPrep 3000 was used for processing, and cytological classification was 
performed according to the primarily used Dutch CISOE-A (composition, inflammation, 
squamous cells, other and endometrium, endocervical cylindrical epithelium, ad-
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equacy) classification. For analysis of cervical smears, the CISOE-A classification system 
was translated into the Bethesda nomenclature; in which borderline or mild dyskaryosis 
equals ASC-US and low-grade squamous intraepithelial lesion (LSIL), and worse than 
borderline or mild dyskaryosis equals high-grade squamous intraepithelial lesion 
(HSIL).24 All abnormal cytology was analyzed independently by two cytotechnicians who 
were aware of the hrHPV-positive status, but unaware of the p16/Ki-67 and HPV16/18 
genotype results. 
Histological results were obtained from records of the pathologists, and missing data 
were retrieved from the Dutch nationwide registry of histopathology and cytopathol-
ogy (PALGA).25 The histology outcomes were classified as CIN2 or worse (≥CIN2) or CIN3 
or worse (≥CIN3), CIN1, or no CIN. AIS was included in the CIN3 group. When multiple 
results were registered per woman, the most severe histological diagnosis was used for 
analysis. Histology samples collected during colposcopy procedures were subjected to 
central pathologist review. If the first pathologist disagreed with the initial diagnosis, 
a pathologist specialized in gynecologic oncology independently reviewed the case 
resulting in a final diagnosis. Majority consensus diagnoses were established on all 
available cervical tissue specimens. Pathologists were blinded to all other study results.
Partial HPV genotyping was done by the Cobas 4800 test (Roche), according to the 
manufacturer’s recommendations in the laboratory of the Department of Medical Mi-
crobiology, Radboud university medical center, Nijmegen, the Netherlands.26 This test 
provides separate result for HPV16 and 18, and a pool of 12 other hrHPV types (i.e., 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). The HPV genotyping results were categorized as 
HPV16/18 positive when HPV16 and/or HPV18 were present, regardless of the presence 
or absence of 12 other HPV types. Other results were scored as non-16/18 HPV positive. 
After hrHPV testing and Pap cytology testing the residual liquid-based cytology (LBC) 
material was stored for approximately two years in the original ThinPrep vials (Hologic 
UK Ltd, Crawley, West Sussex, UK) at room temperature (storage between 4 and 30° 
Celsius is advised by the manufacturer). A slide for p16/Ki-67 was prepared from the re-
sidual PreservCyt material using the ThinPrep 2000 Processor (Hologic). The CINtec PLUS 
Cytology kit (Roche mtm Laboratories AG, Mannheim, Germany) was used according to 
the instructions of the manufacturer. Staining was performed on a Ventana benchmark 
ultra. (Roche mtm Laboratories AG, Mannheim, Germany), and each run included one 
control specimen. 
Six trained observers each independently reviewed one-third of the cases for the 
presence of dual-stained cells, resulting in two independent results for each case. A 
case was considered positive if one or more cervical epithelial cells were stained both 
with a red nuclear stain for Ki-67 and a brown cytoplasmic stain for p16, independent 
of cellularity criteria (Figure 1). Cases were considered negative when no staining or 
only single staining of p16 or Ki-67 was observed in a single cell. A case was scored as 
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inadequate if background staining prohibited adequate evaluation, no p16 and/or Ki-67 
staining was visible as internal control, or if slides did not meet the squamous cellularity 
criteria as specified in the Hologic criteria (≥5,000 cells per slide). Inadequate cases were 
excluded from evaluation. In case of disagreement between two observers, a consensus 
score using a multi-headed microscope was obtained. The observers were unaware of 
the Pap cytology result, HPV16/18 genotyping result, or follow-up data. Our data on 
p16/ki-67 triage of hrHPV-positive women was compared with previous studies found in 
a systematic search combining synonyms for p16/Ki-67 dual-stain and HPV. Information 
on sensitivity, specificity, number of participants, hrHPV status, cytology result, and p16/
Ki-67 stain was obtained from relevant studies.
Descriptive statistics were used to calculate sensitivities, specificities, predictive val-
ues with corresponding 95% confidence intervals (CI), and referral rate (REF). The extent 
of overdiagnosis was estimated by using the number of referrals needed to diagnose 
(NRND) one lesion with endpoint ≥CIN2 or ≥CIN3, this equals by dividing one by the PPV. 
Differences in sensitivity and specificity between the comparator strategy and the other 
strategies were evaluated with McNemar’s χ2 test with continuity correction. Statisti-
cal analyses were conducted using SPSS version 20.0.1. Differences in sensitivity and 
specificity were estimated with R, version 3.0.1.27
BA
Figure 1. Example of p16/Ki-67 dual staining in cervical cytology.
A) A p16/Ki-67 dual-stain positive single-cell. B) A p16/Ki-67 dual-stained cluster of cells. A case is consid-
ered dual-stain positive if one or more cervical epithelial cells are stained with a red nuclear stain for Ki-67 
and a brown cytoplasmic stain for p16.
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resulTs
In the PROHTECT-3B study, 35,477 women were offered self-sampling for hrHPV testing. 
Out of 10,027 women who participated in the study, 834 (8.3%) were hrHPV-positive 
on a self-sample. Of the 834 hrHPV-positive women, 287 were excluded because of 
inadequate follow-up, 47 because no LBC left-over sample was available, and 38 women 
because no histology sample was available for revision, leaving 462 cases available for 
p16/Ki-67 dual-stain cytology and hrHPV genotyping (Figure 2). The mean age of the 
study group was 42 years, with a median age of 38 years (range, 33-63 years). 
Offered self-sampling for hrHPV testing
n = 35,477
Returned self-sampled material for hrHPV testing
n = 10,027
Tested hrHPV-positive on self-sampled material
n = 834
HrHPV-positive cases with study-enpoint available for
p16/Ki-67 dual stain and HPV16/18 genotyping
n = 462
Excluded n = 9,913
- HrHPV negative n = 9,146
- Invalid result n = 47
Valid result p16/Ki-67 dual-stain and HPV16/18
genotyping, with revised study endpoint
n = 247
Histologic endpoint n = 188 (76%)
- Carcinoma n = 8 (3%)
- CIN3 n = 68 (27%)
- CIN2 n = 41 (17%)
- CIN1 n = 19 (8%)
- no CIN n = 52 (21%)
HrHPV negative and cytology
negative during follow-up* n = 59 (24%)
- <CIN2 n = 59 (24%)
Excluded n = 372
- Inadequate follow-up n = 287
- Histology sample not available n = 38
- Cytology sample not available n = 47
Non-participants n = 25,450
Excluded n = 215
- Invalid result HPV16/18 genotyping n = 2
- Invalid result p16/Ki-67 dual-stain n = 213
- Cell count too low (n = 207)
- No Ki-67 internal control (n = 4)
- Too much background staining (n = 2)
Figure 2. Trial Profile.
* HrHPV negative and cytology negative during follow-up; women with an initial cytology test result nega-
tive for intraepithelial lesion or malignancy, and after six months a negative for intraepithelial lesion or 
malignancy result and an hrHPV-negative test are considered to have less than CIN2 (<CIN2).
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From the total group of 462 cases available for p16/Ki-67 dual staining, 136 were posi-
tive, 113 negative, and 213 were inadequate. In 207 of the latter, the cell count was too 
low, in four cases no Ki-67 internal control was visible, and in two cases the background 
staining made adequate evaluation impossible. The low cell count in the majority of 
cases was probably due to the fact that too little of the sample material was left after 
previous tests. Of the remaining 249 women, two had an inadequate genotyping result; 
leaving 247 cases available for analysis. There was no difference in age between the 
included and excluded women with a median age of 38 years in both groups and a 
mean age of 42 years and 41 years respectively. The excluded group contained more 
low-grade and normal histology results. Resulting in 47% ≥CIN2 and 71% CIN1 or less 
(≤CIN1) in the included group, and 29% ≥CIN2 and 53% ≤CIN1 in the excluded group. 
From the total of 247 women with a valid result for p16/Ki-67 dual-stain and HPV16/18 
genotyping, 159 (64%) women had an abnormal cytology result of ASC-US or worse, 
136 women (55%) had a p16/Ki-67 positive score, and 99 women (40%) were positive 
for HPV16/18 (Table 1). Of the total group of 247 women, 188 women had a revised 
histological endpoint: eight women had a cervical carcinoma, 68 were diagnosed with 
CIN3, 41 with CIN2, 19 with CIN1, and 52 with no CIN. The remaining 59 women were 
considered to have no CIN, based on both an hrHPV negative and NILM cytology result 
after six months (Figure 2). Revision of the 188 histology results yielded a similar result in 
153 (81%), cases and a different result in 35 cases (19%) Revision leaded to shift of three 
cases scored as ≥CIN2 towards <CIN2, and 12 cases scored as <CIN2, towards ≥CIN2, 
resulting in a 3.6% higher ≥CIN2 prevalence after revision. 
Table 1. Test results of p16/Ki-67 dual-stain in regard to Pap cytology and HPV16/18 genotyping.
Pap cytology
TotalnIlM AsC-us and lsIl HsIl
p16/ki-67 positive HPV16/18 positive 4 18 57 79 (32%)
HPV16/18 negative 9 23 25 57 (23%)
Total 13 41 82 136 (55%)
p16/ki-67 negative HPV16/18 positive 10 7 3 20 (8%)
HPV16/18 negative 65 20 6 91 (37%)
Total 75 27 9 111 (45%)
Total 88 (36%) 68 (27%) 91 (37%) 247 (100%)
≥ASC-US = atypical squamous cells of undetermined significance or worse; HPV = human papillomavirus; 
HSIL = high-grade squamous intraepithelial lesion; LSIL = low-grade squamous intraepithelial lesion; NILM 
= negative for intraepithelial lesion or malignancy.
In this post-hoc analysis of the PROHTECT-3B study, first the performance of six base-
line triage strategies by p16/Ki-67 dual stain, Pap cytology and HPV16/18 genotyping 
was explored with endpoints ≥CIN2 and ≥CIN3. Baseline triage with cytology testing 
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with an ASC-US threshold was used as comparator strategy. This strategy yielded a sen-
sitivity of 93% (95% CI 85-98), with a specificity of 49% (95% CI 41-56), PPV of 45% (95% 
CI 37-53) and NPV of 94% (95% CI 87-98) for ≥CIN3. Five women with CIN3 were missed 
with this strategy. P16/Ki-67 dual staining showed a similar sensitivity of 92% (95% CI 
84 -97), with an increased specificity of 61% (95% CI 54-69) for ≥CIN3. Six women with 
CIN3 were missed with this strategy. HPV16/18 genotyping alone showed a significantly 
lower sensitivity of 75% (95% CI 64-97), with 19 missed CIN3 cases, and a significant 
improvement in specificity of 75% (95% CI 68-82) for ≥CIN3 with a referral rate of only 
40%.
Three strategies showed similar sensitivity with improved specificity, in regard to 
the comparator strategy for ≥CIN3. Similar was defined by a non-significant difference 
from Pap cytology triage. The first strategy was p16/Ki-67 triage of all hrHPV-positive 
women. The second strategy was baseline cytology with p16/Ki-67 triage restricted to 
hrHPV-positive women with ASC-US or LSIL cytology, which showed a sensitivity of 92% 
(95% CI 84-97), with the highest specificity of 64% (95% CI 56-71), and a false negative 
result for six women with CIN3. The third strategy was 16/Ki-67 triage of hrHPV-positive 
women with NILM, ASC-US or LSIL cytology, resulted in an equal sensitivity of 96% (95% 
CI 89-99), with a specificity of 58% (95% CI 50-65), and three false negative cases for 
CIN3. Combined p16/Ki-67 dual staining with HPV16/18 genotyping showed a similar 
sensitivity, with only two missed CIN3 lesions, and a similar specificity, compared with 
Pap cytology triage. Adding p16/Ki-67 triage to hrHPV-positive women with normal 
cytology detected four women with CIN3, and another eight with CIN2, however, at the 
cost of 32 and 24 unnecessary referrals, respectively (Table 2). 
For ≥CIN2 the comparator cytology strategy showed a sensitivity of 94% (95% CI 88-
98) with a specificity of 62% (95% CI 53-71), PPV of 69% (95% CI 61-76) and NPV of 92% 
(95% CI 84-97). The strategy combining p16/Ki-67 triage of ASC-US and LSIL cytology 
also yielded a similar sensitivity but with a statistically significant increase in specificity 
for ≥CIN2, compared with Pap cytology triage. The sensitivity of this strategy was 89% 
(95% CI 82-94) with a specificity of 79% (95% CI 70-85) (Table 3). 
Our systematic search yielded five studies that previously reported on triage of hrHPV-
positive women with all cytology categories, representing 3,270 women.22,28-31 Results 
are summarized in Table 4. Results of these studies show sensitivities ranging from 83% 
to 93% for ≥CIN2 and 87% to 95% for ≥CIN3. Specificities range from 53% to 75% for 
≥CIN2 and 48% to 57% for ≥CIN3. Only the specificity for ≥CIN3 found in this study falls 
outside the range, but is not significantly higher compared with previously published 
numbers. 
The overall κ-value of dual-stain cytology for comparing scores of two independent 
evaluators was 0.67 (95% CI 0.59-0.76), which is considered substantial according to the 
classification of Landis and Koch.32 
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dIsCussIOn
In this study we evaluated the clinical utility of p16/Ki-67 dual staining, either or not com-
bined with Pap cytology and/or HPV16/18 genotyping, for the identification of ≥CIN2 
and ≥CIN3 in hrHPV-positive women from a non-responder screening cohort. Three of 
the proposed strategies for triaging hrHPV-positive women showed increased specific-
ity with similar sensitivity for ≥CIN3, compared with Pap cytology. These strategies were: 
p16/Ki-67 triage of all hrHPV-positive women, p16/Ki-67 triage of hrHPV-positive women 
with ASC-US or LSIL cytology, and p16/Ki-67 triage of hrHPV-positive women with NILM, 
ASC-US or LSIL cytology. With a ≥CIN2 threshold only the strategy with p16/Ki-67 triage 
of hrHPV-positive women with ASC-US or LSIL cytology showed increased specificity 
with similar sensitivity compared with Pap cytology triage of hrHPV-positive women. 
Our findings on sensitivity and specificity of p16/Ki-67 triage of hrHPV-positive women 
independent of cytology result are comparable with previously published studies, with 
only small differences in sensitivity and specificity between Pap cytology and p16/Ki-67 
dual-stain. These studies have been performed with different hrHPV tests and different 
cell collection medium. Also, the populations in these studies are different, some are 
performed in a general population, others in an outpatient population, and none were 
previously performed in a non-responder population, which could explain slightly dif-
ferent results. A recent large study on p16/Ki-67 performance in hrHPV-positive women 
by Wentzensen et al.29 shows an increased specificity with a maintained sensitivity for 
≥CIN3 detection, compared with Pap cytology in triage of hrHPV-positive women. This 
was also confirmed by Luttmer et al. 22 who show a good clinical performance of p16/Ki-
67 dual-stained cytology as triage method for hrHPV-positive women with an increase 
in sensitivity and specificity for ≥CIN3. A previously performed study on p16/Ki-67 triage 
of hrHPV-positive women with normal cytology showed that p16/Ki-67 dual-stained 
cytology detects more than 70% of underlying ≥CIN3 lesions in hrHPV-positive women 
with normal cytology at baseline. They conclude to state that this strategy is suitable for 
triaging these women to colposcopy.33 Our study also confirms the additional detection 
of high-grade lesions in hrHPV-positive women with a normal cytology result, however, 
at the cost of additional colposcopy referrals.
 Previous studies have also analyzed the clinical value of p16/Ki-67 triage of women 
with low-grade or normal cytology in hrHPV-positive cohorts. To our knowledge, none 
of them show results on sensitivity, specificity and predictive values of overall triage 
strategies with p16/Ki-67 triage of certain Pap cytology subgroups in hrHPV-positive 
women. This approach gives an overview of the whole triage strategy, instead of only 
results on triage of a certain cytology subgroup. Our data show that adding p16/Ki-67 
triage to either low-grade only, or alternatively, low-grade and normal Pap cytology in 
hrHPV-positive women would improve the specificity of the triage-step, while maintain-
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ing similar sensitivity. With improved specificity by additional p16/Ki-67 triage of these 
low-grade and/or normal cytology results, unnecessary colposcopy referrals could be 
prevented. By adding p16/Ki-67 triage for women with ASC-US or LSIL cytology, the 
referral rate can be lowered from 64% to 53% with a decrease in NRND of ≥CIN3 lesion 
from 2.2 to 1.9. These strategies can easily be combined with Pap cytology triage of 
hrHPV-positive women which will be used in the new Dutch cervical cancer screening 
program which started in January 2017. 
P16/Ki-67 dual-stain was also combined with HPV16/18 genotyping. An attractive fea-
ture of HPV16/18 genotyping is that this triage method could be implemented without 
additional costs, because most hrHPV tests also have the ability of immediate HPV16/18 
genotyping. In this study, triage with HPV16/18 genotyping shows an increase in speci-
ficity, however, at the cost of a lower sensitivity. 
An advantage of p16/Ki-67 dual-stain over Pap cytology is the reduced role of mor-
phology. It has been previously shown that p16/Ki-67 dual-stain shows substantial to 
good reproducibility with almost identical performance by novice evaluators compared 
with reference evaluations, indicating that it can be implemented in clinical practice 
with limited training.34,35 The Kappa found in this study was lower-than-expected, 
this might be caused by the overall low quality of the samples. A disadvantage of the 
technique is that it cannot be reliably used on self-sampled material, as cellularity of 
cervical indicator cells in these samples is limited, resulting in a low sensitivity.36 Women 
testing hrHPV-positive on self-samples would therefore still need to visit their doctor 
for an additional clinician-taken cervical smear for triage. As such, in this setting direct 
triage strategies applicable to self-samples like HPV16/18 or other biomarkers such as 
DNA methylation analysis are preferred.7,37 Dual staining neither rules-out the need for 
follow-up, and in case the technique is used as additional triage tool after Pap cytology 
triage, this would result in additional triage-costs. A wide variety of novel triage tests 
for hrHPV-positive women is currently being extensively studied for triage purposes. 
Molecular techniques based on host- and viral DNA methylation markers, and differ-
ences in gene-expression can be used as triage method in the future, possibly even 
with predictive characteristics.38-40 Most of these markers have not yet been sufficiently 
validated to be ready for implementation in screening programs, but among them p16/
Ki-67 dual-stained cytology or host cell DNA methylation analysis, with or without ad-
ditional HPV16/18 genotyping, are attractive options for the near future.41   
An important strength of the study is that the study design is comparable to future 
cervical screening program with primary hrHPV testing. The potential bias of HPV knowl-
edge increases cytology sensitivity and decreases cytology specificity, which gives more 
reason for adding p16/Ki-67 to triage of hrHPV-positive women.9,42 A limitation of this 
study is the large number of samples that had to be excluded because of a limited cell 
count, most likely due to insufficient left-over material, or because of the longer shelf-
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life used in this study than advised by the manufacturer, which was within six weeks of 
collection. 
As most of these samples are expected to be negative (because if a dual-stained cell 
was visible, the sample was scored as positive), the specificities found in this study might 
be an underestimation, with a slight overestimation of sensitivity. Another potential bias 
could be the fact that this study was performed in a non-responder population, this 
might result in slightly different results in a responder population with an expected 
lower hrHPV positivity rate.   
The Netherlands and Australia will be among the first countries to initiate full hrHPV-
based organized cervical cancer screening. It is expected that an increasing number of 
countries will also replace Pap cytology-based screening with hrHPV-based screening. 
The high sensitivity, reproducibility of the test, and possibility of high-throughput 
testing, are advantages of hrHPV-based screening. Triage with cytology is an obvious 
option because of the widespread knowledge on this technique. In line with others, our 
results indicate that the specificity of triage in hrHPV-based screening programs can 
be increased by replacing Pap cytology with p16/Ki-67 dual stain, or adding dual-stain 
cytology as an additional triage step for low-grade Pap cytology. 
Because the quality of Pap cytology worldwide varies, and two of the selected strate-
gies are based on quality of Pap cytology and differences in sensitivity and specificity 
are limited, it would be preferable to choose for primary p16/Ki-67 dual-stain triage of 
hrHPV-positive women. We therefore conclude that p16/Ki-67 dual-stained cytology 
of hrHPV-positive women shows increased specificity for ≥CIN3 with a maintained ad-
equate sensitivity compared with Pap cytology in triage of hrHPV-positive women. 
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AbsTrACT
Objective Studies of see-and-treat management of cervical intraepithelial neoplasia 
(CIN) vary in their inclusion criteria, resulting in a broad range of overtreatment rates. 
To determine overtreatment rates in see-and-treat management of women referred for 
colposcopy because of suspected CIN, in order to define circumstances supporting see-
and-treat management.
Methods MEDLINE, EMBASE, and the Cochrane Library were searched from inception 
up to 12 May 2014. Studies of see-and-treat management in women with a reported 
cervical smear result, colposcopic impression, and histology result were included. 
Methodological quality was assessed with the Newcastle-Ottawa scale. We used the 
inverse variance method for pooling incidences, and a random effects model was used 
to account for heterogeneity between studies. Overtreatment was defined as treatment 
in patients with no CIN or CIN1. 
results Thirteen studies (n= 4,611) were included. The overall overtreatment rate in 
women with a high-grade cervical smear and a high-grade colposcopic impression was 
11.6% (95% confidence interval (CI) 7.8-15.3). The overtreatment rate in women with a 
high-grade cervical smear and low-grade colposcopic impression was 29.3% (95% CI 
16.7-41.9), and in the case of a low-grade smear and high-grade colposcopic impres-
sion it was 46.4% (95% CI 15.7-77.1). In women with a low-grade smear and low-grade 
colposcopic impression, the overtreatment rate was 72.9% (95% CI 68.1-77.7).
Conclusion The pooled overtreatment rate in women with a high-grade smear and 
high-grade colposcopic impression is at least comparable with the two-step procedure, 
which supports the use of see-and-treat management in this subgroup of women.
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InTrOduCTIOn
Cervical cancer is the fourth most common cancer in women worldwide, with about 
half a million newly diagnosed cases per year.1 Cervical cancer screening has decreased 
the incidence of cervical cancer in the last decades, especially in the developed world.2,3 
Women with abnormal cervical smears are generally referred for a diagnostic colpos-
copy. Low-grade cervical intraepithelial lesions ((CIN) grade 1), are usually monitored by 
watchful waiting, and regress to normal without treatment in the majority of cases.4 In 
high-grade intraepithelial lesions (CIN grade 2 or worse), treatment is recommended in 
most cases. The two-step procedure is generally accepted and consists of initial colpos-
copy with biopsy, followed by treatment at a second visit if the biopsy shows CIN2 or 
worse. The overtreatment rate of this procedure varies between 11 and 35%.5-13 Different 
definitions of overtreatment are described iI the literature, but in this systematic review 
overtreatment is defined as the percentage of women undergoing treatment without 
the presence of a high-grade lesion. The main reason for overtreatment in a two-step 
procedure is probably the limited concordance between biopsy and histology of the 
excised lesion, varying between 71.4 and 85.8%,5,6,9,14,15 mainly caused by high intra- and 
inter-observer variability. 
A see-and-treat procedure of cervical abnormalities combines colposcopy and 
treatment of the lesion in one visit, with subsequently higher patient compliance, 
lower treatment costs, and less emotional stress and anxiety for the women.16-21 A 
loop electrosurgical excision procedure (LEEP) is performed immediately under local 
anesthesia when the colposcopist is convinced that the cervical lesion is a high-grade 
CIN. The overtreatment rate for this procedure varies between 13.3 and 83.3%,17 with 
a subsequent risk of morbidity (hemorrhage, infection and cervical stenosis),16,22,23 and 
increased risk of future premature labor due to cervical insufficiency.24-27 
Many studies of this see-and-treat strategy have been performed, including different 
patient groups, with wide ranges in age and referral cervical smear criteria, with different 
thresholds to perform a see-and-treat LEEP, and with a variety of excision techniques. 
These studies show a broad range of overtreatment rates for suspected high-grade 
intraepithelial lesions,17 which makes it difficult to establish in which cases see-and-treat 
management is justified or should be avoided. 
The objective of this systematic literature review is to estimate overtreatment rates of 
see-and-treat management of women requiring colposcopic evaluation for suspected 
CIN, in relation to the referral cervical smear and colposcopic impression, in order to 
define circumstances supporting see-and-treat management. 
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MeTHOds
We searched MEDLINE, EMBASE, and the Cochrane Library from inception up to 12 May 
2014 for studies of see-and-treat management in women with suspected CIN (Supple-
mental material Table S1). The search query combined synonyms for see-and-treat 
management, CIN, colposcopy and LEEP. We also performed a reference, related article, 
and conference proceedings search. Duplicate articles were manually filtered using the 
bibliographic database of EndNote version X5.
Studies were eligible for inclusion if the following criteria were fulfilled. 1) A preceding 
cervical smear had to be reported. Atypical squamous cells of undetermined significance 
(ASC-US) and low-grade intraepithelial lesion (LSIL) cervical smear results were defined 
as low-grade, whereas high-grade squamous intraepithelial lesion (HSIL) and atypical 
squamous cells (ASC-H) smear results were defined as high-grade. 2) A colposcopic 
evaluation with LEEP was performed in one visit, with a colposcopic impression dif-
ferentiating between high- and low-grade CIN. 3) A histological outcome was reported, 
classified as low-grade with a histology result of no CIN, or CIN1, and as high-grade when 
the histology result was CIN2 or worse. 4) At least ten or more see-and-treat patients 
were included. Language was restricted to English. Two reviewers (RMFE and RLMB) 
independently assessed the eligibility of the identified papers. Any disagreements were 
resolved by discussion with a third reviewer (MMR).  
From the relevant articles, we extracted information on study design, characteristics, 
number of participants, and outcomes. The primary outcome of interest was overtreat-
ment, which we defined as treatment in patients with a final histopathology result of no 
CIN or CIN1. Two reviewers independently determined the quality score of the included 
studies according to the Newcastle-Ottawa scale for cohort studies, with a maximum 
score of nine stars.28 Seven stars or higher is considered high quality, between four and 
six stars is considered intermediate quality, and between one and three stars is consid-
ered low quality. We designed the review protocol in accordance with Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for reporting 
of meta-analyses, which was registered in PROSPERO (CRD42014010440). 
Individual study results in different subgroups were plotted: 1) a high-grade referral 
cervical smear and a high-grade colposcopic impression; 2) a high-grade referral cervi-
cal smear and low-grade colposcopic impression; 3) a low-grade referral cervical smear 
and a high-grade colposcopic impression; and 4) a low-grade referral cervical smear and 
a low-grade colposcopic impression. The inverse variance method was used for pooling 
incidences and to calculate the corresponding 95% confidence intervals (CI). The I2 test 
was used to measure heterogeneity. As heterogeneity between studies was expected, 
a random-effects meta-analysis was used for the primary analyses. A fixed value of 0.5 
was added to all cells of a table in the groups where a zero-cell count was observed, 
Evidence Supporting See-and-Treat Management of Cervical Intraepithelial Neoplasia
87
5
in order to calculate standard error.29 Sensitivity analyses were performed to study the 
effect of small studies on the overtreatment rate by excluding studies with less than 100 
included see-and-treat patients, and to study the effect of excluding the largest study by 
Bosgraaf et al. Review Manager version 5.0 was used for all analyses. We followed both 
the Meta-analysis of Observational Studies in Epidemiology (MOOSE) and the PRISMA 
guidelines in reporting the results.30 
resulTs
We retrieved 3,732 publications (Figure 1), of which 66 were considered potentially 
eligible. Studies were excluded because they appeared to be duplicates (n=1,221), not 
relevant (n=2,441), or written in a non-English language (n=4). After reading the full text, 
another 53 studies were excluded because they did not meet the inclusion criteria: three 
studies did not include see-and-treat patients; ten studies were unable to differentiate 
see-and-treat patients from other patient groups; nine studies did not report on cervical 
smear results; and two did not report on histology results. In another 18 studies, it was 
not possible to define the colposcopic impression, and in 11 studies it was not possible 
to link cervical smear, colposcopic impression and histology result. Finally, 13 studies 
were included, representing 4,611 see-and-treat patients.
Table 1 summarizes the characteristics of the different studies. Four studies included 
women with high- and low-grade cervical smear results, and nine studies only included 
women with high-grade cervical smear results. Seven studies included women with 
low- and high-grade colposcopic impression and six studies only included women with 
high-grade colposcopic impression. All 13 studies included women with high-grade 
cervical smear and high-grade colposcopic impression. The overall quality of the studies 
was moderate to high (Supplemental material Table S2). 
In women with a high-grade cervical smear and a high-grade colposcopic impression 
(n=3,403), the pooled overtreatment rate is 11.6% (95% CI 7.8-15.3; I2=90%) (Figure 2). In 
the seven studies that include only women with a high-grade smear and low-grade col-
poscopic impression (n=374), the pooled overtreatment rate is 29.3% (95% CI 16.7-41.9; 
I2=80%) (Figure 3). In Figure 4, the subgroup of women with a low-grade cervical smear 
and high-grade colposcopic impression (n= 506) is shown. The pooled overtreatment 
rate is 46.4% (95% CI 15.7-77.1; I2=98%). In the subgroup of women with a low-grade 
smear and low-grade colposcopic impression (n=328), shown in Figure 5, the pooled 
overtreatment rate is 72.9% (95% CI 68.1-77.7; I2=0%). The sensitivity analysis excluding 
small studies, did not change the interpretation of our results. The sensitivity analysis, 
excluding the largest study by Bosgraaf et al., did not result in clinically significant 
changes in the data.  
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dIsCussIOn
Our review shows that an overtreatment rate of 11.6% in see-and-treat management of 
women with a high-grade smear and high-grade colposcopic impression is at least com-
parable with the two-step overtreatment rates reported in literature, varying from 11 to 
35%. This observation supports the see-and-treat strategy in this subgroup of women, 
who also benefit from the additional advantages of undergoing a slingle procedure.
In women with discrepancy between the cervical smear and colposcopic impression, 
we report an overtreatment rate that is higher than the two-step overtreatment rate. We 
therefore believe that in these two subgroups a biopsy prior to treatment is advisable in 
young and fertile women. In women with a completed family, or who are menopauzal 
or sterilized, a see-and-treat procedure may be considered after shared decision-making 
with the patient. In case of a low-grade smear and low-grade colposcopic impression, in 
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Figure 1. Flowchart of the systematic review process, per Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA).
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which we found a high pooled overtreatement rate, there is no indication for see-and-
treat management, unless preferred for other reasons. 
The major strengths of this study are the systematic approach, the inclusion of a large 
number of patients (n=4,611), and the criteria used for inclusion (i.e. reported cervical 
smear, colposcopic impression, and histology). We have provided a comprehensive 
assessment of the risk of overtreatment in four subgroups, which are relevant to both 
clinicians and patients. Some potential limitations should also be discussed. First, impor-
tant information regarding age of the patients are not included in our analyses, as these 
were either not reported or reported in such a heterogeneous way that stratification of 
the analysis was not possible. Our quality assessment shows overall moderate to high 
quality, indicating that there is a low risk of methodological bias. Second, colposcopic 
impression is a subjective measure in the differentiation between high- and low-grade 
CIN, and the quality partially depends on the training and experience of the colposco-
pist, which we were unable to extract from most studies. Third, the study by Bosgraaf et 
Table 1. Characteristics of the included studies.
Author year Country Total 
number of 
patients
Included ‘see-
and-treat’ 
patients
referral 
cervical smear 
Colposcopic 
impression
Aue-aungkul31 2011 Thailand 192 192 ASC-US, ASC-H, 
LSIL, HSIL, 
Carcinoma
Low-grade, high-
grade
Bosgraaf16 2013 The Netherlands 4,808 2,335 ASC-US, ASC-H, 
LSIL, HSIL, 
Carcinoma
Low-grade, high-
grade
Charoenkwan32 2004 Thailand 55 51 HSIL Normal, low-grade, 
high-grade
Cho5 2009 South-Korea 1,011 432 Normal, ASC-
US, LSIL, HSIL
High-grade
Errington33 2006 UK 607 378 HSIL High-grade
Irvin34 2002 USA 61 50 HSIL High-grade
Kietpeerakool35 2009 Thailand 108 58 ASC-H Normal, low-grade, 
high-grade
Megevand36 1996 South-Africa 2,619 22 HSIL High-grade
Monteiro37 2009 Brazil 900 294 HSIL High-grade
Sadan9 2007 Israel 144 79 HSIL High-grade
Smith38 2001 UK 870 461 LSIL, HSIL Normal, low-grade, 
high-grade
Suntornlimsiri39 2004 Thailand 592 167 HSIL Low-grade, high-
grade
Szurkus40 2002 USA 104 92 HSIL Normal, low-grade, 
high-grade
Total 12,071 4,611
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Study Number of 
patients
Overtreatment 
rate (%)
No CIN/ 
low-grade CIN
High-grade CIN/ 
carcinoma
  Aue-aungkul 2011 110 7.3 8 102
  Bosgraaf 2013 1543 4.5 70 1473
  Charoenkwan 2004 46 4.3 2 44
  Cho 2009 287 18.1 52 235
  Errington 2006 378 15.6 59 319
  Irvin 2002 50 18.0 9 41
  Kietpeerakool 2009 40 10.0 4 36
  Megevand 1996 22 0.0 0 22
  Monteiro 2009 294 8.8 26 268
  Sadan 2007 79 29.1 23 56
  Smith 2001 380 13.7 52 328
  Suntornlimsiri 2004 140 7.9 11 129
  Szurkus 2003 34 29.4 10 24
Total 3403 11.6 326 3077
Incidence
(95% CI)
0.07 (0.02 to 0.12) 
0.05 (0.04 to 0.06)
0.04 (0.00 to 0.11) 
0.18 (0.14 to 0.23)
0.16 (0.12 to 0.19)
0.18 (0.07 to 0.29)
0.10 (0.00 to 0.20)
0.00 (0.00 to 0.06) 
0.09 (0.06 to 0.12)
0.29 (0.19 to 0.39)
0.14 (0.10 to 0.17)
0.08 (0.03 to 0.12)
0.29 (0.14 to 0.45)
0.12 (0.08 to 0.15)
  Heterogeneity: I2 = 90%
0 0.25 0.50
Incidence
(95% CI)
Overtreatment rate
Figure 2. Forest plot of overtreatment rate in women with a high-grade cervical smear and high-grade 
colposcopic impression.
Study Number of 
patients
Overtreatment 
rate (%)
No CIN/ 
low-grade CIN
High-grade CIN/ 
carcinoma
  Aue-aungkul 2011 23 26.1 6 17
  Bosgraaf 2013 238 28.6 68 170
  Charoenkwan 2004 5 0.0 0 5
  Kietpeerakool 2009 18 66.7 12 6
  Smith 2001 5 0.0 0 5
  Suntornlimsiri 2004 27 37.0 10 17
  Szurkus 2003 58 41.4 24 34
Total 374 29.3 120 254
Incidence
(95% CI)
0.26 (0.08 to 0.44) 
0.29 (0.23 to 0.34)
0.00 (0.00 to 0.22) 
0.67 (0.45 to 0.88)
0.00 (0.00 to 0.22)
0.37 (0.19 to 0.55)
0.41 (0.29 to 0.54)
0.29 (0.17 to 0.42)
Heterogeneity: I2 = 80%
0 0.5 1.0
Incidence
(95% CI)
Overtreatment rate
Figure 3. Forest plot of overtreatment rate in women with a high-grade cervical smear and low-grade col-
poscopic impression. 
Study Number of 
patients
Overtreatment 
rate (%)
No CIN/ 
low-grade CIN
High-grade CIN/ 
carcinoma
  Aue-aungkul 2011 40 42.5 17 23
  Bosgraaf 2013 257 29.2 75 182
  Cho 2009 145 82.1 119 26
  Smith 2001 64 31.3 20 44
Total 506 46.4 231 275
Incidence
(95% CI)
0.43 (0.27 to 0.58) 
0.29 (0.24 to 0.35)
0.82 (0.76 to 0.88) 
0.31 (0.20 to 0.43)
0.46 (0.16 to 0.77)
Heterogeneity: I2 = 98%
0 0.5 1.0
Incidence
(95% CI)
Overtreatment rate
Figure 4. Forest plot of overtreatment rate in women with a low-grade cervical smear and high-grade col-
poscopic impression.  
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al.16 includes a large proportion of the total of patients included in this meta-analysis. 
Sensitivity analysis excluding this study showed no clinically significant changes in the 
data. Fourth, the heterogeneity between studies was considerable, resuling in a wide 
confidence interval. Fifth, we found some asymmetry in the funnel plots, suggesting 
publication bias and, in particular, that smaller low-quality studies might not have been 
published. Our sensitivity analyses, however, showed that our results were robust to 
the removal of small studies, so we do not expect that any unpublished smaller studies 
would change our results.
Our results are largely in agreement with the guidelines of the American Society for 
Colposcopy and Cervical Pathology (ASCCP), although they do not include colposcopic 
impression as a criterion for see-and-treat management. The ASCCP guideline states 
that it is acceptable to treat women with a high-grade smear according to the see-
and-treat strategy, except in case of pregnancy or age between 21-24 years old.41 We 
believe it would be an addition to include the colposcopic impression as a prerequisite, 
because our results confirm an increased overtreatment rate in low-grade colposcopic 
impression as compared with high-grade colposcopic impression, in women with a 
high-grade smear. Our results are also in agreement with the guideline of the European 
Federation for Colposcopy and Pathology of the Lower Genital Tract (EFC), because 
they recommend targeting any CIN in ≥90% of the excised specimens in see-and-treat 
management.42 We show that this percentage is already achievable by a threshold of 
CIN2 or worse, indicating that the EFC guideline may be adjusted accordingly. The EFC 
and the guidelines of the British National Health Services Cervical Screening Programme 
(NHSCSP) advise not to perform a see-and-treat strategy in borderline or mild dyskaryo-
sis smears, and only use see-and-treat management in exceptional cases, which is in 
line with our results. Regarding quality control, we agree with the NHSCSP in using see-
and-treat management in this group of women only when an audit has identified that 
CIN2/3 or high-grade cervical glandular intraepithelial neoplasia is present in ≥90% of 
the excised specimens.43 
In conclusion, our findings suggest that the use of see-and-treat management is 
supported by evidence in women with a high-grade smear and high-grade colposcopic 
Figure 5. Forest plot of overtreatment rate in women with a low-grade cervical smear and low-grade col-
poscopic impression. 
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impression. The pooled overtreatment rate in this group is at least comparable with 
the overtreatment rate in the two-step approach (11.6% versus 11-35%). In case of a 
discrepancy between cervical smear and colposcopic impression, a two-step procedure 
remains justifiable. 
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suPPleMenTAl MATerIAl
Table s1. Search strategy for identification of studies in PubMed.
(((see and treat[tiab] OR single session[tiab] OR one session[tiab] OR one visit[tiab] OR single visit[tiab] OR 
single clinic visit[tiab] OR one procedure[tiab] OR three step[tiab] OR combined treatment[tiab] OR diagnostic 
treatment[tiab] OR one stop[tiab] OR single stop[tiab] OR first visit[tiab]) 
AND
(Uterine Cervical Dysplasia[mesh] OR Uterine Cervical Neoplasms[mesh] OR Cervical Intraepithelial 
Neoplasia[mesh] OR cervical intraepithelial[tiab] OR cervical intra-epithelial[tiab] OR CIN[tiab] OR Cervical 
abnormalit*[tiab] OR cervical neoplas*[tiab] OR cervical cancer*[tiab] OR cervical dysplasia[tiab] OR Cervix 
carcinoma*[tiab] OR Cervix cancer*[tiab] OR Cervix dysplasia[tiab])) 
NOT
(radiation[tiab] OR radiotherap*[tiab] OR chemotherap*[tiab])) 
OR 
((“colposcopy”[mesh] OR Colposcop*[tiab]) 
AND
(“conization”[mesh] OR loop excision[tiab] OR LEEP[tiab] OR loop electrosurgical excision procedure[tiab]  
OR LLETZ[tiab] OR LETZ[tiab] OR large loop diathermy excision[tiab] OR LEC[tiab] OR conization*[tiab] OR 
conisation*[tiab]))
Terms used for search strategy in MEDLINE, EMBASE, and The Cochrane Library from inception to May 12th 
2014. Terms with [tiab] reflect free text terms appearing in title or abstract.
Table s2. Risk of bias assessment.
reference selection Comparability Outcomes Final score
Aue-aungkul 2011 **** *** 7 of 9
Bosgraaf 2013 *** * *** 7 of 9
Charoenkwan 2004 *** * *** 7 of 9
Cho 2009 **** ** *** 9 of 9
Errington 2006 *** *** 6 of 9
Irvin 2002 **** * *** 8 of 9
Kietpeerakool 2009  **** *** 7 of 9
Megevand 1996 *** ** *** 8 of 9
Monteiro 2009 *** *** 6 of 9
Sadan 2007 **** *** 7 of 9
Smith 2001 *** * *** 7 of 9
Suntornlimsiri 2004 *** * *** 7 of 9
Szurkus 2002 *** * *** 7 of 9
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AbsTrACT
Objective Numerous new alternative digital colposcopy techniques have been devel-
oped, of which multimodal hyperspectroscopy (MHS) showed a high sensitivity in previ-
ous studies. The objective of this prospective single-center cohort study was to evaluate 
the clinical value of MHS for detecting high-grade cervical intraepithelial neoplasia in a 
colposcopy referral population and colposcopy follow-up population, to assess whether 
MHS could be safely used to improve care for women at risk for high-grade cervical 
intraepithelial neoplasia.  
Methods A total of 125 women from a colposcopy referral population and colposcopy 
follow-up population were evaluated with MHS and tested for the presence of high-risk 
human papillomavirus (hrHPV) with HPV16/18 genotyping. Spectroscopic measure-
ments of the cervix were taken and compared with an endpoint based on histology, 
hrHPV and cytology. Evaluable data for analysis were collected for 102 of the subjects. 
Sensitivity, specificity and predictive values were calculated for MHS and colposcopic 
impression based on conventional colposcopic examination. 
results From the total study population of 102 patients, 47 were enrolled in the col-
poscopy referral group and 55 in the colposcopy follow-up group. The MHS yielded a 
sensitivity of 93.6% (95% CI 78.6-99.2), with a corresponding specificity of 42.3% (95% 
CI 30.6-54.6) in the group with a composite endpoint. No adverse effects occurred, and 
patient acceptability was high. 
Conclusion MHS is a digital colposcopy technique that offers an easy, rapid, well-tol-
erated point-of-care assessment with a high sensitivity for the presence of high-grade 
cervical intraepithelial lesions, however, with a low specificity, resulting in limited clini-
cal value.
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InTrOduCTIOn
Colposcopy involves the visualization of the cervix using a stereoscopic binocular mi-
croscope of low magnification to identify cervical lesions.1 The reported performance of 
colposcopic examination varies because of interobserver and intraobserver variability,2,3 
with an average sensitivity ranging between 55% and 89% and a specificity of 52% to 
85%.4-7 This may result in missed lesions on one hand, and in unnecessary biopsies and 
overtreatment on the other hand. 
To improve colposcopic examination, numerous new alternative digital colposcopy 
techniques have been developed. Previous studies have shown that a digital cervical 
scan based on fluorescence and reflectance spectroscopy, also referred to as multimodal 
hyperspectroscopy (MHS), is a potential method for triage of women at risk for moder-
ate- and high-grade dysplasia.8,9 The technology of multimodal spectroscopy is based 
on the combination of both reflectance characteristics and tissue fluorescence. Fluores-
cent spectra detect metabolic activity of epithelial cells, which change during carcino-
genesis,10 and reflectance spectroscopy detects morphologic changes that occur when 
normal epithelial cells develop into neoplastic cells.11,12 By combining fluorescence and 
reflectance spectroscopy, a prediction of tissue type is obtained, based on morphologic 
and biochemical changes that occur during pathogenesis of neoplasia.
The goal of this study was to provide a prospective evaluation of the clinical value of 
MHS for detecting high-grade cervical intraepithelial neoplasia (CIN) in a Dutch colpos-
copy referral population and colposcopy follow-up population, in order to investigate 
whether MHS could be safely used to improve care for women at risk for high-grade CIN. 
MeTHOds
We conducted a prospective single-center cohort study from November 2014 to Decem-
ber 2015. Women 18 years or older were consecutively evaluated for inclusion before 
their visit to the outpatient clinic of the department of Obstetrics and Gynecology of the 
Radboud university medical center, Nijmegen, the Netherlands. They visited the outpa-
tient clinic for a scheduled colposcopic examination after an abnormal cervical smear 
(defined by the atypical squamous cells of undetermined significance threshold) or a 
scheduled follow-up cervical smear after previous colposcopic examination. Women 
were excluded if; they were pregnant at the time of the examination or if they were 
pregnant in the previous three months, were undergoing treatment for cervical cancer, 
or had received previous pelvic radiotherapy. 
After obtaining informed consent, women were prepared for pelvic examination. 
Multimodal hyperspectroscopy was performed before the colposcopic examination or 
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before a cervical smear was taken. Excessive mucus or blood was removed from the cer-
vix with a gauze. The MHS was calibrated, and the cervical tube was inserted through the 
speculum into the vagina using a live video feed, until the external ostium of the cervix 
was visible and focused in the field of view. Measurements were made automatically 
under software control for one minute. After completion of the scan, a second video 
image was displayed to ensure that the external ostium of the cervix was still in view 
and there was no significant movement. The cervical tube was then removed. The MHS 
results were scored as low risk, moderate risk, and high risk of high-grade CIN. Investiga-
tors and patients were blinded from the MHS output. 
After finishing the MHS scan, colposcopic examination or a follow-up cervical smear 
was performed, according to the Dutch guidelines.13 Colposcopic examination was con-
ducted with the use of acetic acid and Lugol’s solution. Either a biopsy was taken from 
suspicious areas of the cervix, an immediate loop electro-excision procedure (LEEP) was 
performed, or a watchful waiting strategy was conducted. The location of biopsies or a 
LEEP was marked on the MHS scan. 
Expert pathologists from the Department of Pathology at the Radboud university 
medical center, Nijmegen, the Netherlands, assessed all LEEP and biopsy specimens, 
classifying them as follows: no CIN, CIN1, CIN2, CIN3 or cervical cancer. Follow-up cervi-
cal smears were assessed by cytotechnologists from the same department and were 
scored by the Dutch CISOE-A (composition, inflammation, squamous cells, other and 
endometrium, endocervical cylindrical epithelium, adequacy) classification system, 
which can be easily translated into the Bethesda nomenclature.14 Pathologists and 
cytotechnicians were blinded from the output of the MHS scan. 
Cervical smears were analyzed for the presence of high risk human papillomavirus 
(hrHPV), using the clinically validated Cobas 4800 test (Roche). This test detects separate 
results for HPV16 and HPV18 and a pooled result for 12 other hrHPV types (31, 33, 35, 39, 
45, 51, 52, 56, 58, 59, 66, and 68). In the colposcopy follow-up population, the diagnostic 
cervical smear was tested for the presence of hrHPV. In the colposcopy referral popula-
tion, an additional cervical smear for hrHPV testing was taken.
Women were asked to fill out a patient acceptability questionnaire after the MHS. This 
questionnaire consisted of a pain scale from 1 to 5 (1 = no discomfort from the MHS 
scan, 2 =  some discomfort, 3 = painful but tolerable, 4 = painful and the procedure had 
to be paused, and 5 =  a setting too painful to continue without intervention, in which 
case the spectroscopic evaluation had to be stopped).  
Up to the 6-month follow-up, data on cytology and histology results were collected. 
This study was approved by the local medical research ethics committee, region Arnhem 
Nijmegen with number 2014-1171, and informed consent from all women enrolled in 
the study was obtained.
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Sensitivity, specificity, positive predictive value (PPV), and negative predictive value 
(NPV), with 95% confidence Intervals (CI) were calculated. First for the colposcopic im-
pression based on conventional colposcopic examination and second for the results of 
the MHS scan as a total group, as well as for different subgroups. Two major subgroups 
are the colposcopy follow-up group and the colposcopy referral group, of which the 
second was subdivided according to the cytology referral result differentiating between 
low-grade and high-grade referral cervical smears. Low-grade referral cervical smears 
include atypical squamous cells of undetermined significance (ASC-US) and low-grade 
squamous intraepithelial lesions cytology (LSIL), and the high-grade group is repre-
sented by high-grade squamous intraepithelial lesions referral cervical smears (HSIL). 
The primary endpoint was based on histology, with either an immediate histology result 
or a 6-month follow-up histology result, or a double- negative cervical smear with a 
negative for intraepithelial lesion or malignancy (NILM) cytology result and a negative 
hrHPV test. Pap cytology alone was used as adjusted endpoint if no primary endpoint 
was available. A composite outcome was obtained using the adjusted endpoints com-
bined with the primary endpoints. A positive (high-grade) endpoint was defined by 
CIN2 or worse (≥CIN2) histology or high-grade squamous intraepithelial lesion or worse 
(≥HSIL) cytology, and a negative endpoint was defined by CIN1 or less (≤CIN1) histol-
ogy, or low-grade squamous intraepithelial lesion or less (≤LSIL) cytology. A colposcopic 
impression of ≥CIN2 was considered positive, and a colposcopic impression of ≤CIN1 
was considered negative. High-risk and moderate-risk MHS results were classified as a 
positive scan result, and low-risk MHS results were classified as negative. 
True positives were defined by all women with a positive scan result and a positive, 
high-grade endpoint. True negatives were women with a negative scan result, and a 
negative, low-grade endpoint. False positives were defined as women with a positive 
scan result and a negative endpoint, and false negatives were women with negative 
scan result and a positive endpoint. The McNemar test was used to compare sensitivity 
and specificity of the colposcopic impression with the sensitivity and specificity of MHS 
in women with a primary and composite endpoint.
resulTs
In total, 152 women fulfilled the inclusion criteria, signed informed consent, and were 
enrolled in the study. In 27 cases (18%), the scan could not be performed; in 13 cases the 
speculum could not be opened wide enough because of pain, in nine cases the device gave 
a technical error, in three cases the calibration time was overdue and there was no time 
for a second calibration, in one case there was too much blood on the cervix, and in one 
case the external ostium could not be visualized. The MHS scan was therefore performed in 
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125 women. In 22 cases (14%), the scan result was invalid, and one woman was diagnosed 
with vaginal intraepithelial neoplasia, which caused the abnormal smear, and was therefore 
excluded from this study, resulting in 102 valid MHS scans (Figure 1). The median age of 
the included 102 women was 37 years, with a range from 20 to 57 years. The study group 
consisted of 55 women in the colposcopy follow-up group, who visited the outpatient 
clinic for a follow-up cervical smear after colposcopic examination, and the 47 women in 
the colposcopy referral group, who visited the clinic for a colposcopic examination. From the 
colposcopy referral group, 31 women visited the outpatient clinic with a low-grade cytology 
referral result and 16women visitied theoutpatient clinic with a high-grade cytology referral 
result. The composite endpoint with regard to the reason for visiting the outpatient clinic is 
shown in Table 1. An high-grade squamous intraepithelial lesion endpoint was found in 16% 
of the colposcopy follow-up group and in 47% of the colposcopy referral group, with the 
highest percentage of 87.5% in the subgroup of women with a high-grade cytology refer-
ral result. Table 2 shows the hrHPV prevalence for each subgroup of reason for visiting the 
outpatient clinic. The colposcopy referral group with high-grade referral cytology yields the 
highest HPV16/18 prevalence with 47%, and in women referred for colposcopic examination 
with low-grade cytology, the lowest hrHPV prevalence of 24% is shown.
Signed informed consent and enrolled in the study
n = 152
MHS scan result
n = 125
Valid MHS scan result available for analysis
n = 102
Primary endpoints n = 73
- CIN3 n = 18
- CIN2 n = 13
- CIN1 n = 6
- No CIN n = 5
- Considered no CIN* n = 31
Adjusted endpoints n = 29
- LSIL n = 4
- ASC-US n = 17
- NILM, HPV+ n = 8
Excluded n = 23
- Invalid scan result n = 22
- Vaginal intraepithelial lesion n = 1
Exclded n = 27
- Scan could not be performed n = 27
Figure 1. Trial Profile. 
*Women with a cytology test result negative for intraepithelial lesion or malignancy (NILM) and an hrHPV-
negative test are considered to have no CIN. ASC-US = atypical squamous cells of undetermined signifi-
cance; CIN = cervical intraepithelial neoplasia; HPV = human papillomavirus; LSIL = low-grade squamous 
intraepithelial lesion; MHS = multimodal hyperspectroscopy.
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Table 3 shows the sensitivity, specificity, PPV and NPV with 95% CI for the colposcopic 
impression based on conventional colposcopic examination and for the total MHS group 
as well as for the different subgroups with a composite endpoint. For all subgroups com-
bined, the sensitivity of MHS for high-grade lesions was 93.6% (95% CI 78.6-99.2), with 
a specificity of 42.3% (95% CI 30.6-54.6). When MHS would be used as a triage method 
to lower colposcopy referrals, six (13%) of the 47 women would not have been referred 
for colposcopic examination, of which five without a high-grade lesion, and one with 
a HPV16/18 positive CIN2 lesion. Sensitivity of the colposcopic impression was 72.7% 
(95% CI 49.8-89.3), with a specificity of 88.0 (95% CI 68.8-97.5), with six missed high-
grade lesions when no biopsy would have been taken. In the group of women visiting 
the outpatient clinic for a follow-up smear after previous colposcopic examination, eight 
women with high-grade lesions would have been detected with the MHS scan, and one 
HPV16/18 positive CIN3 would have been missed. Thus, the MHS in the colposcopy ex-
amination group had a significant (P<0.001) higher sensitivity but lower specificity than 
the colposcopic impression based on conventional colposcopic examination.
Table 1. Prevalence of composite endpoints in each group. 
normal endpoint (%) lsIl endpoint (%) HsIl endpoint (%) Total
Colposcopy referral group 6 (13%) 19 (40%) 22 (47%) 47
     Low-grade cytology referral 4 (13%) 19 (61%) 8 (26%) 31
     High-grade cytology referral 2 (12.5%) 0 (0%) 14 (87.5%) 16
Colposcopy follow-up group 38 (69%) 8 (15%) 9 (16%) 55
Total 44 (43%) 27 (27%) 31 (30%) 102
HSIL = high-grade squamous intraepithelial lesion; LSIL= low-grade squamous intraepithelial lesion.
Table 2. hrHPV prevalence in each group.
HPV16/18 positive 
(%)
Other hrHPV-
positive (%)
hrHPV negative 
(%)
Total
Colposcopy referral group 13 (33%) 16 (40%) 11 (27%) 40
     Low-grade cytology referral 6 (24%) 13 (52%) 6 (24%) 25
     High-grade cytology referral 7 (47%) 3 (20%) 5 (33%) 15
Colposcopy follow-up group 19 (37%) 9 (17%) 24 (46%) 52
Total 32 (35%) 25 (27%) 35 (38%) 92
Of the total of 102 cases, ten hrHPV results were missing. 
Of the total group, 73 women had a primary endpoint. The sensitivity of MHS for this 
group with a primary endpoint is 93.6% (95% CI 78.6-99.2), with a specificity of 47.6% 
(95% CI 32.0-63.6). For the colposcopic impression the sensitivity is 72.7% (95% CI 49.8-
89.3), with a specificity of 72.7% (95% CI 39.0-94.0) (Table 4). In addition, in this group, 
MHS had a significant (P<0.004) higher sensitivity with a lower specificity compared 
with the colposcopic impression based on conventional colposcopic examination.
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Table 3. Sensitivity, specificity, PPV, and NPV for each group with a composite endpoint. 
TP FP Tn Fn
sensitivity 
(95% CI)
specificity 
(95% CI)
PPV
(95% CI)
nPV
(95% CI)
Colposcopic impression 
based on conventional 
colposcopy
16 3 22 6
72.7
(49.8-89.3)
88.0
(68.8-97.5)
84.2
(60.4-96.6)
78.6
(59.1-91.7)
MHs scan
Colposcopy referral group 21 20 5 1
95.5
(77.2-99.9)
20.0
(6.8-40.7)
51.2
(35.1-67.1)
83.3
(35.9-99.6)
      Low-grade cytology 
referral
7 18 5 1
87.5
(47.4-99.7)
21.7
(7.5-43.7)
28.0
(12.1-49.4)
83.3
(35.9-99.6)
      High-grade cytology 
referral
14 2 0 0
100
(76.8-100)
0.0
(0.0-84.2)
87.5
(61.7-98.5)
NA
Colposcopy follow-up 
group
8 21 25 1
88.9
(51.8-99.7)
54.4
(39.0-69.1)
27.6
(12.7-47.2)
96.2
(80.4-99.9)
Total MHs 29 41 30 2
93.6
(78.6-99.2)
42.3
(30.6-54.6)
41.4
(29.8-53.8)
93.8
(79.2-99.2)
CI = confidence interval; FN = false negative; FP = false positive; MHS = multimodal hyperspectroscopy; 
NPV = negative predictive value; PPV = positive predictive value; TN = true negative; TP = true positive. 
Table 4. Sensitivity, specificity, PPV, and NPV for each group with a primary endpoint.
TP FP Tn Fn
sensitivity 
(95% CI)
specificity 
(95% CI)
PPV
(95% CI)
nPV
(95% CI)
Colposcopic impression 
based on conventional 
colposcopy
16 3 8 6
72.7
(49.8-89.3)
72.7
(39.0-94.0)
84.2
(60.4-96.6)
57.1
(28.9-82.3)
MHs scan
Colposcopy referral group 21 9 2 1
95.5
(77.2-99.9)
18.2
(2.3-51.8)
70.0
(50.6-85.3)
66.7
(9.4-99.2)
      Low-grade cytology  
referral
7 7 2 1
87.5
(47.4-99.7)
22.2
(2.8-60.0)
50.0
(23.0-77.0)
66.7
(9.4-99.2)
      High-grade cytology 
referral
14 2 0 0
100
(76.8-100)
0.0
(0.0-84.2)
87.5
(61.7-98.5)
NA
Colposcopy follow-up 
group
8 13 18 1
88.9
(51.8-99.7)
58.1
(39.1-75.5)
38.1
(18.1-61.6)
94.7
(74.0-99.9)
Total MHs 29 22 20 2
93.6
(78.6-99.2)
47.6
(32.0-63.6)
56.9
(42.3-70.7)
90.9
(70.8-98.9)
CI = confidence interval; FN = false negative; FP = false positive; MHS = multimodal hyperspectroscopy; 
NPV = negative predictive value; PPV = positive predictive value; TN = true negative; TP = true positive. 
No adverse effects were reported. Patient acceptability of the scan was high with an 
84% score of no discomfort, one paused MHS examination, and an average score of 1.14 
(95% CI 1.06-1.22) on the acceptability questionnaire (Table 5). 
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Table 5. Patient acceptability of the MHS digital colposcopy scan.
number (%)
No discomfort 86 (84%)
Some discomfort 9 (9%)
Painful but tolerable 2 (2%)
Painful and the procedure had to be paused 1 (1%)
Too painful to continue without intervention 0 (0%)
Missing 4 (4%)
dIsCussIOn
The overall sensitivity of the MHS device for detecting high-grade cervical lesions is 
significantly higher compared with the colposcopic impression based on conventional 
colposcopic examination. The scan also shows good patient acceptability. The specific-
ity of the MHS device is, however, significantly lower, resulting in a limited clinical value. 
Our results are in line with previously published studies performed with the MHS de-
vice. Early studies have shown the value of this technique in identifying CIN lesions.15-17 
A more recent large study by Twiggs et al.8 included 1,607 women from a colposcopy re-
ferral population. The MHS scan was well tolerated and resulted in a sensitivity of 91.3% 
(95% CI 87.3-94.3), and a specificity of 38.9% (95% CI 34.9-43.1) for ≥CIN2. A second 
study by DeSantis et al.9 included 572 women from a colposcopy referral population 
and a colposcopy follow-up population, similar to our population. They also concluded 
that the test was simple to implement, well accepted by subjects and showed a high 
sensitivity with a limited specificity. In a recent systematic review, six studies on MHS 
were analyzed and a meta-analysis of 2,530 women included in these studies showed an 
overall sensitivity of 93% (95% CI 89-95) and specificity of 62% (95% CI 47-76). The MHS 
technique was compared with two other digital colposcopy techniques of which MHS 
showed the highest sensitivity, but not the highest specificity.18 A difference between 
this study and the previously performed studies is that this study has been performed 
with a newer and improved device, which only needs 1 minute of scan time, compared 
with the older devices which needed at least 4.5 minutes of scan time. 
The sensitivity of MHS is highest in women with a high-grade cervical smear who vis-
ited the outpatient clinic for colposcopic examination. It is, however, debatable whether 
this group of women needs triage before colposcopic examination after a high-grade 
cytology referral smear, because  more than 90% of women with a high-grade referral 
smear indeed show a high-grade lesion.19 In triage of women with a low-grade cytology 
referral smear, the MHS may be of more value. In this group of women with a histologic 
endpoint, the sensitivity of MHS was 87.5% (95% CI 47.4-99.7), compared with 72.7% 
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(95% CI 49.8-89.3) of conventional colposcopic examination. However, only six women 
(19.4%) with low-grade referral smears would not have been referred, of which one with 
a high-grade CIN lesion, and the specificity of MHS was much lower compared with the 
colposcopic impression. In the colposcopy follow-up population, the MHS scan might 
play a role in identifying women with a high risk on high-grade cervical lesions during 
follow-up. The MHS scan showed a positive result for 30 women, of which eight were true 
positives, and 26 women would not have been referred for colposcopic examination, of 
which one would be a false negative, resulting in one missed ≥CIN2 lesion. Follow-up 
with MHS may however be more costly compared with Pap cytology follow-up, and it 
does not rule out the need for visiting a doctor or use of a speculum. 
Advantages of implementing MHS before colposcopic examination are the high 
sensitivity and increased NPV of MHS, compared with the colposcopic impression based 
on conventional colposcopic examination. This is important because it results in a low 
number of missed high-grade CIN lesions, and a negative MHS results gives a high as-
surance of the absence of a high-grade CIN lesion. Another advantage may be that the 
device can be used by a trained healthcare worker without colposcopic experience, it is 
less time-consuming compared with conventional colposcopy, and therefore possibly 
cheaper. However, the specificity and PPV of the MHS scan are low, resulting in a large 
proportion of women still being referred for conventional colposcopic examination. This 
large proportion of women will contain a high number of false positives which are still 
referred for conventional colposcopic examination. This may result in high costs of MHS 
per woman not referred for conventional colposcopic examination, making it less likely 
to be cost-effective to use MHS as an additional step before conventional colposcopic 
examination. Another limitation of the test is the absence of knowledge on clinical value 
of the MHS scan on detecting lesions in the endocervical canal. In our study, no women 
with endocervical high-grade lesions were included; it was therefore impossible to 
determine if the MHS scan detects lesions limited to the endocervix. 
From the total group of 152 women, the scan could not be performed in 27 women 
(18%). The most frequent reason was because of too much pain by opening the specu-
lum wide enough for the cervical guide to pass. The size of the cervical guide should, 
however, not be smaller because a certain size is needed for scanning the entire cervix at 
once. Other options would be a device that can be used without a speculum or a smaller 
device with a point-probe technique for multiple measurements; this might, however, 
be less easy to use. Furthermore, patient support might need improvement to obtain a 
better state of relaxation for the patient, resulting in less complaints of pain by opening 
the speculum.  The second most frequent reason why the scan could not be performed 
was due to technical errors, which should be addressed by the manufacturer. Another 
22 women (14%) were excluded because of an invalid scan result, which could possibly 
be avoided by better cleaning the cervix before scanning. In our study the device was on 
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study setting, and we could not see if the scan was valid; in a clinical setting this would 
indeed be possible and a new scan could be performed after cleaning the cervix again. 
Not all women from the colposcopy follow-up group and colposcopy referral group had 
a histologic endpoint. Results from the composite endpoint were therefore based on cy-
tology results and histology results combined. This may have caused bias of the results. 
However, sensitivity, specificity, and predictive values did not differ much between the 
primary endpoint group and the group with a composite endpoint. 
An increasing number of countries are on the verge of implementing hrHPV-based 
cervical cancer screening. This screening strategy has a high sensitivity, but a limited 
specificity, which is a result of the assays’ inability to distinguish transient from persis-
tent hrHPV infections. This limited specificity of hrHPV-based screening will result in an 
increased number of referrals for colposcopic evaluation, with the risk of unnecessary 
colposcopic examination and unnecessary treatment.20 Referral rates for conventional 
colposcopic examination could possibly be reduced by implementing digital colpos-
copy techniques as triage method to separate women with a high risk of high-grade 
CIN in need of colposcopic examination, from women with a low risk of high-grade CIN, 
which could be managed with follow-up smears. Sensitivity of a technique needs to be 
high to safely limit missing high-grade lesions, and a decent specificity should limit the 
number of unnecessary referrals. 
In summary, cervical multimodal hyperspectroscopy is a digital colposcopy technique 
that offers an easy, rapid, well tolerated point-of-care assessment with a high sensitivity 
for the presence of high-grade CIN lesions, but with low specificity, and a failure to pro-
duce a result in 32% in this study, resulting in a limited clinical value. A large study in an 
hrHPV-positive population should point out whether this MHS scan may be safely used 
to limit colposcopy referrals from a population-based screening program, especially in 
the group with low-grade cytology results.
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AbsTrACT
Objective To assess the diagnostic value of alternative (digital) colposcopy techniques 
for detection of cervical intraepithelial neoplasia (CIN) 2 or worse in a colposcopy popu-
lation.
Methods MEDLINE, EMBASE, ClinicalTrials.gov, and the Cochrane Library were searched 
from inception up to January 11, 2016, for studies that evaluated the diagnostic value 
of alternative (digital) colposcopy techniques. Inclusion criteria were: 1) an alternative 
(digital) colposcopy technique was used in a colposcopy population; 2) A histological 
outcome was reported, classified as CIN, differentiating between mild dysplasia or less 
(≤CIN1), and moderate dysplasia or worse (≥CIN2); 3) The entire cervix was scanned 
at once, or a per-woman analysis was performed; 4) No other topical application than 
acetic acid and Lugol’s solution was used; 5) At least three eligible studies had to be 
available within a single technique; and 6) Studies obtained research ethics approval. 
Language was restricted to English. 
results Two reviewers assessed the eligibility of the identiﬁed articles. Disagreements 
were resolved by a third reviewer. Thirteen studies met the inclusion criteria. We found 
six studies on fluorescence and reflectance spectroscopy, including 2,530 women, with 
a pooled sensitivity of 93% (95% confidence interval (CI) 89-95), and specificity of 62% 
(95% CI 47–76). Four studies on dynamic spectral imaging were found including 1,173 
women, with a pooled sensitivity of 69% (95% CI 48–85), and specificity of 83% (95% CI 
76–88). We found three studies on optical coherence tomography including 693 women, 
with a pooled sensitivity of 48% (95% CI 32–64), and specificity of 77% (95% CI 52–91). 
Previously published conventional colposcopy results showed a sensitivity of 61% (95% 
CI 58–63) and a specificity of 85% (95% CI 83-86).
Conclusion Alternative (digital) colposcopy techniques may result in increased sensitiv-
ity and specificity, but no recommendation for introduction in clinical practice can be 
made yet. 
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InTrOduCTIOn
Colposcopy is the visualization of the cervix using a stereoscopic binocular microscope 
of low magnification (10x to 40x).1 Colposcopic examination combined with a biopsy 
and histological evaluation is the gold standard for identifying cervical intraepithelial 
neoplasia (CIN). However, limitations of colposcopy include a low-to-average sensitivity 
of 61% (95% confidence interval (CI) 58–63) and a specificity of 85% (95% CI 83-86),2 
resulting in missed lesions, unnecessary biopsies or overtreatment, and a high degree of 
interobserver and intraobserver variability.3,4 Improving diagnostics and management 
of women with CIN lesions is therefore desirable. 
Alternative colposcopy techniques such as digital colposcopy might improve diag-
nosis and management of women with CIN lesions. Digital colposcopy is defined as 
every form of colposcopy using image enhancement by a computer.5 The use of digital 
colposcopy techniques has been increasingly studied in the last decade. These stud-
ies all claim promising results on improving detection of CIN lesions when compared 
with colposcopy alone, although previously published sensitivity and specificity results 
highly vary.  
The variety of digital colposcopy techniques can be categorized into groups based on 
their mechanism of detection of CIN lesions. Computerized colposcopy and telecolpos-
copy, both adjunct to regular colposcopy, may be used to improve regular colposcopic 
assessment. These techniques use computerized images of the cervix without taking 
any additional measurements.6,7 Spectroscopy is a non-invasive technique that involves 
light or an electric current to detect CIN lesions based on morphologic and biochemi-
cal changes that occur during pathogenesis of neoplasia.8,9 This technique includes 
optical spectroscopy (fluorescence, reflectance, and Raman spectroscopy),10 electrical 
impedance spectroscopy,10,11 Truscreen,12,13 and dynamic spectral imaging.10 Another 
technique, optical coherence tomography uses infrared light to distinguish normal 
cervical tissue from CIN.14-16 Lastly, confocal (endo)microscopy is used to reconstruct a 
three-dimensional image, without removing tissue. This enables detection of intracel-
lular details, although with limited field of view.17,18 
Methods used for digital colposcopy can be divided into two groups; single point-
probes that measure a small site (2-3mm) of the cervix, and widespread or multispectral 
imaging, which measures the entire cervix on multiple sites at once,19 therefore allowing 
use of the device by healthcare workers with limited knowledge on cervical abnormali-
ties.20
Various digital alternative colposcopy techniques have been developed lately, and it is 
difficult to get a proper overview of these techniques and their qualities. Therefore, the 
aim of this systematic review is to assess the diagnostic value of a variety of alternative 
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digital colposcopy techniques for detection of moderate dysplasia or worse (≥CIN2) in a 
colposcopy population.  
We aimed to include all previously described techniques in this review. However, only 
three techniques finally met our inclusion criteria.
 (1) Fluorescence and reflectance spectroscopy combines two methods of spectrum 
analysis: fluorescent spectra represent metabolic activity of epithelial cells, which 
changes during carcinogenesis,21 and reflectance spectroscopy detects morphologic 
changes that occur when normal epithelial cells develop into neoplastic cells.22,23 The 
device scans the entire cervix in 1 minute. By combining fluorescence and reflectance 
spectroscopy, a prediction of tissue type depending on morphologic and biochemical 
changes that occur during pathogenesis of neoplasia is obtained. A strength of this 
technique is the possibility of multimodal measuring, resulting in an easy-to-use single 
scan which can be used independently from colposcopy. However, this single scan 
measures a limited area of the cervix, which could possibly result in missed lesions.
(2) Dynamic spectral imaging is a colposcopy technique that creates a color-coded 
map of the entire cervix based on the intensity and time-evolution of the changes that 
develop when acetic acid is applied to both neoplastic and normal cells, with acetow-
hitening effect representing the severity of cervical neoplasia.24-26 The location of the bi-
opsy is objectively determined and biopsies or a loop electrosurgical excision procedure 
(LEEP) can be taken based on this color-coded map. This makes accurate colposcopic as-
sessment possible for healthcare workers with limited colposcopy experience and might 
lower unnecessary biopsies. A possible restraint of dynamic spectral imaging is the long 
lasting acetowhitening effect, which lasts up to 45 minutes. If the first assessment fails, a 
second assessment may not be reliable because it can interfere with the time-evolution 
of acetowhitening effect of the first examination. 
 (3) Optical coherence tomography is a noninvasive imaging technique that uses near-
infrared light to measure low-coherence interferometry of tissue.14,15 It scans the entire 
cervix and is mainly used as an adjunct to colposcopy. Optical coherence tomography 
provides a higher resolution and better differentiation between diseased and normal 
tissue at superficial levels compared with established imaging techniques such as 
computed tomography, magnetic resonance imaging, positron emission tomography, 
ultrasonography, and nuclear imaging.27 A possible restraint of optical coherence to-
mography is the possibility of misinterpretation caused by inflammatory changes of the 
cervix.28 Furthermore, optical coherence tomography scans only one quadrant at a time; 
therefore four scans are needed to assess the entire cervix. Optical coherence tomog-
raphy is used additionally to colposcopy in the reviewed studies and will therefore not 
lower colposcopy referrals.
Alternative Colposcopy Techniques: A Systematic Review and Meta-analysis
117
7
MeTHOds
We systematically searched MEDLINE, EMBASE, ClinicalTrials.gov, and the Cochrane 
Library from inception up to September 21, 2015, for studies on digital colposcopy for 
the detection of cervical intraepithelial lesions. On January 11, an additional search was 
performed to include studies from September 21, 2015, up to January 11, 2016. The 
search query combined synonyms for cervical intraepithelial lesions, digital colpos-
copy and diagnostic accuracy (Supplemental material Table S1). We also performed a 
reference and related article search. Duplicate articles were manually filtered using the 
bibliographic database EndNote version X5.
Studies were eligible for inclusion if the following criteria were fulfilled: 1) a digital 
colposcopy technique was used to determine the diagnostic value in a colposcopy 
population, defined as women referred for colposcopy with an abnormal Pap cytology 
result or symptoms suggesting CIN or women referred for follow-up colposcopy; 2) A 
histological outcome was reported, classified as CIN, differentiating between mild dys-
plasia or less (≤CIN1), and moderate dysplasia or worse (≥CIN2); 3) The entire cervix was 
scanned at once or a per-woman analysis was performed; 4) No other than acetic acid 
and Lugol’s solution, as topical application, was used; 5) At least three eligible studies 
were available within each individual technique. In case of less than three studies, this 
technique was excluded from this systematic review and meta-analysis; and 6) studies 
obtained research ethics approval. Language was restricted to English. Two reviewers 
(MH and RMFE) independently assessed the eligibility of the identiﬁed articles. Any 
disagreements were resolved by discussion with a third reviewer (RLMB).
From the relevant articles information on study design, year of publication, digital 
colposcopy technique, number of participants, age of participants, sensitivity and speci-
ficity of conventional colposcopy, and outcome of digital colposcopy technique was 
extracted. The primary outcome of interest was the detection of ≥CIN2 by the digital 
colposcopy technique. 
Two reviewers individually assessed the risk of bias and the applicability of the studies, 
using the Quality Assessment of Diagnostic Accuracy studies scoring system,29 which 
is a validated tool for assessment of the methodological quality and applicability of 
diagnostic test accuracy studies. The four domains scored are: patient selection, index 
test, reference standard and flow and timing. The system indicates the risk of bias and 
applicability of the study as low, high or unknown. 
The review protocol was designed in accordance with Preferred Reporting Items for 
Systematci Reviews and Meta-Analyses (PRISMA) guidelines for the reporting of system-
atic reviews and meta-analyses,30 which was registered in PROSPERO (CRD42015027895). 
Data from each study were inserted in Review Manager version 5.0 to calculate 
sensitivity, specificity and the 95% CI. To determine pooled estimates of sensitivity and 
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specificity with 95% CI, the METADAS tool was used within the statistical software pack-
age SAS version 9.2. to perform a random-effects bivariate logistic regression analysis. 
Forest plots were drawn to visualize variation in sensitivity and specificity. A sensitivity 
analysis was performed to explore the effect of excluding the study by Park et al, which 
only includes women with high-grade Pap cytology results.
resulTs
In the initial search we retrieved 8,282 publications (Figure 1) of which 153 were consid-
ered potentially eligible. Studies were excluded because they appeared to be duplicates 
(n = 3,009), not relevant (n = 5,105), or written in a non-English language (n = 15). After 
reading the full text, another 141 studies were excluded because they did not meet 
the inclusion criteria:  29 studies were conference abstracts; in 57 studies the objective 
was not to define diagnostic value of the digital colposcopy technique in a colposcopy 
population; 31 studies did not perform a per-women analysis; in nine studies the CIN2 
threshold was not used and could not be determined; in eight studies it was not pos-
sible to calculate sensitivity and specificity; three studies used a form of topical applica-
tion before optical imaging; and one study was a sub study of another included study. 
Two studies on electrical impedance and one study on reflectance spectroscopy were 
excluded because for these techniques, less than three eligible studies remained. Only 
one study from the second search met the inclusion criteria, including a total number 
of 13 studies. All studies were prospective cohorts. We found six studies on fluorescence 
and reflectance spectroscopy, representing 2,530 women;31-36 four studies on dynamic 
spectral imaging, representing 1,173 women;24-26,37 and three studies on optical coher-
ence tomography, representing 693 women.27,38,39 Data on age of the participants is not 
included in the results, because this was reported in such a heterogeneous way making 
it impossible to show mean age, median age, or age range for all studies. The overall 
quality of the studies was moderate to high (Supplemental material Figure S2). Five 
studies had low risk of bias and low risk of applicability concerns in all seven domains. 
Three studies had an unclear risk of bias in one domain, one study had an unclear risk 
of bias in two domains and one study had a high risk of bias in one domain. Two studies 
had a high risk of bias in one domain and an unclear risk of bias in another; one study of 
these two studies had an unclear risk of applicability concern. 
Fluorescence and reflectance spectroscopy combines two methods of spectrum 
analysis, which results in a prediction of tissue type depending on morphologic and bio-
chemical changes. Table 1 summarizes the characteristics of the studies on fluorescence 
and reflectance spectroscopy. Four studies included women from a colposcopy referral 
population, and two also included women from a colposcopy follow-up population. Park 
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et al. included only women with high-grade Pap cytology results referred for colpos-
copy. Study populations range from 29 to 1,447 women. The pooled data from these six 
studies on fluorescence and reflectance spectroscopy shows a sensitivity of 93% (95% CI 
89–95) and a pooled specificity of 62% (95% CI 47–76) (Figure 2). The sensitivity analysis, 
excluding the study by Park et al.,34 resulted in a sensitivity of 94% (95% CI 90-97) and a 
specificity of 60% (95% CI 44-74).
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Figure 1. Flowchart of the systematic review process, per Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA).
Dynamic spectral imaging is a colposcopy technique that measures the acetowhiten-
ing effect of cervical cells to determine the severity of CIN. The characteristics of the 
different studies on dynamic spectral imaging are summarized in Table 1. All four stud-
ies included women from a colposcopy referral population, of which one also included 
women from a colposcopy follow-up population. Study populations range from 183 to 
443 women. Pooling the data from the studies on dynamic spectral imaging results in 
a sensitivity of 69% (95% CI 48–85) combined with a specificity of 83% (95% CI 76–88) 
(Figure 3).
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Optical coherence tomography uses near-infrared light to differentiate normal from 
diseased cells. Table 1 summarizes the characteristics of the different studies with opti-
cal coherence tomography, all including only women from a colposcopy referral popula-
tion. Study populations range from 182 to 299 women. The pooled sensitivity for optical 
coherence tomography is 48% (95% CI 32–64) with a pooled specificity of 77% (95% CI 
52–91) (Figure 4).
dIsCussIOn
Fluorescence and reflectance spectroscopy shows the highest pooled sensitivity of 
the three discussed techniques, which is higher than the sensitivity of conventional 
colposcopy. However, its specificity is lower than conventional colposcopy. Dynamic 
spectral imaging shows the highest specificity, similar to conventional colposcopy, with 
a sensitivity also similar to conventional colposcopy.2 Because alternative colposcopy 
techniques are still in development, randomized controlled trials to compare alterna-
tive techniques to conventional colposcopy are still lacking, and no recommendation 
for introduction in clinical practice can be made yet. The choice for a certain digital 
colposcopy device may depend on the use of the device in clinical setting.  When a 
high sensitivity is desirable to assure as little as possible missed cervical abnormalities, 
Table 2. Cost of alternative digital colposcopy compared with conventional colposcopy.40
luViva 
(fluorescence 
and reflectance 
spectroscopy)
dysIs 
(dynamic spectral 
imaging)
niris 
(optical coherence 
tomography)
Conventional 
colposcopy
Purchase price (£) 11,500 18,000-22,000
Device $49,500 
Probe: $2,700
6,000-12,000
Consumables per 
woman (£)
17.25 3.5 $30.00 2.00
Service and 
maintenance cost (£)
320 for replacement 
light source every 
2 years
1,600 for 
maintenance 
contract after 
warranty
Not applicable
10% of the list price 
is typically charged 
for a service 
contract
Anticipated life span 
(y)
5 5 7-10 5
Average time per 
treatment (min)
1 Less than 15 4 Less than 15
Modified from National Institute for Health and Clinical Excellence. Diagnostics assessment program. Ad-
junctive colposcopy technologies for examination of the uterine cervix - DySIS, LuViva Advanced Cervical 
Scan, Niris Imaging System and Zilico APX-100. Final scope. September, 2011. Available at: https://www.
nice.org.uk/guidance/DG4/documents/adjunctive-colposcopy-technologies-for-examination-of-the-uter-
ine-cervix-dysis-and-niris-imaging-system-diagnostics-assessment-report2. Retrieved June 7, 2016.
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fluorescence and reflectance spectroscopy could be considered. The combination of 
two spectrum analyses may be the reason for the high sensitivity of this technique. 
Fluorescence and reflectance spectroscopy may thus be used as triage method of high-
risk human papillomavirus-positive women or women with abnormal cytology, in order 
to limit colposcopy referrals, resulting in reduced unnecessary colposcopies and costs. 
The additional value of dynamic spectral imaging is limited given its similar specificity 
and sensitivity to conventional colposcopy. However, the objective assessment of this 
digital technique may be an advantage over conventional colposcopy. Additionally, 
previously performed studies showed that the sensitivity of conventional colposcopy 
increases by combining it with dynamic spectral imaging.25 Therefore, a combination 
of conventional colposcopy and dynamic spectral imaging might be considered but 
will increase costs. Optical coherence tomography is best used adjunct to colposcopy 
according to the included studies, because it can give an optical biopsy, but has limited 
sensitivity and specificity. In countries with a high risk of loss to follow-up, or limited 
experience in colposcopy, digital colposcopy techniques may be beneficial in screening 
or triage purposes. An immediate result is shown, which gives the opportunity for treat-
ment in the same visit. All three techniques may be performed by a trained healthcare 
worker, whereas a colposcopist requires more training to perform colposcopy with the 
most accurate outcome. Moreover, digital colposcopy techniques provide an objective 
assessment of cervical epithelia, whereas colposcopy is subjective based on human 
interpretation. 
The main aim of this review was to assess the diagnostic value of alternative digital 
colposcopy techniques; however, cost estimates are important to give more insight into 
clinical applicability of the techniques. The price of a conventional colposcopy device 
varies between £6,000 and £12,000.40 The price of alternative colposcopy techniques var-
ies widely between $11,500 and $49,500.40 Table 2 summarizes the costs for alternative 
digital colposcopy and conventional colposcopy. Of the three techniques, fluorescence 
and reflectance spectroscopy is the cheapest, but is not cheaper than conventional col-
poscopy devices. Because it is important to first show additional value of an alternative 
technique, we did not perform a cost-effectiveness analysis for these devices. 
A major strength of this study is that this is a meta-analysis on the diagnostic 
value of digital colposcopy techniques for detection of cervical neoplasia. We found no 
other meta-analysis based our systematic search. Other strengths are the systematic 
approach, number of studies and techniques included, the criteria used for inclusion 
(i.e. colposcopy population, histology endpoint, cut-off point at CIN2, and a per woman 
analysis), and the moderate to high quality of the included studies resulting in a low risk 
of methodological bias. 
A limitation is the relatively wide 95% CI for the pooled data on optical coherence 
tomography, because of limited numbers of included women in this group. This leads to 
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less reliable results, and makes it difficult to conclude on the diagnostic value and the 
clinical use of the technique. Additionally, sensitivity of dynamic spectral imaging and 
specificity of fluorescence and reflectance spectroscopy show a relatively wide 95% CI, 
combined with small 95% CI’s on sensitivity of fluorescence and reflectance spectros-
copy and specificity of dynamic spectral imaging. Second, other potential techniques 
(e.g. Raman spectroscopy, Truscreen, electrical impedance spectroscopy, and confo-
cal microscopy) could not be included in this meta-analysis, because there were not 
enough or no studies on these techniques to match the inclusion criteria. Third, data 
on age of the women are not included in the analysis, because this was reported in 
such a heterogeneous way. Fourth, the study by Park et al. included only women with 
high-grade cervical results. However, sensitivity analysis excluding this study showed no 
significant difference in pooled results.  
The clinical value of alternative colposcopy techniques varies between techniques, as 
well as the costs of these alternative devices. Alternative digital colposcopy techniques 
may result in increased or similar sensitivity and specificity compared with conven-
tional colposcopy and hold aspects attractive for clinical use. However, because these 
alternative colposcopy techniques are still in development, and randomized controlled 
trials comparing alternative techniques to conventional colposcopy are still lacking, no 
recommendation for introduction in clinical practice can be made yet.
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suPPleMenTAl MATerIAl
Table s1: Search strategy.
(Cervix Uteri[mesh]) OR (Endocervix[tiab]) OR (Squamocolumnar junction[tiab]) OR (Cervi*[tiab]) OR 
(CIN[tiab]) OR (Squamous intraepithelial lesion [tiab]) OR (SIL[tiab]) OR (HSIL[tiab]) OR (LSIL[tiab]) NOT 
Neck 
AND
(Tomography[tiab]) OR (Spectros*[tiab]) OR (Reflectance*[tiab]) OR (Fluorescence*[tiab]) OR 
(hyperspectr*[tiab]) OR (LuViva[tiab]) OR (Telecolposcopy[tiab]) OR (Multispectr*[tiab]) OR (Dysis[tiab]) 
OR (Spectra*[tiab]) OR (Optical colpo*[tiab]) OR (Advanced cervical scan[tiab]) OR (Optical ima*[tiab]) 
OR (Microcolpo*[tiab]) OR (Point probe[tiab]) OR (Confocal endo*[tiab]) OR (Confocal microscopy[tiab]) 
OR (Computerized colpo*[tiab]) OR (Spectrum analysis [mesh]) OR (Digital[tiab]) OR (Truscreen[tiab])
AND
(Sensitivity[tiab]) OR (Specificity[tiab]) OR (Positive predictive value[tiab]) OR (Negative predic-
tive value[tiab]) OR (Receiver operating characteristics [tiab]) OR (Area under the curve[tiab]) OR 
(Diagnos*[tiab]) OR (Sensitivity and Specificity[mesh]) OR (ROC[tiab]) OR (AUC[tiab]) OR (true 
positive[tiab]) OR (false positive[tiab])
Terms used for search strategy in MEDLINE, EMBASE, ClinicalTrials.gov and The Cochrane Library from in-
ception to January 11th 2016. Terms with [tiab] reflect free text terms appearing in title or abstract.
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Figure s2. Risk of Bias and Applicability Concerns.
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AbsTrACT
Objective High-risk human papillomavirus (hrHPV) screening is rapidly becoming 
the cornerstone of cervical cancer prevention. Because of the low specificity of hrHPV 
screening for young women, the Dutch screening program starts at the age of 30 years. 
However, young women with cervical cancer are missed with this screening strategy. 
The objective of this study was to investigate how hrHPV detection before the age of 30, 
may relate to risk of high-grade cervical lesions after the age of 30. 
Methods We retrospectively analyzed follow-up data from a prospective cohort study 
on HPV prevalence in 2,065 unscreened Dutch women between 18 and 29 years of age. 
Women performed multiple self-collected cervico-vaginal samples for HPV detection 
and genotyping from 2007 to 2009. Women 30 years of age before the 1st of June 2015 
were invited for the first cervical cancer screening round in the Netherlands, and were 
included in the present study. Based on the original study, they were categorized as; 
hrHPV negative, a cleared hrHPV infection, or a persistent hrHPV infection. Anonymized 
follow-up data for each group was obtained from the Dutch nationwide registry of his-
topathology and cytopathology (PALGA). Composite outcome measures with cytology 
and histology were obtained, defined as; normal, low-grade squamous intraepithelial 
lesion (LSIL) or high-grade squamous intraepithelial lesion (HSIL). The correlation be-
tween follow-up results and time of hrHPV clearance, persistence, and genotypes was 
analyzed.
results A pathology result was registered for 962 women, of which 841 (87.4%) showed 
normal cervical smear results, 82 (8.5%) had a LSIL result, and 39 (4.1%) had a HSIL result. 
The prevalence of HSIL was 19.3% in women who had a persistent HPV infection at a 
younger age. This is significantly higher (p<0,001) compared with the HSIL prevalence of 
1.5% in women who were HPV-negative at a younger age, as well as the HSIL prevalence 
of 3.1% in women who cleared the hrHPV infection in the past. 
Conclusion Women who had a persistent hrHPV in their 20s, showed an increased risk of 
a HSIL lesion in their early 30s. We should therefore consider the advantages of screen-
ing for persistent hrHPV infections before the age of 30.
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InTrOduCTIOn
Infections with human papillomavirus (HPV) are common; over 80% of the sexually 
active women have been genitally infected by one or more HPV types at some point 
in their life.1 Most HPV infections are transient and clear spontaneously.2 However, 
a persistent infection with a high-risk HPV (hrHPV) is thought to be a prerequisite for 
the development of cervical precancer and cancer.3,4 HPV16 and HPV18 are the most 
carcinogenic hrHPV genotypes and cause 70% of all cervical cancers.5 
The risk of sexual transmission of HPV generally peaks early in sexual life and declines 
with higher age.6 Therefore, younger women test positive for hrHPV more frequently 
than women over 30 years of age.7 The majority of infections does not lead to cervical 
cancer at such a young age. Screening of young women with hrHPV is often discouraged 
because of the limited specificity of the test with a high risk of unnecessary diagnostics 
or overtreatment.
From 1996 to 2016 Dutch women were screened in a cytology-based organized 
5-yearly cervical cancer screening program, from 30 to 60 years of age. The Dutch Na-
tional Cancer Registry shows that 7.3% of all cervical cancers are diagnosed in women 
between 20 and 29 years of age and another 10.1% is diagnosed in women between 
30 and 35 years of age. This results in a group of 17.4% of all cervical cancers detected 
before the age of 35. Starting cytology screening at the age of 30 did not prevent these 
cases. An hrHPV-based cervical cancer screening strategy with cytology triage for 
women under 30 could potentially prevent these cancers by detecting hrHPV infections 
and cervical intraepithelial neoplasia (CIN) before they progress to cancer.8 
The objective of this study was to investigate how hrHPV detection before the age of 
30, may relate to the risk of high-grade cervical lesions after the age of 30 years. 
MeTHOds
In this cohort study, we retrospectively analyzed follow-up data from a large prospective 
cohort study on HPV prevalence, incidence and clearance in women under the age of 30 
which was performed in the Netherlands in 2007.9,10 In total, 2,065 unscreened women 
between 18 and 29 years of age were included. Women performed a 3-monthly self-col-
lected cervico-vaginal sample for 12 months. All women received a self-sample kit and 
questionnaires by mail and performed the cervico-vaginal self-sample in the privacy of 
their own home. Self-samples were tested for the presence of HPV with full genital HPV 
genotyping. Polymerase chain reaction (PCR)-based hrHPV testing on self-samples has 
been shown equally sensitive compared with clinician-based samples.11 When women 
were hrHPV-positive after 12 months, another 12 months’ follow-up with 6-monthly HPV 
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testing was offered. If women were hrHPV-positive at the end of 24 months, a clinician-
taken smear for cytology testing was advised. Patient characteristics of this group of 
2,065 women are previously described.10,12 The self-samples were tested for the pres-
ence of HPV by using the highly sensitive SPF10-DEIA, and genotyping of HPV positive 
samples was performed with the SPF10-LiPA.12 
From the total cohort of 2,065 women, 1,333 were over 30 years of age at June 1st 2015 
and were included in this study, because at that point they had been invited for the first 
screening round of the national cervical cancer screening program in the Netherlands. 
Women who were only tested once in the initial study were excluded because HPV 
persistence or clearance could not be determined with one single test. Women with 
two or more hrHPV negative test results, and no hrHPV-positive results were classified as 
‘hrHPV negative’. Women with one or more hrHPV-positive test result followed by only 
hrHPV negative test results were classified as ‘cleared infection’. Women who still tested 
hrHPV-positive at the end of the 24-month period were classified as ‘persistent infection’. 
The ‘persistent infection’ and ‘cleared infection’ groups were subcategorized according 
to the presence or absence of HPV16 or HPV18, independent of the presence of the 
other hrHPV genotypes (i.e., 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68 and 73). 
Women were categorized according to their HPV test result. Anonymized 8-year 
follow-up data for each group were obtained from the Dutch nationwide registry of 
histopathology and cytopathology (PALGA). Date of birth and first four letters of the 
surname were used as a personal identifier. For all women, cervical cytology and histol-
ogy results registered up to June 1st 2015 were collected.  Results were anonymized by 
assigning a random study-number.
If a histology result was available; the most severe histology result was used as out-
come measure, otherwise the most severe cytology result was used as outcome measure. 
The Dutch CISOE-A (composition, inflammation, squamous, other and endometrium, 
endocervical cyclindrical epithelium, adequacy) classification system was used to report 
the test results for the cervical smears, which can easily be translated into the Bethesda 
nomenclature.13 The first six months of follow-up after the final sample for the initial 
prospective study were censored from analysis because these were most likely results 
from the advised clinician-taken sample for cytology and would possibly not have been 
detected without the study. Women with HSIL or cervical cancer results in these first 
six months were excluded from follow-up because treatment of these lesions most 
likely affected the natural follow-up. Furthermore, women for whom no valid cytology 
or histology result was registered after the first six months, were excluded, as well as 
women with an uncertain identity.  The identity was uncertain when the woman’s first 
name from the study database did not match the first name from the PALGA database, 
because it is possible that these are two different women with the same surname and 
date of birth. 
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Composite outcome measures were obtained, defined as; negative for intraepithelial 
lesion and malignancy (NILM), including normal histology and normal cytology results; 
low-grade squamous intraepithelial lesions (LSIL), including CIN1 histology and atypical 
cells of undetermined significance (ASC-US) and LSIL cytology; and high-grade squa-
mous intraepithelial lesions (HSIL), including histology results of CIN grade 2 or worse 
and HSIL cytology. 
The correlation between composite outcome during follow-up and hrHPV presence, 
clearance, persistence, and different genotypes was analyzed. Also, the duration of the 
hrHPV infection until clearance was analyzed in regard to the outcome. Significance 
was calculated using the Fisher’s Exact test, with a p<0.05 threshold for significance. All 
statistical analyses were performed using SPSS version 22.0. 
The study was approved by the scientific committee of PALGA. The study was exempt 
from institutional review board approval because data were gathered retrospectively 
and analyzed anonymously.
resulTs
From the cohort of 1,333 women, one or more valid cervical pathology result was 
obtained from 1,018 women. For 235 women, no valid cervical pathology result was 
registered, and for 80 women the identity was uncertain. Forty-six women had no reg-
istered pathology result after the first six months of follow-up and were excluded. For 
ten women, a high-grade result was registered in the first six months and these were 
also censored for further follow-up. This resulted in a group of 962 (72.2%) women >30 
years of age for which follow-up data was available (Figure 1). These 962 women were 
subcategorized in groups according to their previous hrHPV results, as described. Of the 
total cohort, 591 women (61.4%) were hrHPV negative, 257 (26.7%) showed a cleared 
hrHPV infection, and 114 (11.9%) had a persistent hrHPV infection (Table 1).
During follow-up, 841 (87.4%) women had a normal cervical smear or normal cervical 
histology, 82 (8.5%) women had LSIL cytology or histology, and 39 (4.1%) women had 
HSIL cervical histology or cytology results registered in the PALGA database (Table 2). 
The prevalence of HSIL in follow-up was 19.3% for women with a 24-month persistent 
hrHPV infection. This is significantly higher (p<0.001) compared with the 1.5%, HSIL 
prevalence in hrHPV-negative women, as well as the 3.1% HSIL prevalence in women 
with a cleared hrHPV infection. In HPV16/18 persistent infections the HSIL prevalence 
was highest with 28.6%. Persistent infections with the other hrHPV types showed a HSIL 
prevalence of 13.9%, which was not significantly different from the persistent HPV16/18 
group (p=0.84). Persistent infections also show the highest percentage of LSIL follow-up, 
although with a lower percentage of LSIL in HPV16/8 infections with 7.1%, compared 
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with an 18.0% incidence of LSIL in persistent other hrHPV infections (Figure 2). Of the 
hrHPV negative group, one woman was diagnosed with micro invasive cervical cancer. 
In total, 17 women were diagnosed with CIN grade 3, of which ten in the persistent 
hrHPV group, and 21 women were diagnosed with CIN grade 2, of which 12 in the per-
sistent hrHPV group (Table 3). As may be expected, hrHPV negative women showed the 
lowest risk of HSIL (1.5%). The highest risk was estimated for women who still showed a 
positive hrHPV test after 12 months, with a HSIL prevalence of 19.5% during follow-up. 
For women who cleared their infection within 12 months, the HSIL risk was significantly 
lower (p<0,001) with a HSIL prevalence of 3.1%. Differences between HPV16/18 and 
other hrHPV types were not studied as groups were too small (Table 4).
Table 1. Characteristics of groups of women in regard to groups based on previous hrHPV results.
groups based on previous hrHPV results n (%)
hrHPV negative 591 (61.4)
Cleared hrHPV infection 257 (26.7)
             Cleared HPV16/18 infection 78 (8.1)
             Cleared other hrHPV infection 179 (18.6)
Persistent hrHPV infection 114 (11.9)
             Persistent HPV16/18 infection 42 (4.4)
             Persistent other hrHPV infection 72 (7.5)
Total 962 (100)
hrHPV = high-risk human papillomavirus. Other hrHPV includes HPV types 31, 33, 35, 39, 45, 51, 52, 53, 56, 
58, 59, 66, 68 and 73.
Performed self-sampling for hrHPV testing
n = 2,065
Eligible for PALGA search
n = 1,333
Women with valid cervical pathology result
registered in PALGA after 6 months of follow-up
n = 962
Excluded n = 315
- No registered valid cervical pathology result n = 235
- Not certain about the identity n = 80
Exclded n = 732
- Not over 30 years old at the 1st of June 2015 n = 732
A valid cervical pathology result registered in PALGA
n = 1,018
Excluded n = 56
- Registered high-grade result in first 6 months of follow-up n = 10
- No registered result after first 6 months of follow-up n = 46
Figure 1. Trial profile. 
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dIsCussIOn
This cohort study shows a significant increase in risk of HSIL in the early 30s of women 
who had a persistent hrHPV in their 20s. Especially women with an hrHPV infection 
still present after 12 months showed a significantly higher risk of HSIL, compared with 
women with an hrHPV infection that was cleard within 12 months.   
Table 2. Histology and cytology follow-up results in regard to groups based on previous hrHPV results.
  groups based on previous hrHPV 
results
normal follow-up 
n (%)
lsIl follow-up
n (%)
HsIl follow-up
n (%)
Total
n
hrHPV negative 537 (90.9) 45 (7.6) 9 (1.5) 591
Cleared hrHPV infection 228 (88.7) 21 (8.2) 8 (3.1) 257
        Cleared HPV16/18 infection 73 (93.6) 4 (5.1) 1 (1.3) 78
        Cleared other hrHPV infection 155 (86.6) 17 (9.5) 7 (3.9) 179
Persistent hrHPV infection 76 (66.7) 16 (14.0) 22 (19.3) 114
        Persistent HPV16/18 infection 27 (64.3) 3 (7.1) 12 (28.6) 42
        Persistent other hrHPV infection 49 (68.1) 13 (18.0) 10 (13.9) 72
Total 841 (87.4) 82 (8.5) 39 (4.1) 962 (100)
Note that numbers and percentages of the subgroups in cleared and persistent infections are added up 
in the total group of cleared and persistent infections, and therefore do not add up to the total columns. 
hrHPV = high-risk human papillomavirus; HSIL = high-grade squamous intraepithelial lesion; LSIL = low-
grade squamous intraepithelial lesion. Other hrHPV includes HPV types 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 
59, 66, 68 and 73.
Table 3 HSIL endpoints in regard to groups based on previous hrHPV results.
groups based on previous HPV results CIn2 CIn3
Invasive 
carcinoma
Total 
n (%)
hrHPV negative 5 3 1 9 (23.1)
Cleared hrHPV infection 4 4 0 8 (20.5)
        Cleared HPV16/18 infection 0 1 0 1 (2.6)
        Cleared other hrHPV infection 4 3 0 7 (17.9)
Persistent hrHPV infection 12 10 0 22 (56.4)
        Persistent HPV16/18 infection 6 6 0 12 (30.8)
        Persistent other hrHPV infection 6 4 0 10 (25.6)
Total 21 (53.8) 17 (43.6) 1 (2.6) 39 (100)
Note that numbers and percentages of the subgroups in cleared and persistent infections are added up 
in the total group of cleared and persistent infections, and therefore do not add up to the total columns. 
hrHPV = high-risk human papillomavirus; HSIL = high-grade squamous intraepithelial lesion; LSIL = low-
grade squamous intraepithelial lesion. Other hrHPV includes HPV types 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 
59, 66, 68 and 73.
In line with our results, previous studies have shown that women with a persistent 
hrHPV infection have a significantly higher risk of developing high-grade CIN lesions 
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compared with those who cleared their infection.14,15 Data from this study adds the 
increased future HSIL risk for these young women. HPV prevalence and persistence 
have especially been shown to be high among sexually active young women; with a 
HPV prevalence up to 54%, of which 34% was a persistent infection.16 It is however 
known that these infections only rarely cause cervical cancer at such young age,8 and 
that overtreatment especially at young age is undesirable because of the risk of cervical 
insufficiency in future pregnancies.17 HrHPV-based screening between the age of 20 and 
30 years is therefore debatable and not performed in all countries. In the Netherlands 
screening starts at the age of 30 in order to prevent overtreatment of young women. 
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Figure 2. Histology and cytology follow-up results in regard to groups based on previous hrHPV results.
hrHPV = high-risk human papillomavirus; HSIL = high-grade squamous intraepithelial lesion; LSIL = low-
grade squamous intraepithelial lesion. Differences marked with an * are statistically significant with a p 
value <0.05.
Table 4. Follow-up results in regard to frequency of subsequent hrHPV detection. 
normal (%) lsIl (%)  HsIl (%) Total (%)
hrHPV negative 537 (90.9) 45 (7.6) 9 (1.5) 591 (100)
1-4x hrHPV-positive (0-9 months)* 230 (89.1) 20 (7.8) 8 (3.1) 258 (100)
5-7x hrHPV-positive (12-24 months)** 74 (65.5) 17 (15.0) 22 (19.5) 113 (100)
Total 841 82 39 962
*1-4 hrHPV infections represent infections that cleared within 3-12 months. **5-7 hrHPV infections repre-
sent infections that did not clear within 12-24 months. hrHPV = high-risk human papillomavirus; HSIL = 
high-grade squamous intraepithelial lesion; LSIL = low-grade squamous intraepithelial lesion.
Various countries differ in the organization of their cervical cancer screening program; 
in terms of type of screening test, invitation methodology, population-based screening 
or opportunistic screening, target population, screening intervals, but also in age of 
A persistent high-risk HPV infection before the age of 30 is associated with a high risk of HSIL later in life
141
8
starting cervical cancer screening. In the Netherlands and Finland screening is offered 
by the government from the age of 30 years with a 5-yearly schedule. Belgium, France, 
Australia, the UK and Italy start earlier and invite women every 3-5 years starting at their 
25th birthday. Sweden starts at the age of 23, and Germany, Canada, and the USA start 
even earlier at 20 or 21 years old and use a 1-5 yearly schedule. Some countries use an 
hrHPV-based screening program, others use Pap cytology as primary screening method, 
and others combine them and use co-testing. However, the cervical cancer incidence in 
these countries is not inevitably linked to the start of screening or screening interval.18 
Germany offers the most screening rounds, but the cervical cancer incidence is lowest 
in Finland where women are screened 5-yearly from the age of 30.17 Participation to the 
screening program is known to be important in lowering cervical cancer incidence, and 
young age is a risk factor for non-participation.18 Participation to screening programs 
may be improved by offering self-sampling for hrHPV testing,19 which has been shown 
to be equally sensitive to clinician-taken samples for hrHPV testing and may be an at-
tractive option for screening young women.20
In the Netherlands in 2015, the 17.4% of all cervical cancers diagnosed between 20 
and 35 years. The majority of these cancers may potentially be avoided if a persistent 
infection in a girls’ 20s was detected and present CIN lesions were treated in time. It 
could for example be considered to start hrHPV-based screening for all women at the 
age of 20 or 25. Data from this study show that the risk of a HSIL lesion is only 3.1% in 
women with an hrHPV infection which is cleared within 12 months, and no carcinomas 
were found in this group. The risk of HSIL is much higher with 19.5% when women still 
test hrHPV positive 12 months after their first positive hrHPV test. Performing cytology 
triage after one single hrHPV-positive test may therefore result in referral of too many 
young women for colposcopic examination with possibly unnecessary diagnostics and 
unnecessary treatment. It may be valuable to individualize screening for young women. 
Young women with one hrHPV-positive result can then be monitored with a watchful 
waiting policy to see whether the infection will clear within 12 months. When these 
infections do not clear within the 12 months, cytology triage should be performed to 
detect the presence of CIN lesions in need of treatment, to prevent development of 
cervical cancer before the age of 30 years. 
On the contrary to the increased risk of HSIL lesions in young women with a persistent 
hrHPV infection, this study shows that women who are hrHPV negative in their early 
adulthood have a low risk (1.5%) of developing a HSIL lesions in the next eight years 
of follow-up. Women who are hrHPV negative before the age of 30, might even benefit 
from longer screening intervals. However, further studies should be performed to see if 
extending screening intervals would be safe. Also, the discovery of one micro-invasive 
squamous cell carcinoma in the hrHPV negative group of this study might contradict 
this suggestion. Because all follow-up data was anonymized we could not identify how 
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many hrHPV negative tests preceded this carcinoma. These were at least two negative 
tests because all women with two or more hrHPV negative test results and no hrHPV-
positive results were scored in this group. Also, we could not identify when these tests 
were hrHPV negative, or if the carcinoma was hrHPV-positive or negative. As follow-up in 
this study was eight years, this carcinoma may also have developed quickly. 
From the total group of 1,333 eligible women, at least 1,018 (76.4%) women had a 
cervical smear taken. This percentage is high compared with cervical cancer screening 
participation in young women in the Netherlands which ranges between 50-60% in 
women from 30 to 35 years of age.21 The knowledge on hrHPV obtained by participat-
ing in the study or knowledge of their hrHPV status may have affected women in their 
choice of having a cervical smear taken in the first cervical cancer screening round. 
Another potential source of bias in this study is the possibility that an infection classified 
as persistent is not truly a persistent infection, but could also be a re-infection with hrHPV. 
Persistence in this study was purely based on the presence of hrHPV. A re-infection how-
ever might still indicate increased susceptibility for hrHPV and additional cytology triage 
might be needed. Also, ASC-US cervical smears were categorized as LSIL in this study. In 
fact these two results are not directly comparable, which could also have caused potential 
bias with increased numbers of LSIL in different groups. This was however done in all 
groups, so potential bias would be present in all groups equally. Furthermore, the first six 
months of follow-up after the final sample for the initial prospective study were censored 
from analysis, and 10 women with HSIL or cervical cancer results in these first six months 
were excluded because treatment of these lesions most likely affected the natural follow-
up. Censoring of these first six months and exclusion of 10 women with HSIL or cervical 
cancer might have caused bias which could cause an underestimation of our results. 
From 2009 on, prophylactic hrHPV vaccination with the bivalent vaccine is offered 
to girls in the Netherlands, with a coverage-rate of 61% in 2016.22 These vaccinated 
women will first enter the organized screening program at the age of 30, which will be 
the case in 2023. Screening strategies for women under the age of 30 will therefore still 
be beneficial as not all girls are vaccinated, and it is unknown to which extent vaccinated 
girls will be protected for cervical cancer caused by hrHPV types other than HPV16 and 
HPV18. These differences in risk-estimates for an hrHPV infection with HPV16 or HPV18 
might be a reason for individualizing screening in the future. Earlier research has shown 
that young women between 21 and 30 years of age in the United States who had not 
initiated HPV vaccination were also less likely to have a cervical smear taken, compared 
with women who initiated vaccination.23 The option of hrHPV self-sampling in the pri-
vacy of their own homes might persuade these young women to indeed participate in 
cervical cancer screening.19 
Multiple studies have shown the value of HPV16/18 genotyping in triage of hrHPV-
positive women.24,25 This study also shows the highest risk of HSIL in women with a 
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persistent HPV16/18 infection, which is twice as high compared with the HSIL risk for 
women with a persistent infection with one of the other hrHPV types. This confirms that 
HPV16/18 genotyping may indeed be useful in individualized screening, triage, and 
follow-up strategies of hrHPV-positive women. However, the numbers in this study are 
too small to draw specific conclusions in this group of young women. 
In conclusion, this study shows that women who had a persistent hrHPV infection in 
their 20s, showed an increased risk of a HSIL lesion in their early 30s. We should therefore 
consider the advantages of screening for persistent hrHPV infections before the age of 30. 
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AbsTrACT
Objective The aim of this study was to determine the risk of human papillomavirus 
(HPV)-related carcinomas and premalignancies in women diagnosed with cervical in-
traepithelial neoplasia grade 3 (CIN3). Knowledge on this risk is important to preventing 
development and progression of other HPV-related premalignancies and carcinomas, by 
considering HPV vaccination and/or by paying increased attention to other HPV-related 
carcinomas and premalignancies when CIN3 is identified.
Methods Women diagnosed with a CIN3 between 1990 and 2010 were identified 
from the Dutch nationwide registry of histopathology and cytopathology (PALGA) and 
matched with a control group of women without CIN3. Subsequently, all cases of high-
risk (hr)HPV-associated high-grade lesions and carcinomas in the anogenital region and 
oropharynx between 1990 and 2015 were extracted. Incidence rate ratios (IRR) were es-
timated for carcinomas and premalignancies of the vulva, vagina, anus and oropharynx. 
results A total of 178,036 women were identified: 89,018 with a previous diagnosis of 
CIN3 and 89,018 matched control subjects without a history of CIN3.  Women with a 
history of CIN3 showed increased risk of HPV-related carcinomas and premalignancies 
with IRRs of; 3.85 (95% CI 2.32-6.37) for anal cancer, 6.68 (95% CI 3.64-12.25) for anal 
intraepithelial neoplasia grade 3 (AIN3), 4.97 (95% CI 3.26-7.57) for vulvar cancer, 13.66 
(95% CI 9.69-19.25) for vulvar intraepithelial neoplasia grade 3 (VIN3), 86.08 (95% CI 
11.98-618.08) for vaginal cancer, 25.65 (95% CI 10.50-62.69) for vaginal intraepithelial 
neoplasia grade 3 (VAIN3), and 5.51 (95% CI 1.22-24.84) for oropharyngeal cancer. This 
risk remained significantly increased, even after long-term follow-up of up to 20 years.
Conclusion This population-based study shows a long-lasting increased risk for HPV-
related carcinomas and premalignancies of the anogenital and oropharyngeal region 
after a CIN3 diagnosis. Studies that investigate methods to prevent this increased risk in 
this group of patients, such as intensified screening or vaccination, are warranted. 
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InTrOduCTIOn
Infections with a high-risk human papillomavirus (hrHPV) are estimated to be the cause 
of 5.2% of all cancers worldwide.1 HrHPV infections in women cause cervical cancer and 
cervical intraepithelial neoplasia (CIN), as well as carcinomas and premalignancies of the 
oropharynx, and anogenital region including the vulva, vagina, and anus. 
The prevalence of hrHPV in cervical cancer is close to 100%. In vaginal cancers, the 
prevalence of hrHPV is 60 to 70%, and in vulvar cancer it ranges from 20 to 50%. In 
anal cancer, an hrHPV infection is found in 88 to 95% of all cases, and 15 to 65% of the 
oropharyngeal cancers are related to the HPV.2,3 
It has been shown that women with a diagnosis of CIN grade 3 (CIN3) are at increased 
risk of carcinomas of the anogenital and head and neck region, probably as the result 
of an infection with an hrHPV.4– 8 However, none of those studies included the risk for 
high-grade premalignancies after a diagnosis of CIN3.4,5,8–10 Knowledge of this risk is 
important to preventing the development and progression of other HPV-related pre-
malignancies and carcinomas, by considering prophylactic HPV vaccination and/or by 
paying increased attention to other HPV-related carcinomas and premalignancies when 
CIN3 is identified. Primary prevention of HPV-related carcinomas and premalignancies 
by prophylactic vaccination is now only available for young women. Older and unvac-
cinated women are therefore still at risk for HPV-related disease in the next decades. 
Treating premalignancies in a cohort may prevent malignancies from developing, and 
the risk for HPV-related carcinomas and premalignancies combined represents the pos-
sible preventive effect of HPV vaccination in women with a CIN3. The aim of this study 
was therefore to determine the risk of HPV-related carcinomas and premalignancies in 
women with a previous histologic diagnosis of CIN3.
MeTHOds
Women with a diagnosis of CIN3 between January 1, 1990 and December 31, 2010, 
were identified from the Dutch nationwide registry of histopathology and cytopathol-
ogy (PALGA). Date of birth and first four letters of the surname were used as a personal 
identifier. Women registered in the database with a benign dermal nevus, but who were 
never diagnosed with CIN3 or cervical carcinoma before or after the diagnosis of nevus, 
were selected from the database as a control group. Registration of a pathology result 
in the database was needed to obtain a control group from the database; a registered 
benign dermal nevus was chosen because it is not related to HPV and can be diagnosed 
in all women. Women with both a CIN3 and a benign nevus diagnosis were included 
in the CIN3 group. Control subjects were assigned a random number and sorted. 
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Subsequently, from the total group of 547,924 matched women with a nevus, random 
frequency matching was done by age and year of detection (both within a range of five 
years), and population density areas; smaller cities with <100,000 inhabitants were con-
sidered low-density areas, and those with >100,000 inhabitants higher-density cities. 
For all identified women, histology results for carcinomas and high-grade premalignan-
cies of the vulva, vagina, perineum, anus, and oropharynx between January 1, 1990 and 
March 1, 2015, were retrieved, resulting in 4 to 25 years of follow-up. In addition, patient 
age and date of diagnosis were retrieved. 
We identified all HPV-related carcinomas and premalignancies diagnosed after the 
CIN3 or benign dermal nevus. Only results with a clear diagnosis of malignancy were 
classified as cancer; when invasiveness was uncertain in a high-grade lesion, the result 
was classified as high-grade premalignancy. Moderate (CIN2) and low-grade (CIN1) 
premalignancies were not included in the high-grade group. Women were censored 
after diagnosis of an HPV-related carcinoma of any site because treatment might in-
fluence the subsequent risk of other carcinomas or premalignancies. Women with an 
HPV-related carcinoma or premalignancy before the CIN3 or benign dermal nevus were 
excluded from analysis, as well as results indicating recurrence or metastases of disease. 
Differentiated vulvar intraepithelial neoplasia (VIN) and vulvar cancer after a previous 
diagnosis of lichen sclerosis, clear cell carcinomas, serous adenocarcinoma, lymphomas, 
melanomas, and basal cell carcinomas were also excluded because these are not likely 
to be related to HPV.11,12
We calculated person-years at risk and the number of observed carcinomas and pre-
malignancies in each group, taking into account censoring as described in the previous 
paragraph. Using Poisson regression with an offset on the basis of the person-years, 
incidence rates (IR) per 100.000 person-years were estimated for both cases and their 
matched controls. Incidence rate ratios (IRR), comparing women with a CIN3 diagnosis 
with the matched control group, were computed, first by analyzing the whole follow-up 
period and secondly by excluding the first year of follow-up, to account for possibly 
prevalent HPV-related carcinomas and premalignancies in the cohort. HPV-related 
carcinomas and premalignancies were analyzed separately and combined into clusters 
of any HPV-related carcinoma and/or any HPV-related premalignancy. The cluster of 
any HPV-related carcinoma includes anal cancer, vulvar cancer, vaginal cancer, and 
oropharyngeal cancer. The cluster of any HPV-related premalignancy includes anal 
intraepithelial neoplasia grade 3 (AIN3), VIN grade 3, and vaginal intraepithelial neo-
plasia grade 3 (VAIN3). The cluster of any malignancy or premalignancy includes anal 
cancer, AIN3, vulvar cancer, VIN3, vaginal cancer, VAIN3, and oropharyngeal cancer. In 
all analyses, person-years were only considered before the first diagnosed carcinoma or 
premalignancy. 
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Age-adjusted IRRs for 5-year follow-up intervals were estimated for up to 25 years 
of follow-up for each carcinoma and premalignancy separately and for the clustered 
carcinomas and premalignancies, by means of a Poisson model with an interaction term 
for the group with a history of CIN3 and follow-up period and a continuous variable for 
age. In addition, IRRs were estimated for women ≤29 years, 30-49 years, 50-69 years, and 
≥70 years for the clustered carcinomas and premalignancies. Kaplan-Meier curves were 
used to visualize the risk of HPV-related carcinomas and premalignancies over time.  
All statistical analyses were performed with SAS version 9.2. Kaplan-Meier curves were 
obtained with SPSS version 22.0.0.1.
The study was approved by the scientific committee of PALGA. The study was exempt 
from institutional review board approval because data were gathered retrospectively 
and analyzed anonymously.
Table 1. Characteristics of study population at inclusion.*
number of patients Percentage Person-years of follow-up
CIn3 history (%) no CIn3 history (%)
Age cohort
<20 years 143 0.2% 1,894 1,905
20-24 years 2,160 2.4% 32,625 32,722
25-29 years 10,523 11.8% 161,919 161,814
30-34 years 25,426 28.6% 350,931 351,628
35-39 years 20,828 23.4% 307,335 306,170
40-44 years 13,390 15.0% 185,361 186,021
45-49 years 7,749 8.7% 104,492 105,295
50-54 years 3,896 4.4% 54,638 54,461
55-59 years 2,156 2.4% 28,199 28,272
60-64 years 1,257 1.4% 16,642 16,703
65-69 years 505 0.6% 7,602 7,683
70-74 years 418 0.5% 5,540 5,570
75-79 years 303 0.3% 3,113 3,220
≥80 years 264 0.3% 1,511 1,535
     Total 89,018 100% 1,261,804 1,262,998
Calendar period
1990-1994 20,354 22.9% 458,469 457,284
1995-1999 20,785 23.3% 364,119 365,151
2000-2004 19,063 21.4% 239,718 239,056
2005-2010 28,816 32.4% 199,498 201,507
     Total 89,018 100% 1,261,804 1,262,998
*The number of patients and percentages of age distribution and calendar period of inclusion are similar in 
both groups because of 5-year matching. CIN3 = cervical intraepithelial neoplasia grade 3.
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resulTs
We identified 178,036 women, of whom 89,018 had a histologic diagnosis of CIN3, be-
tween 1990 and 2010, and an equal number of women in the matched control group of 
women without a history of CIN3. The median age at diagnosis was 35 years in women 
with a previous diagnosis of CIN3, and 36 years in the control group. Characteristics of 
the study population at inclusion are listed in Table 1. During a median follow-up of 
14 years in both groups (range, 4 to 25 years), 1,261,804 person-years were accrued in 
the group with a previous diagnosis of CIN3. After censoring, a total of 299 HPV-related 
carcinomas and 634 HPV-related premalignancies were found in the group with a previ-
ous diagnosis of CIN3. In the control group, 1,262,998 person-years were accrued, with 
48 HPV-related carcinomas and 50 HPV-related premalignancies (Table 2). 
The risk of developing HPV–related carcinomas and premalignancies of the anus, 
vulva, vagina, and oropharynx is strongly associated with a previous diagnosis of CIN3, 
with a significant increase in the group with a history of CIN3 (Figure 1). The IRRs for 
anal cancer and AIN3, comparing women with a previous diagnosis of CIN3 with those 
without a previous diagnosis of CIN3 were 3.85 (95% CI 2.32-6.37) and 6.68 (95% CI 3.64-
12.25), respectively. For vulvar cancer and VIN3, the IRRs were 4.97 (95% CI 3.26-7.57) and 
13.66 (95% CI 9.69-19.25), respectively. Vaginal cancer and VAIN3 showed the highest 
IRRs with 86.08 (95% CI 11.99-618.08) for vaginal cancer, and 25.65 (95% CI 10.50-62.69) 
for VAIN3, as the result of low IRs in the control group. Oropharyngeal cancer showed an 
IRR of 5.51 (95% CI 1.22-24.84). The IRR for any HPV-related carcinoma was 6.24 (95% CI 
4.60-8.46), for any HPV-related premalignancy the IRR was 12.75 (95% CI 9.56-17.00), and 
for any HPV-related carcinoma or premalignancy the IRR was 9.68 (95% CI 7.77-12.05). 
Excluding the first year after inclusion resulted in IRR estimates that were not notably 
different (Table 2). 
The age-adjusted IRR stratified by time interval since first diagnosis showed a 
short-term and long-lasting increased risk of developing HPV-related carcinomas and 
premalignancies in women with a previous diagnosis of CIN3, when compared with the 
control group of women without a CIN3 diagnosis. Even up to 20 years after the CIN3 
diagnosis, this risk remained increased (Table 3). The increased cumulative incidence 
over time is clearly visualized in the Kaplan-Meier curves (Figure 2). For the cluster of 
any HPV-related carcinoma or premalignancy, the IRR decreased over time; however, an 
increased risk was still visible after long-term follow-up (Figure 3).
IRR stratified by attained age showed that the risk of carcinoma or premalignancies for 
women with a hitstory of CIN3 might be dependent on age. The IRR of any HPV-related 
premalignancy and of any carcinoma or premalignancy was highest in women ≤29 years 
of age, both with an IRR > 30. The IRR for women with any HPV-related carcinoma was 
not available. In the group of women between 30 and 49 years of age, the risk was lower 
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compared with women ≤29 years of age; however, the risk was higher compared with 
older age groups, with IRRs of 8.09 (95% CI 4.81-13.58) for any HPV-related carcinoma, 
16.68 (95% CI 11.14-24.96) for any HPV-related premalignancy, and 13.62 (95% CI 9.76-
19.01) for any HPV-related carcinoma or premalignancy (Supplemental material Table 
S1).
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Figure 1. Estimated Incidences rate of HPV-related carcinomas and premalignancies, comparing women 
with and without a history of CIN3.
The first year after diagnosis of CIN3 or benign dermal nevus was included in the incidence rate visualized 
in this figure. Error bars indicate 95% confidence intervals of estimated incidence rates. * indicates a signifi-
cant difference in incidence rates of the group with a history of CIN3 compared with the  group without a 
history of CIN3. Data are in Table 2. AIN3 = anal intraepithelial neoplasia grade 3; CIN3 = cervical intraepi-
thelial neoplasia grade 3; VAIN3 = vaginal intraepithelial neoplasia grade 3; VIN3 = vulvar intraepithelial 
neoplasia grade 3. 
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Figure 3. Incidence rate ratio of any HPV-related carcinoma or premalignancy comparing women with a 
previous diagnosis of CIN3 with women without CIN3, versus time. 
Any HPV-related carcinoma or premalignancy includes anal cancer, anal intraepithelial neoplasia grade 
3, vulvar cancer, vulvar intraepithelial neoplasia grade 3, vaginal cancer, vaginal intraepithelial neoplasia 
grade 3, and oropharyngeal cancer. Squares represent the incidence rate ratio at certain follow-up points. 
Error bars indicate 95% confidence intervals of estimated incidence rates. The dotted line is based on sim-
ple linear regression for visualization purposes. Data are in Table 3. 
dIsCussIOn
This population-based cohort study, which included 178,036 women, showed an 
increased risk of premalignancies as well as carcinomas of anus, vulva, vagina, and oro-
pharynx in women with a previous diagnosis of CIN3 compared with women without a 
previous diagnosis of CIN3. The increased risk was still present up to 20 years after the 
CIN3 diagnosis. 
Our results are consistent with previously published studies on HPV-related car-
cinomas in women with a CIN diagnosis, with risks ratios ranging from 2.2 to 4.4 for 
vulvar cancer, 6.7 to 18.5 for vaginal cancer, 1.8 to 5.9 for anal cancer, and 1.2 for oral/
pharyngeal tumors.4,5,7–9 No studies have analyzed the risk of HPV-related high-grade 
premalignancies. In general, high-grade premalignancies are treated before cancer 
can occur. Our data on IRs of high-grade premalignancies showed high IRRs, indicating 
that in the group of women with CIN3, carcinomas may have been prevented by early 
detection and treatment of high-grade premalignancies. Our data overall show higher 
IRRs compared with published studies. This might be caused by differences in our study 
design compared with published studies. Some studies used expected IRs on the basis 
of national averaged IRs, which may also include carcinomas in women with a CIN3 in 
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Table 3. Observed numbers of carcinomas and premalignancies, person-years of follow-up, and estimated 
age-adjusted incidence rate ratios (IRR) of carcinomas and premalignancies of anus, vulva vagina and oro-
pharynx of women with a history of CIN3, compared with women without a history of CIN3, stratified by 
time since first diagnosis of CIN3 or benign dermal nevus. 
<1 year 1-4 years 5-9 years 10-14 years 15-19 years 20-24 years
Person-
years (On)
Irr
(95% CI)
Person-
years (On)
Irr
(95% CI)
Person-
years (On)
Irr
(95% CI)
Person-
years (On)
Irr
(95% CI)
Person-
years (On)
Irr
(95% CI)
Person-
years (On)
Irr
(95% CI)
Anal cancer
    CIN3 history 88,938 (4) 1.33 353,476 (10) 5.01 357,688 (21) 21.14 253,774 (20) 5.00 153,874 (11) 2.21 54,053 (7) 1.69 
    No CIN3 history 99,988 (3) (0.30-5.96) 353,797 (2) (1.10-22.85) 359,894 (1) (2.84-157.12) 253,496 (4) (1.71-14.62) 154,776 (5) (0.77-6.37) 52,048 (4) (0.49-5.76)
AIn3
    CIN3 history 88,932 (7) 3.50 353,413 (19) 9.52 357,546 (22) 3.17 253,615 (17) NA 153,721 (11) NA 53,992 (4) 3.86 
    No CIN3 history 88,986 (2) (0.73-16.86) 353,787 (2) (2.22-40.86) 359,863 (7) (1.35-7.41) 253,471 (0) 154,766 (0) 52,041 (1) (0.43-34.53)
Vulvar cancer
    CIN3 history 88,940 (15) 14.94 353,488 (19) 2.37 357,698 (32) 8.04 253,794 (33) 6.54 153,904 (22) 3.09 54,063 (8) 7.56
    No CIN3 history 88,988 (1) (1.98-112.98) 353,797 (8) (1.04-5.41) 359,894 (4) (2.84-22.74) 253,496 (5) (2.55-16.76) 154,776 (7) (1.32-7.24) 52,048 (1) (0.95-60.47)
VIn3
    CIN3 history 88,859 (81) 16.22 352,773 (128) 16.05 356,618 (112) 28.26 252,701 (82) 6.85 153,001 (55) 27.81 53,725 (18) 4.36
    No CIN3 history 88,983 (5) (6.58-40.03) 353,765 (8) (7.86-32.78) 359,832 (4) (10.42-76.61) 253,432 (12) (3.74-12.56) 154,718 (2) (6.78-114.02) 52,029 (4) (1.48-12.88)
Vaginal cancer
    CIN3 history 88,938 (23) NA 353,476 (20) NA 357,688 (20) NA 253,774 (16) NA 153,874 (6) NA 54,053 (1) 0.98
    No CIN3 history 88,988 (0) 353,797 (0) 359,894 (0) 253,496 (0) 154,776 (0) 52,048 (1) (0.06-15.69)
VAIn3
    CIN3 history 88,885 (52) NA 353,103 (43) NA 357,268 (20) 20.31 253,460 (11) 3.70 153,672 (2) 2.04 53,999 (0) NA
    No CIN3 history 88,988 (0) 353,797 (0) 359,891 (1) (2.72-151.51) 253,488 (3) (1.03-13.25) 154,771 (1) (0.19-22.47) 52,047 (0)
Oropharyngeal cancer
    CIN3 history 88,938 (0) NA 353,476 (2) NA 357,688 (1) NA 253,774 (2) NA 153,874 (3) NA 54,053 (3) 2.89
    No CIN3 history 88,988 (1) 353,797 (0) 359,894 (0) 253,496 (0) 154,776 (0) 52,048 (1) (0.30-27.76)
Any HPV-related carcinoma*
    CIN3 history 88,940 (42) 8.38 353,488 (51) 5.08 357,698 (74) 14.87 253,794 (71) 7.81 153,904 (42) 3.43 54,063 (19) 2.56
    No CIN3 history 88,988 (5) (3.32-21.19) 353,797 (10) (2.58-10.01) 359,894 (5) (6.01-36.77) 253,496 (9) (3.90-15.62) 154,776 (12) (1.80-6.51) 52,048 (7) (1.07-6.08)
Any HPV-related premalignancy**
    CIN3 history 88,805 (133) 19.05 352,388 (175) 17.60 356,146 (140) 12.89 252,308 (102) 7.34 152,722 (63) 21.31 53,648 (21) 4.08
    No CIN3 history 88,981 (7) (8.91-40.73) 353,755 (10) (9.30-33.28) 359,801 (11) (6.98-23.81) 253,407 (14) (4.20-12.83) 154,705 (3) (6.69-67.85) 52,022 (5) (1.54-10.82)
Any HPV-related carcinoma or premalignancy†
     CIN3 history 88,805 (164) 16.44 352,388 (211) 12.49 356,146 (191) 13.83 252,308 (157) 7.54 152,722 (91) 6.60 53,648 (33) 2.57
    No CIN3 history 88,981 (10) (8.68-31.13) 353,755 (17) (7.62-20.47) 359,801 (14) (8.04-23.79) 253,407 (21) (4.78-11.88) 154,705 (14) (3.76-11.59) 52,022 (12) (1.38-5.18)
* any HPV-related carcinoma includes anal cancer, vulvar cancer, vaginal cancer and oropharyngeal cancer. 
** any HPV-related premalignancy includes AIN3, VIN3 and VAIN3. After the first premalignancy women 
were censored. † any HPV-related carcinoma or premalignancy includes anal cancer, AIN3, vulvar cancer, 
VIN3, vaginal cancer, VAIN3 and oropharyngeal cancer. After the first carcinoma or premalignancy women 
were censored. AIN3 = anal intraepithelial neoplasia grade 3; 
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Table 3. Observed numbers of carcinomas and premalignancies, person-years of follow-up, and estimated 
age-adjusted incidence rate ratios (IRR) of carcinomas and premalignancies of anus, vulva vagina and oro-
pharynx of women with a history of CIN3, compared with women without a history of CIN3, stratified by 
time since first diagnosis of CIN3 or benign dermal nevus. 
<1 year 1-4 years 5-9 years 10-14 years 15-19 years 20-24 years
Person-
years (On)
Irr
(95% CI)
Person-
years (On)
Irr
(95% CI)
Person-
years (On)
Irr
(95% CI)
Person-
years (On)
Irr
(95% CI)
Person-
years (On)
Irr
(95% CI)
Person-
years (On)
Irr
(95% CI)
Anal cancer
    CIN3 history 88,938 (4) 1.33 353,476 (10) 5.01 357,688 (21) 21.14 253,774 (20) 5.00 153,874 (11) 2.21 54,053 (7) 1.69 
    No CIN3 history 99,988 (3) (0.30-5.96) 353,797 (2) (1.10-22.85) 359,894 (1) (2.84-157.12) 253,496 (4) (1.71-14.62) 154,776 (5) (0.77-6.37) 52,048 (4) (0.49-5.76)
AIn3
    CIN3 history 88,932 (7) 3.50 353,413 (19) 9.52 357,546 (22) 3.17 253,615 (17) NA 153,721 (11) NA 53,992 (4) 3.86 
    No CIN3 history 88,986 (2) (0.73-16.86) 353,787 (2) (2.22-40.86) 359,863 (7) (1.35-7.41) 253,471 (0) 154,766 (0) 52,041 (1) (0.43-34.53)
Vulvar cancer
    CIN3 history 88,940 (15) 14.94 353,488 (19) 2.37 357,698 (32) 8.04 253,794 (33) 6.54 153,904 (22) 3.09 54,063 (8) 7.56
    No CIN3 history 88,988 (1) (1.98-112.98) 353,797 (8) (1.04-5.41) 359,894 (4) (2.84-22.74) 253,496 (5) (2.55-16.76) 154,776 (7) (1.32-7.24) 52,048 (1) (0.95-60.47)
VIn3
    CIN3 history 88,859 (81) 16.22 352,773 (128) 16.05 356,618 (112) 28.26 252,701 (82) 6.85 153,001 (55) 27.81 53,725 (18) 4.36
    No CIN3 history 88,983 (5) (6.58-40.03) 353,765 (8) (7.86-32.78) 359,832 (4) (10.42-76.61) 253,432 (12) (3.74-12.56) 154,718 (2) (6.78-114.02) 52,029 (4) (1.48-12.88)
Vaginal cancer
    CIN3 history 88,938 (23) NA 353,476 (20) NA 357,688 (20) NA 253,774 (16) NA 153,874 (6) NA 54,053 (1) 0.98
    No CIN3 history 88,988 (0) 353,797 (0) 359,894 (0) 253,496 (0) 154,776 (0) 52,048 (1) (0.06-15.69)
VAIn3
    CIN3 history 88,885 (52) NA 353,103 (43) NA 357,268 (20) 20.31 253,460 (11) 3.70 153,672 (2) 2.04 53,999 (0) NA
    No CIN3 history 88,988 (0) 353,797 (0) 359,891 (1) (2.72-151.51) 253,488 (3) (1.03-13.25) 154,771 (1) (0.19-22.47) 52,047 (0)
Oropharyngeal cancer
    CIN3 history 88,938 (0) NA 353,476 (2) NA 357,688 (1) NA 253,774 (2) NA 153,874 (3) NA 54,053 (3) 2.89
    No CIN3 history 88,988 (1) 353,797 (0) 359,894 (0) 253,496 (0) 154,776 (0) 52,048 (1) (0.30-27.76)
Any HPV-related carcinoma*
    CIN3 history 88,940 (42) 8.38 353,488 (51) 5.08 357,698 (74) 14.87 253,794 (71) 7.81 153,904 (42) 3.43 54,063 (19) 2.56
    No CIN3 history 88,988 (5) (3.32-21.19) 353,797 (10) (2.58-10.01) 359,894 (5) (6.01-36.77) 253,496 (9) (3.90-15.62) 154,776 (12) (1.80-6.51) 52,048 (7) (1.07-6.08)
Any HPV-related premalignancy**
    CIN3 history 88,805 (133) 19.05 352,388 (175) 17.60 356,146 (140) 12.89 252,308 (102) 7.34 152,722 (63) 21.31 53,648 (21) 4.08
    No CIN3 history 88,981 (7) (8.91-40.73) 353,755 (10) (9.30-33.28) 359,801 (11) (6.98-23.81) 253,407 (14) (4.20-12.83) 154,705 (3) (6.69-67.85) 52,022 (5) (1.54-10.82)
Any HPV-related carcinoma or premalignancy†
     CIN3 history 88,805 (164) 16.44 352,388 (211) 12.49 356,146 (191) 13.83 252,308 (157) 7.54 152,722 (91) 6.60 53,648 (33) 2.57
    No CIN3 history 88,981 (10) (8.68-31.13) 353,755 (17) (7.62-20.47) 359,801 (14) (8.04-23.79) 253,407 (21) (4.78-11.88) 154,705 (14) (3.76-11.59) 52,022 (12) (1.38-5.18)
* any HPV-related carcinoma includes anal cancer, vulvar cancer, vaginal cancer and oropharyngeal cancer. 
** any HPV-related premalignancy includes AIN3, VIN3 and VAIN3. After the first premalignancy women 
were censored. † any HPV-related carcinoma or premalignancy includes anal cancer, AIN3, vulvar cancer, 
VIN3, vaginal cancer, VAIN3 and oropharyngeal cancer. After the first carcinoma or premalignancy women 
were censored. AIN3 = anal intraepithelial neoplasia grade 3; 
CI = confidence interval; CIN3 = cervical intraepithelial neoplasia grade 3; IRR = incidence rate ratio; NA 
= not available; ON = observed number; VAIN3 = vaginal intraepithelial neoplasia grade 3; VIN3 = vulvar 
intraepithelial neoplasia grade 3. 
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the control group, whereas others used relative risks. Furthermore, the studies by Kal-
liala et al.4 and Gaudet et al.8 included women with CIN1 and/or CIN2, of which CIN1 is 
known to show a lower prevalence of hrHPV, compared with CIN2-3.13 
Our results showed the highest IRRs for vaginal cancer and VAIN3 and the lowest IRR 
for anal cancer, which was still 3.85 (95% CI of 2.32-6.37).  Vaginal abnormalities are in 
proximity to cervical abnormalities; this makes a vaginal co-infection, with development 
of a vaginal carcinoma or premalignancy, more likely in women with a CIN3. This risk 
is much lower in women with no history of CIN3, which was shown by a low IR in the 
control group, resulting in a high IRR in vaginal cancer and VAIN after a CIN3. Also, in 
vulvar carcinomas and premalignancies, a loco-regional effect of HPV may explain an 
increased incidence of these lesions in women diagnosed with CIN3. Women diagnosed 
with a CIN3 are commonly followed up with cervical smears or colposcopic examina-
tion. This may also result in increased detection of premalignancies of the vagina and 
vulva, with a higher IR in women with a CIN3 compared with women without a CIN3; 
this could result in an overestimation of IRR, especially in these two premalignancies. 
Also, not all anal, vulvar, vaginal, and oropharyngeal carcinomas and premalignancies 
are related to HPV; therefore, not all malignancies and premalignancies detected during 
follow-up in this study are related to HPV. We attempted to exclude carcinomas and 
premalignancies that were definitely not related to HPV. However, in the majority of 
cases, HPV tests were not performed on the histology samples; thus, some carcinomas 
and premalignancies not caused by HPV still would have been included. However, these 
carcinomas and premalignancies have been included in both the CIN3 group and in 
the control group  of women without CIN3, with an expected similar number of cases; 
therefore, in estimated IRRs, these numbers cancel each other out. The overall increased 
IRR might also be explained by a woman’s inability or limited ability to clear an hrHPV 
infection. A limited ability or inability to clear hrHPV infections did result in a persistent 
hrHPV infection with development of a CIN3 lesion, but could have also resulted in other 
HPV-related carcinomas and premalignancies. The long-lasting increased risk might also 
be explained by increased susceptibility to new hrHPV infections and recrudescence 
of disease because of an inability to clear the infection. It is known that smoking and 
immunodeficiency increases the risk of persistent hrHPV infections with an increased 
risk of (pre)malignant development.14-16 Data on smoking or immune status were not 
registered in the PALGA database, and could therefore not be included in our analysis. 
Previously published results, however, show no increased risk explained by smoking.9 
When looking at IRR over time, almost all IRRs showed a steady decline of increased 
risk during the long-term follow-up, with the lowest increased risk after 20 to 24 years. 
The Kaplan-Meier figures of all HPV-related carcinomas and premalignancies also con-
firmed this long-term increased risk. The increased risk of the cluster of any HPV-related 
carcinoma or premalignancy over time showed a decrease over time with an IRR of 16.44 
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(95% CI 8.68-31.13) in the first year, and an IRR of 2.57 (95% CI 1.38-5.18) after 20 years. 
This indicates that although the risk of HPV-related carcinomas and premalignancies 
decreased over time, it was still significantly increased up to 20 years after the CIN3 
diagnosis. A previous study by Gaudet et al.8 also showed dropping incidences of ma-
lignancies in time, but to the contrary, Kalliala et al.4 showed an increased standardized 
IR for malignancies over time after CIN3 treatment. For clusters of all carcinomas and/
or all premalignancies, we also observed decreasing IRRs with advancing age. This data 
should be interpreted with some caution because the effect of a low incidence of malig-
nancies in younger age groups might also be a confounding factor. 
Ideally, we want to prevent the development of HPV-related carcinomas or high-grade 
premalignancies, or at least discover premalignancies before they progress to cancer. 
Higher alertness for HPV-related lesions in women with CIN3 might therefore be advis-
able. During colposcopy, it is relatively easy to look for vaginal carcinoma and premalig-
nancies. Current guidelines advise to also examine the vaginal walls during colposcopic 
examination, and when an abnormal smear is not explained by cervical abnormalities, 
a vaginoscopy can be considered. When VAIN is diagnosed, it can be treated with sur-
gical excision, laser evaporation or imiquimod; however, recurrent disease is a known 
problem.17 Also, screening for vulvar and anal carcinoma and premalignancies might be 
easily combined with cervical diagnostics. Visual inspection will be easy to implement, 
but presently data are lacking that screening of these areas results in a lower cancer in-
cidence. Indeed, there are no current screening programs for VIN, AIN, or oropharyngeal 
lesions, but if premalignancies are encountered, they are treated.18,19 
Because an infection with hrHPV is causal to the development of other HPV-related 
carcinomas and high-grade premalignancies, prophylactic HPV vaccination may have 
a preventive effect on development of these lesions. However, the role of prophylactic 
vaccination in adult women is debated. Previous vaccination trials have shown that 
noninfected adults could potentially benefit from HPV vaccination.20,21 Garland et 
al.22 showed that women undergoing surgical therapy for cervical lesions after vacci-
nation with the bivalent vaccine may benefit from vaccination, with a reduced risk of 
developing subsequent ≥CIN2 positivity. Studies in women with a current infection with 
hrHPV showed varying results. Two recent studies showed a reduced incidence of sub-
sequent HPV-related disease in women vaccinated with the quadrivalent HPV vaccine 
after surgical treatment for CIN3 when compared with surgically treated women who 
did not receive the HPV vaccination.23,24 On the contrary, a recent study by Hildesheim 
et al.25 showed no evidence for a vaccine effect on detectable HPV infections in hrHPV-
positive women and women undergoing treatment for cervica premalignancy. Also, 
the small potential harms of vaccination should be taken into account, alongside the 
fact that HPV infections leading to premalignancies or malignancies may have been 
acquired before the HPV vaccination. It is therefore not fully clarified how clinically and 
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cost-effective prophylactic hrHPV vaccination would be in women treated for CIN3. Ran-
domized controlled trials and cost-effectiveness studies might answer these questions. 
Our study, however, showed that short- and long-term risks of HPV-related abnormali-
ties are strongly increased in women diagnosed with CIN3. Patients should be informed 
on an individual basis about this increased risk. The Dutch guideline presently advises 
to consider hrHPV vaccination in women diagnosed with CIN3, until more conclusive 
evidence on vaccine effect after treatment for CIN3 is available.17  
The introduction of prophylactic HPV vaccination is expected to reduce the incidence 
of HPV-related cancers; postvaccination surveillance studies have supported this by 
showing a significant reduction of 68% in type 16 and 18 infections in countries with 
female vaccination coverage of ≥50%.26-29 However, monitoring remains essential to 
identify possible waning of efficacy, or replacement of HPV-type. Because vaccination 
programs for young women only started in 2007, it will take many more years before 
the effects of HPV vaccination will become visible in the total adult female population. 
In conclusion, this population-based data set shows further evidence of the increased 
risk of HPV-related carcinomas and premalignancies of the anogenital and oropharyn-
geal regions after a diagnosis of CIN3, and gives a clear view of women at risk for HPV 
related disease. Studies that investigate methods to prevent this increased risk in this 
group of patients, such as intensified screening or vaccination, are warranted. 
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10
generAl dIsCussIOn
Multiple aspects of improving cervical cancer prevention have been explored in this the-
sis, providing a multidimensional approach towards improving cervical cancer preven-
tion programs. The Netherlands is among the first countries that recently implemented 
hrHPV-based population screening, and it can be expected that hrHPV-based screening 
will rapidly become the cornerstone of cervical cancer screening in many countries. 
With this major shift in cervical cancer screening, we should look closely at the steps 
following a high-risk human papillomavirus (hrHPV) positive test result. Improvement 
of these steps may eventually lead to a more accurate, women-friendly, and personal-
ized cervical cancer prevention program. In this general discussion, conclusions from 
the previously described studies are put into perspective from different point-of-views, 
and clinical implications are explored alongside a future prospect on cervical cancer 
prevention.
As I AM A wOMAn
As a woman, most importantly I do not want to get cervical cancer. Unfortunately, at this 
point we cannot totally prevent women worldwide from getting cervical cancer. There-
fore, an optimized cervical cancer prevention program should be obtained with current 
knowledge, to make sure cervical cancer incidences and mortality will be lowered as 
much as possible. For me as a woman, this would be a cervical cancer screening program 
in which a negative screening and triage test is maximally conclusive in having no risk of 
cervical cancer, at least until the next screening round. On the other hand, I also do not 
want a high chance of an unnecessary referral advice, which could result in unwanted 
anxiety or overtreatment. I definitely would not want to get cervical cancer at a young 
age. If screening of women below the age of 30 would be needed to prevent getting 
cancer at a young age, I might consider participating in such a screening program, even 
at the cost of unnecessary diagnostics. Future research should be focused on optimizing 
cervical cancer prevention programs. As hrHPV-based cervical cancer screening can be 
performed on self-sampled specimens, it may be expected that self-sampling will play 
an increasing role in hrHPV-based cervical cancer screening programs.1 Cervicovaginal 
self-sampling has shown to be well tolerated by women and it increases participation of 
non-responders to a screening program, however, this is only shown in a study setting.2,3 
I would want to have the opportunity of using a cervicovaginal self-sampling device as 
a safe cervical screening method. 
If a colposcopic evaluation is required, I would want to be treated based on my specific 
situation, thus on an individualized basis. I expect to be informed about all possible 
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options and would want to have a say in the choice of additional diagnostics, treatment, 
or a watchful waiting policy, based on a personalized evidence based risk assessment. 
If my risk on hrHPV related disease is increased, I expect to be informed of this specific 
risk and would want to be informed about any possible preventive measurements for 
developing a carcinoma. As described in this thesis, some women show an increased risk 
for hrHPV-related disease and may therefore require different screening or treatment. 
First, unvaccinated women with a persistent hrHPV infection at young age do show a 
significantly increased risk of developing high-grade cervical intraepithelial neoplasia 
(CIN) lesions during the first years of follow-up, compared with hrHPV negative women 
and women who cleared their hrHPV infection. This might indicate a possible increased 
susceptibility for an hrHPV infection, due to a shortcoming immune system, so new 
infections or recrudescence after viral latency are more common. Secondly, women di-
agnosed with a high-grade CIN lesion also show an increased risk for other HPV induced 
carcinomas of the head-and-neck and anogenital region. This risk has been confirmed 
with Dutch population-based data showing an increased risk even after 20 years of 
follow-up. Additionally, a strongly increased long-term risk for hrHPV-related premalig-
nancies is shown. Knowledge on this risk on premalignancies is important to prevent 
development of hrHPV-related premalignancies and prevent progression of hrHPV-
related premalignancies into carcinomas, by considering for example prophylactic HPV 
vaccination after treatment for high-grade CIN lesions. For now, only young women are 
being vaccinated, and older women still remain at risk for hrHPV-related premalignan-
cies and carcinomas. The role of prophylactic vaccination in adult women is however 
debated. Some studies have shown a reduced incidence of subsequent HPV-related 
disease in women receiving prophylactic hrHPV vaccination after treatment for CIN3; 
however, this has not been confirmed by all studies.4-6 As a woman, I would want to be 
informed about evidence on prophylactic HPV vaccination and increased attention on 
other HPV-related lesions, and discuss the about pros and cons for these two preventive 
strategies with my physician. I would strongly consider these options when my personal 
risk of HPV-related lesions would be increased. 
IF I were A gyneCOlOgIsT
As a gynecologist, I want to inform my patients on the risks of hrHPV infections and 
the chances of clearance and developing CIN lesions or other hrHPV-related disease, as 
well as offer them the best treatment options. I also need to be up-to-date on the pros 
and cons of hrHPV self-sampling offered in this new cervical cancer screening program 
in the Netherlands, as I expect questions from my patients on this subject. For now, 
self-sampling will only be available for women in the cervical cancer screening program. 
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I think self-sampling should also become available for women in a follow-up setting in 
whom taking a cervical smear for cytology is difficult or not possible because of anxiety 
or other reasons. 
With the limited specificity of the hrHPV test, and Pap cytology triage in case of an 
hrHPV-positive result, referral rates for colposcopic examination will rise. Especially 
in the first few years with an estimated increase in colposcopy referrals of 131%, with 
the highest expected increase in low-grade CIN lesions.7 I think it is therefore essen-
tial to improve colposcopic examination as this is the next step after a positive triage 
result.8 Individualized treatment should be applied in the colposcopy clinic; first by con-
sidering a watchful waiting policy to prevent overtreatment in hrHPV-positive women 
with low-grade cytology. Especially in young and fertile women I would advise to be 
cautious with excisional treatment; and second I would propose to consider see-and-
treat management in women with a high-grade cervical smear result and high-grade 
colposcopic impression as this thesis has shown this is safe and acceptable in this group.
As a gynecologist, I would expect to see progress in the development of digital col-
poscopy techniques and would like to stay up-to-date on this subject during meetings 
or conferences on colposcopy, to see if these techniques might be further improved 
to be valuable for my colposcopy clinic. A major advantage of these techniques is the 
objective assessment of the cervix. However, presently their added value is too low for 
introduction within the colposcopy program, because some techniques show limited 
sensitivity and others show low specificity. The sensitivity and specificity of these strate-
gies have to be high in order to be useful as triage method or in follow-up diagnostics.
Furthermore, as a gynecologist my knowledge on alternatives to surgical treatment 
in case of a CIN lesion should be up-to-date. New emerging therapies like Imiquimod 
treatment, or therapeutic vaccination are being investigated. Imiquimod is a Toll-like 
7 receptor agonist, that works as a topical immune response modulator, effecting 
upregulation of interferon and activation of dendritic cells. Imiquimod application has 
significantly increased histological regression of CIN lesions and clearance of HPV.9 Also, 
early studies on therapeutic vaccination for treating CIN lesions show promising results. 
Additionally, some studies have shown some effectiveness of prophylactic vaccines in 
preventing CIN recurrence. These two vaccine strategies should be further explored to 
see if prophylactic vaccines have the ability to prevent new CIN lesions from developing, 
and if therapeutic vaccines have enough potential for the treatment of cervical lesions.5,10 
IF I were A POlICy MAker 
I think the new hrHPV-based cervical cancer screening program contributes to better 
healthcare. This new program is expected to be 13-15% more effective in preventing 
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cervical cancer and cervical cancer deaths. The hrHPV-based program is more cost-effec-
tive with a decrease of 35% for screening costs, and a 20% decrease in costs combining 
diagnostics and treatment. In quality-adjusted life years (QALY) the new program shows 
a good cost-effectiveness of €3,497.- per QALY (39% less), and it is therefore expected to 
improve cervical cancer screening effectiveness and coverage combined with lowered 
costs compared with the Pap cytology-based screening program.7 I strongly believe 
women should be in control of their own welfare and think the offering of self-sampling 
is a major contribution to the program. As a policy maker, I would focus on closely 
monitoring this new cervical screening program, to see how these adjustments eventu-
ally affect participation, and detection of cervical cancer and high-grade CIN lesions. 
This information is valuable for further improvement of our own program as well as for 
other countries considering implementing hrHPV-based cervical cancer screening and 
include hrHPV self-sampling in their screening program.
I would work on creating funds to stimulate collaboration between policy makers, re-
searchers and doctors to improve an aligned screening and treatment strategy, resulting 
in a more women-friendly cervical cancer prevention program. As I expect self-sampling 
to become an important screening tool, I would promote collaboration of policy mak-
ers and researchers on improving triage directly on self-samples to determine the risk 
for hrHPV-positive women and to lower unnecessary colposcopies. Also by informing 
general practitioners and gynecologists on the content of the new screening program 
and the increased colposcopy referral rates, medicalization and unnecessary treatment 
should be prevented. 
On the longer term, I would investigate adjustments to the screening program that 
should be made once vaccinated girls will enter the program. In the Netherlands, girls are 
vaccinated since 2009 with the bivalent prophylactic HPV vaccine, which protects against 
HPV16 and HPV18. Vaccination coverage in the Netherlands has climbed from 52% in 
2009 to almost 61% in 2016, and the first vaccinated women will enter the organized 
screening program at the age of 30, which will be the case in 2023. This group of young 
women is vaccinated with the bivalent vaccine and it is yet unknown to which extent 
these women will be protected for cervical cancer caused by types other than HPV16 and 
HPV18 by cross protection. Also, the extent of type-replacement is still not fully known. 
Screening will therefore also remain necessary for these vaccinated women, alongside 
screening for unvaccinated women. The future screening population will therefore 
consist of women with different risk profiles on hrHPV infections and development of 
HPV-related lesions. It will then be important to work towards individualized screening 
based on risk prediction by combining vaccination status, previous hrHPV results and 
other factors as smoking or immune status of each woman, and base an individualized 
screening program on this knowledge. This will increase individualized patient-centered 
care as women with a low risk might need less or no screening, compared with women 
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with a higher risk. When the vaccination program will possibly switch to another vaccine 
with broader HPV coverage, screening programs should also be adjusted accordingly, or 
might eventually even become unnecessary for these women. 
IF I were A POsT-dOCTOrAl reseArCHer  
If I were a post-doctoral researcher one of my major research topics would be the dis-
covery and use of new molecular markers for the triage of hrHPV-positive women. In the 
coming cervical cancer screening program, Pap cytology will be used as triage method 
for hrHPV-positive women in the Netherlands. This technique has a limited sensitivity, 
excludes the use of self-sampled material, and requires 6-month follow-up of hrHPV-
positive women with normal cytology to limit the risk of a missed lesion.11 Studies have 
shown that triage could be improved on short notice by combining Pap cytology with 
HPV16/18 genotyping, or replacing it with p16/Ki-67 dual staining, as shown in this 
thesis.12,13 This improves the specificity of Pap cytology triage of hrHPV-positive women, 
and thus limits unnecessary colposcopy referral rates. These strategies are however still 
morphology-dependent. Molecular biomarkers on the other hand are objective, highly 
reproducible, do not need high cellularity and some have already been proven to be 
applicable on self-samples.12,14-19 Methylation levels are known to increase with a longer 
duration of a HPV infection, and with the severity of cervical lesions. Unfortunately, 
at this point in time, none of the studied triage strategies can differentiate all women 
with a high risk from women with a low risk for high-grade CIN. Molecular triage of 
hrHPV-positive women might also differentiate productive from transforming infections 
and some studies have already shown to be able to predict development of high-grade 
lesions.20 Thus, a molecular triage test could predict which hrHPV infections have caused 
or will eventually cause a high-grade CIN or cervical cancer. In this way, unnecessary 
treatment during colposcopic examination and continuous follow-up could possibly 
be avoided. If I were a post-doctoral researcher, I would work on the discovery of new 
molecular markers to further personalize screening. The ultimate goal for me would 
be a technique that gives a highly-individualized result with predictive potential, and 
a screening or triage technique based on integration of HPV may show these abilities. 
One of the major other but more basic research areas as a post-doctoral researcher 
would therefore be to study the integration of HPV into the human genome. There are 
three main research questions in this aspect. The first question to answer is; why does 
integration take place? Although many women acquire an hrHPV infection at a certain 
point in their life, in only a minority the HPV DNA integrates into the human host. Inte-
gration is considered as a first step in the oncogenic pathway leading to cervical cancer. 
It is not exactly known why HPV integrates into the human DNA in some infections, 
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while it does not in others. A second and third research question in line with the former 
are; when does integration take place, and how does integration take place? It is well-
known that the majority, if not all, cervical carcinomas contain integrated hrHPV DNA, 
the exact time of integration is unknown. Integration takes place more-or-less randomly 
in the human host DNA but has always a relation with a disruption of the viral E2 gene. 
Is there a structural DNA component or sequence involved as a hot-spot for integration? 
What specifically differentiates hrHPV types from low-risk HPV types in this context? This 
knowledge could possibly be used to prevent HPV from integrating, or to better detect 
integrated HPV which can be used to develop a more sensitive and more specific screen-
ing or triage method based on molecular characteristics.
FuTure PersPeCTIVe
Cervical cancer prevention programs are on the verge of major adjustments after the 
introduction of primary hrHPV-based cervical cancer screening. Alternative opportuni-
ties for triage of hrHPV-positive women are widely available and current research in-
creases knowledge on these different techniques. The increased numbers of referrals for 
colposcopic examination, with many women with low-grade cytology with a relatively 
low risk of high-grade CIN lesions, will require adjustments from gynecologists to their 
current colposcopy clinic, to be able to give the best care available for the future. Vacci-
nated girls will enter the screening program and extending knowledge on increased risk 
of HPV-related disease in certain groups will eventually lead to individualized screening 
based on personalized risk estimates, combined with individualized treatment, to finally 
lead to a more accurate, women-friendly, and personalized cervical cancer prevention 
program. 
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Summary
suMMAry
Studies on multiple dimensions of improving cervical cancer prevention are described 
in this thesis. Research focusses on three important aspects of cervical cancer preven-
tion, and may lead to an improved more women-friendly cervical cancer prevention 
program. Chapter 1 introduces the background and different aspects of cervical cancer 
prevention, followed by research aims and the outline of this thesis. 
Three chapters in part I of this thesis describe studies on triage of high-risk human 
papillomavirus (hrHPV) positive women. HrHPV testing is expected to replace Pap 
cytology as primary screening method for cervical cancer screening in an increasing 
number of countries. The high sensitivity, combined with a low specificity makes tri-
age of hrHPV-positive women necessary to limit unnecessary referrals for colposcopic 
examination. In chapter 2 we present an overview of the state-of-the-art on triaging 
hrHPV-positive women. This chapter differentiates between morphological biomarkers, 
molecular biomarkers and combined triage strategies. We analyze worldwide literature 
on clinical value of a large variety of biomarkers, and compare available triage strate-
gies to a yet non-existing ideal strategy. This ideal strategy consists of biomarkers that 
can be applied on the primary screening sample, and which would result in a highly 
sensitive and specific test that differentiates women with cervical cancer or high-grade 
cervical intraepithelial neoplasia (CIN) lesions from women with a low risk for these le-
sions who can safely return to the next screening round. This overview of worldwide 
literature shows that experience with morphology-based Pap cytology makes this a 
valuable triage method. However, molecular biomarkers show more promising results in 
recent research. These markers are more objective, are highly reproducible, and can be 
combined to improve qualities of different single biomarkers. It is expected that cervical 
cancer screening will transform to a full molecular screening program in the future. 
Chapter 3 describes a study on the clinical value of HPV16/18 genotyping combined 
with Pap cytology as triage method for women with hrHPV-positive self-samples. 
Physician-taken samples from 520 women who tested hrHPV-positive on a self-sample 
were evaluated for Pap cytology with previous knowledge of the hrHPV-positive status, 
and HPV16/18 genotyping with the Cobas 4800 test (Roche). Eighteen baseline triage 
strategies were evaluated for sensitivity, specificity, predictive values and referral rates. 
Three strategies combining HPV16/18 genotyping and Pap cytology were considered 
improved, in regard to the comparator strategy of Pap cytology at an atypical cells of 
undetermined significance (ASC-US) threshold which yielded a sensitivity of 93.5% (95% 
CI 87.7-97.1) and specificity of 58.5% (95% CI 53.7-63.2). These three strategies are; the 
presence of HPV16 and/or a Pap cytology result of low-grade squamous intraepithelial 
lesion or worse (≥LSIL), the strategy with presence of HPV16 and/or HPV18, and/or a Pap 
cytology result of ≥HSIL, and the strategy with presence of HPV16 and/or a Pap cytology 
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result of high-grade squamous intraepithelial lesion or worse (≥HSIL). This final strategy 
yielded the highest specificity of 74.9% (95% CI 70.5-78.9) with a sensitivity of 94.4% 
(95% CI 89.0-97.7) similar to the comparator strategy, and a decrease in referral rate from 
52.2% to 39.5%. These results indicate that in case of prior knowledge of hrHPV pres-
ence, triage by Pap cytology may be improved by adjusting its threshold, and combining 
it with HPV16/18 genotyping.
In chapter 4 we evaluated the clinical utility of p16/Ki-67 dual staining for the 
identification of CIN in hrHPV-positive women from a non-responder screening cohort. 
P16/Ki-67 dual staining, Pap cytology and HPV16/18 genotyping were performed on 
physician-taken liquid-based samples from 495 women who tested hrHPV-positive 
on self-sampled material. Different triage strategies involving p16/Ki-67 dual staining 
were evaluated for sensitivity, specificity, and predictive value for ≥CIN2 and ≥CIN3, and 
compared with Pap cytology with an ASC-US threshold. Centrally revised histology or an 
adjusted endpoint with combined hrHPV negative and cytology negative follow-up at 
six months was used as gold standard. Triage of hrHPV-positive samples with Pap cytol-
ogy with an ASC-US threshold showed a sensitivity of 93% (95% CI 85-98) with a specific-
ity of 49% (95% CI 41-56) for ≥CIN3. Three triage strategies with p16/Ki-67 showed a 
significantly increased specificity with similar sensitivity for ≥CIN3: P16/Ki-67 triage of 
all hrHPV-positive samples had a specificity of 61% (95% CI 54-69). Applying p16/Ki-67 
triage to only hrHPV-positive women with low-grade Pap cytology showed a specificity 
of 64% (95% CI 56-71). For hrHPV-positive women with low-grade and normal Pap cytol-
ogy, triage with p16/Ki-67 showed a specificity of 58% (95% CI 50-65). Differences in 
sensitivity and specificity are limited between the three selected strategies. Because the 
quality of Pap cytology worldwide varies this study concludes that 16/Ki-67 triage of all 
hrHPV-positive samples would be the most reliable strategy in triage of hrHPV-positive 
women with an increased specificity and similar sensitivity compared with Pap cytology 
triage.
Part II of this thesis contains three studies on improving colposcopic examination fol-
lowing a positive screening and/or triage result. First, chapter 5 describes a systematic 
review of literature and a meta-analysis of current data on see-and-treat management 
of CIN. Three major literature databases were searched for studies on see-and-treat man-
agement in women with a reported cervical smear result, colposcopic impression and 
final histology result, to determine overtreatment rates in see-and-treat management 
of women referred for colposcopic examination because of suspected CIN. Thirteen 
studies, with a total of 4,611 women were included. By an inverse variance method, inci-
dences were pooled and a random-effects model was used to account for heterogeneity 
between studies. The overall overtreatment rate in women with a low-grade smear and 
low-grade colposcopic impression was highest with 72.9% (95% CI 68.1-77.7). In case of 
a high-grade cervical smear an a high-grade colposcopic impression the overtreatment 
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rate was lowest with 11.6% (95% CI 7.8-15.3). This was at least comparable with the 
overtreatment rate of a two-step procedure which varied between 11-35% in literature, 
therefore justifying see-and-treat management in this group of women. In case of a 
discrepancy between the cervical smear an colposcopic evaluation, age, wish to have 
children in the future, and risk of loss-to-follow-up should be taken into account when 
considering see-and-treat management. 
The second chapter in this part is chapter 6. This chapter focusses on an alternative 
colposcopy technique, multimodal hyperspectroscopy (MHS), that combines fluores-
cence and reflectance spectroscopy. The objective of this prospective single-center 
cohort study was to evaluate the clinical value of MHS for detecting high-grade cervical 
intraepithelial neoplasia in a colposcopy referral population and colposcopy follow-up 
population, to assess whether MHS could be safely used to improve care for women at 
risk for high-grade CIN. A total of 125 women from a colposcopy referral population 
and colposcopy follow-up population were evaluated with MHS and tested for the pres-
ence of hrHPV with HPV16/18 genotyping. Spectroscopic measurements of the cervix 
were taken and compared with an endpoint based on histology, hrHPV and cytology. 
Evaluable data for analysis were collected for 102 of the subjects. Sensitivity, specificity 
and predictive values were calculated for MHS and colposcopic impression based on 
conventional colposcopic examination. MHS yielded a sensitivity of 93.6% (95% CI 78.6-
99.2), with a corresponding specificity of 42.3% (95% CI 30.6-54.6) in the group with a 
composite endpoint. No adverse effects occurred and patient acceptability was high. 
With these results, we can conclude that MHS is a digital colposcopy technique that of-
fers an easy, rapid, well tolerated point-of-care assessment with a high sensitivity for the 
presence of high-grade cervical intraepithelial lesions, however, with a low specificity, 
resulting in limited clinical value.
Thirdly, chapter 7 presents the results of a systematic review and meta-analysis on 
alternative colposcopy techniques. This study was performed to assess diagnostic value 
of alternative (digital) colposcopy techniques for detection of CIN lesions in a colpos-
copy population. Four major data sources were searched for studies with the following 
inclusion criteria: a digital colposcopy technique was used in a colposcopy population, 
a histologic outcome was reported differentiating between mild dysplasia or less, and 
moderate dysplasia or worse, the entire cervix was scanned at once or a per-woman 
analysis was performed, no other topical application than acetic acid and Lugol’s solu-
tion was used, and, at least three eligible studies had to be available within a single 
technique. Thirteen studies met the inclusion criteria of which six on fluorescence and 
reflectance spectroscopy including 2,530 women, four on dynamic spectral imaging 
including 1,173 women, and three studies on optical coherence tomography including 
693 women. Fluorescence and reflectance spectroscopy showed the highest pooled sen-
sitivity of 93% (95% CI 89-95) with a specificity of 62% (95% CI 47-76). Dynamic spectral 
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imaging showed the highest pooled specificity of 83% (95% CI 76-88), with a sensitivity 
of 69% (95% CI 48-85). Previously published conventional colposcopy results showed 
a sensitivity of 61% (95% CI 58-63) and specificity of 85% (83-86%), indicating that 
alternative (digital) colposcopy techniques may result in similar or increased sensitivity 
or specificity. The choice for a certain digital colposcopy device may therefore depend 
on the use of the device in a clinical setting. However, because alternative colposcopy 
techniques are still in development, and randomized controlled trials to compare alter-
native techniques with conventional colposcopy are still lacking, no recommendations 
for introduction in clinical practice can be made yet. 
Two studies in part III of this thesis focus on the future risks of high-risk HPV infections. 
The aim of the study in chapter 8 was to investigate future risks of high-grade CIN 
lesions and cervical cancer in young women who tested hrHPV-positive before the age 
of 30. We retrospectively investigated how hrHPV detection before the age of 30, might 
be associated with the risk of high-grade CIN lesions after the age of 30. Follow-up data 
from a cohort study on HPV prevalence in 2,065 unscreened Dutch women between 
18 and 29 years of age was obtained. Women were asked to perform 3-monthly self-
samples for hrHPV testing. Women were categorized as; either hrHPV negative, a cleared 
hrHPV infection, or a persistent hrHPV infection, and anonymized follow-up data for 
each group was obtained from the Dutch nationwide registry of histopathology and 
cytopathology (PALGA). A pathology result was registered for 962 women. The preva-
lence of HSIL was 19.3% in women who had a persistent HPV infection at a younger age. 
This was significantly higher (p<0,001) compared with the HSIL prevalence of 1.5% in 
women who were HPV-negative at a younger age, as well as the HSIL prevalence of 3.1% 
in women who cleared the hrHPV infection in the past. With this retrospective study can 
be concluded that women who had a persistent hrHPV in their 20s, showed an increased 
risk of a HSIL lesion in their early 30s. The advantages of screening for persistent hrHPV 
infections before the age of 30 should be considered to lower cervical cancer incidence 
in young women. 
Chapter 9 takes future risks of hrHPV infections one step further, and focusses on 
determining the risk of HPV-related carcinomas and premalignancies in women who 
are already diagnosed with high-grade CIN lesions. Knowledge on this risk is important 
to consider HPV vaccination and/or intensified screening for other HPV-related carci-
nomas and premalignancies when CIN3 is identified. Women diagnosed with a CIN3 
between 1990 and 2010 were identified from the Dutch nationwide registry of histopa-
thology and cytopathology (PALGA) and matched with a control group without CIN3. 
Subsequently, all hrHPV associated high-grade lesions and carcinomas of the anogenital 
region and oropharynx between 1990 and 2015 were extracted. Incidence rate ratios 
(IRR) were estimated for carcinomas and premalignancies of the vulva, vagina, anus and 
oropharynx. This resulted in a total group of 178,036; 89,018 with a previous diagnosis 
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of CIN3, and 89,018 matched controls without a history of CIN3. Women with a history 
of CIN3 showed increased risk of all HPV-related carcinomas and premalignancies with 
IRRs ranging from 3.85 for anal cancer, to 86.08 for vaginal cancer. The risk of hrHPV-
related lesions remained significantly increased, even after long-term follow-up, up to 
20 years. It can therefore be concluded that women with a high-grade CIN diagnosis 
show a long-lasting increased risk on HPV-related carcinomas and premalignancies of 
the anogenital and oropharyngeal region. Studies investigating successful methods to 
prevent this increased risk in this group of patients, like intensified screening or vaccina-
tion, are warranted.
Finally, the content of this thesis is discussed in broader sense in chapter 10. The 
main focus of this chapter is on different point of views on multiple aspects of cervical 
cancer prevention. Furthermore, future perspectives of cervical cancer prevention are 
discussed.
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Samenvatting
sAMenVATTIng
Dit proefschrift beschrijft studies naar verschillende mogelijkheden voor het verbeteren 
van preventie van cervixcarcinoom. De focus ligt op drie aspecten van de preventie van 
cervixcarcinoom die kunnen zorgen voor een verbeterd, meer vrouwvriendelijk pre-
ventieprogramma. In Hoofdstuk 1 worden verschillende aspecten van preventie van 
cervixcarcinoom beschreven, tezamen met onderzoeksdoelen en de hoofdlijnen van dit 
proefschrift. 
deel I van dit proefschrift bestaat uit drie hoofdstukken over triage van hoog-risico 
humaan papillomavirus (hrHPV) positieve vrouwen. In een groeiend aantal landen zal 
screening middels Pap cytologie vervangen worden door primaire screening met een 
hrHPV test. Omdat de hoge sensitiviteit van hrHPV screening gecombineerd is met een 
lagere specificiteit, is triage van hrHPV positieve vrouwen noodzakelijk om onnodige 
verwijzingen voor colposcopie te voorkomen. Hoofdstuk 2 toont een overzicht van 
wereldwijde literatuur over triage van hrHPV positieve vrouwen, waarbij wordt gediffe-
rentieerd tussen morfologische biomarkers, moleculaire biomarkers en gecombineerde 
triage strategieën. De klinische waarde van verschillende biomarkers wordt beschreven 
en vergeleken met een nog niet bestaande ideale triage strategie. Deze ideale strategie 
zou bestaan uit een biomarker die op het primaire screening materiaal met een hoge 
sensitiviteit en specificiteit differentieert tussen cervixcarcinoom of hooggradige 
cervicale intra-epitheliale neoplasieën (CIN) en vrouwen met een laag risico op deze 
afwijkingen die geen verder onderzoek behoeven en veilig terug kunnen keren naar 
het bevolkingsonderzoek. Dit hoofdstuk laat zien dat Pap cytologie, ten gevolge van de 
uitgebreide ervaring met deze techniek, een waardevolle triage methode is. Moleculaire 
biomarkers tonen echter veelbelovende resultaten in recent onderzoek. Deze markers 
zijn objectief, reproduceerbaar en kunnen gecombineerd worden waarbij de goede ei-
genschappen van verschillende biomarkers gecombineerd zorgen voor een verbeterde 
triage methode. De verwachting is dat screening op cervixcarcinoom in de toekomst zal 
veranderen in een volledig moleculair screening programma. 
In hoofdstuk 3 beschrijven we een studie naar de klinische waarde van triage van 
hrHPV positieve vrouwen met HPV16/18 genotypering en Pap cytologie. Van 520 
vrouwen die hrHPV positief getest waren op een zelftest, werden uitstrijkjes afgenomen 
door huisartsen. Deze uitstrijkjes werden beoordeeld op Pap cytologie met kennis van 
hrHPV positieve status en HPV16/18 genotypering met de Cobas 4800 test (Roche). 
De sensitiviteit, specificiteit, voorspellende waarden en het aantal verwijzingen werd 
bekeken voor 18 triage strategieën. In vergelijking met de standaard triage methode 
met alleen Pap cytologie met een afkapwaarde van atypische cellen van onzekere sig-
nificantie (ASC-US), toonden drie van de 18 strategieën betere resultaten in triage. De 
standaard strategie toonde een sensitiviteit van 93.5% (95% CI 87.7-97.1), specificiteit 
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van 58.5% (95% CI 53.7-63.2) en percentage verwijzingen van 52.2%. De strategie met 
HPV16 en/of Pap cytologie van minimaal laaggradige squameuze intra-epitheliale neo-
plasie (≥LSIL), de strategie met HPV16 en/of Pap cytologie met minimaal hooggradige 
squameuze intra-epitheliale neoplasie (≥HSIL) en de strategie met HPV16 en/of HPV18 
en/of Pap cytologie ≥HSIL toonden een vergelijkbare sensitiviteit met een verhoogde 
specificiteit en een verlaagd aantal verwijzingen. De laatstgenoemde strategie toonde 
een sensitiviteit van 94.4% (95% CI 89.0-97.7) met de hoogste specificiteit van 74.9% 
(95% CI 70.5-78.9) en een verlaagd percentage verwijzingen van 39.5%. Deze resultaten 
indiceren dat bij bekende hrHPV positieve samples, triage middels alleen Pap cytologie 
verbeterd zou kunnen worden door de afkapwaarde van cytologie aan te passen en te 
combineren met HPV16/18 genotypering. 
De klinische bruikbaarheid van p16/Ki-67 dubbelkleuring voor identificatie van CIN 
in hrHPV positieve vrouwen van een non-responder screening cohort wordt beschre-
ven in hoofdstuk 4. Van 495 vrouwen die hrHPV positief getest waren op een zelftest, 
werden uitstrijkjes afgenomen door huisartsen. Deze uitstrijkjes werden getest middels 
p16/Ki-67 dubbelkleuring, Pap cytologie en HPV16/18 genotypering. De sensitiviteit, 
specificiteit en voorspellende waarden voor ≥CIN2 en ≥CIN3 werden bepaald voor 
verschillende gecombineerde triage strategieën en vergeleken met de standaard tri-
age van Pap cytologie met een afkapwaarde van ASC-US. De gouden standaard was 
centraal gereviseerde histologie of een aangepast eindpunt waarbij het uitstrijkje dat 
na zes maanden genomen werd hrHPV negatief was met een normale Pap cytologie. 
Triage van hrHPV positieve vrouwen op de standaard methode middels cytologie met 
een afkapwaarde van ASC-US toonde een sensitiviteit van 93% (95% CI 85-98), met een 
specificiteit van 49% (95% CI 41-56) voor ≥CIN3. Drie triage strategieën met p16/Ki-67 
tonen een verhoogde specificiteit met vergelijkbare sensitiviteit voor ≥CIN3: p16/ki-67 
triage van alle hrHPV positieve samples toont een specificiteit van 61% (95% CI 54-69), 
p16/Ki-67 triage van alleen hrHPV positieve vrouwen met laaggradige Pap cytologie 
toont een specificiteit van 64% (95% CI 56-71) en p16/Ki-67 triage van normale en laag-
gradige cytologie toont een specificiteit van 58% (95% CI 50-65). Omdat de verschillen 
in sensitiviteit en specificiteit erg klein zijn tussen de drie groepen en de kwaliteit van 
Pap cytologie wereldwijd erg wisselend is, zou de meest betrouwbare strategie zijn om 
p16/Ki-67 triage toe te passen op alle hrHPV positieve vrouwen. 
deel II van dit proefschrift bestaat uit een drietal studies over verbeteren van colposco-
pisch onderzoek na een positieve screening en/of triage test. Hoofdstuk 5 beschrijft een 
systematisch review en meta-analyse over see-and-treat behandeling van CIN-laesies. 
Het doel van deze studie was om te bepalen wat het risico is op overbehandeling bij de 
see-and-treat benadering. We doorzochten drie grote literatuur databases naar studies 
over see-and-treat management bij vrouwen met een geregistreerde Pap cytologie uit-
slag, colposcopische impressie en het uiteindelijke histologie resultaat. Dit resulteerde 
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in 13 studies met in totaal 4,611 vrouwen. Middels omgekeerde variantie werden er ge-
poolde incidentie waarden bepaald en met een random-effect model werd er rekening 
gehouden voor heterogeniteit tussen de studies. Het risico op overbehandeling is het 
groots bij een laaggradig Pap cytologie resultaat en een laaggradige colposcopische 
impressie met 72.9% (95% CI 68.1-77.7). Bij een hooggradig Pap cytologie resultaat en 
een hooggradige colposcopische impressie is het risico op overbehandeling het laagst 
met 11.6% (95% CI 7.8-15.3). Dit risico is vergelijkbaar met het risico op overbehandeling 
(11-35%) bij een aanpak waarbij eerst een biopt wordt afgenomen om de diagnose te 
bevestigen. Dit maakt dat see-and-treat management veilig toegepast kan worden in 
een groep vrouwen met een hooggradig Pap cytologie resultaat en een hooggradig 
colposcopisch beeld. In het geval van een discrepantie tussen de Pap cytologie en het 
colposcopisch beeld zouden leeftijd, kinderwens en risico van uitval bij follow-up mee-
genomen moeten worden in besluit wel of geen see-and-treat toe te passen. 
Hoofdstuk 6 legt de focus op multimodale hyperspectroscopie (MHS), een digitale 
colposcopie techniek die fluorescentie- en reflectie spectroscopie combineert en in 
plaats van conventionele colposcopie gebruikt zou kunnen worden. Het doel van de 
prospectieve cohortstudie beschreven in dit hoofdstuk, was om de klinisch waarde te 
bepalen van MHS in het opsporen van CIN-laesies in een colposcopie populatie be-
staande uit nieuw verwezen patiënten en follow-up patiënten, om zo te bepalen of MHS 
veilig gebruikt kan worden om zorg voor vrouwen at risk voor hooggradige CIN-laesies 
te verbeteren. Spectroscopische metingen middels MHS en hrHPV test met HPV16/18 
genotypering werden uitgevoerd bij 125 vrouwen van een colposcopie populatie. Deze 
resultaten werden vergeleken met een eindpunt gebaseerd op histologie, hrHPV en 
cytologie. Voor 102 vrouwen waarvan complete data beschikbaar was werd de sensiti-
viteit, specificiteit en voorspellende waarden berekend voor MHS en voor de colposco-
pische impressie bij conventionele colposcopie. MHS toonde een sensitiviteit van 93.6% 
(95% CI 78.6-99.2), met een specificiteit van 42.3% (95% CI 30.6-54.6) in de groep met 
een samengesteld eindpunt. De acceptatie van de techniek door patiënten was hoog 
en er was geen sprake van bijwerkingen.  Concluderend kan gesteld worden dat MHS 
een digitale colposcopie techniek is die een gemakkelijke, snelle en goed getolereerde 
beoordeling geeft met een hoge sensitiviteit voor de aanwezigheid van hooggradige 
CIN-laesies, echter met een lage specificiteit, waardoor de klinische waarde beperkt is. 
Hoofdstuk 7 gaat een stapje verder op het gebied van digitale colposcopie technieken. 
In dit hoofdstuk wordt een systematisch review met een meta-analyse gepresenteerd 
over verschillende alternatieve (digitale) colposcopie technieken, die gebruikt zouden 
kunnen worden voor detectie van CIN-laesies in een colposcopie populatie. Middels 
vier grote databases werden studies geïncludeerd waarbij: een digitale colposcopie 
techniek gebruikt was in een colposcopie populatie, een histologische uitkomst be-
schreven stond die differentieerde tussen ≤CIN1 en ≥CIN2, de volledige cervix gescand 
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werd, of een analyse per vrouw was gedaan, behoudens Lugol en azijnzuur geen middel 
gebruikt was om de cervix aan te kleuren en minimaal drie studies van één specifieke 
techniek beschikbaar waren. Dertien studies voldeden aan de inclusiecriteria waarbij 
zes studies naar fluorescentie- en reflectie spectroscopie met in totaal 2,530 vrouwen, 
vier studies naar dynamische spectrale beeldvorming met totaal 1,173 vrouwen en drie 
studies naar optische coherentietomografie met totaal 693 vrouwen. Fluorescentie- en 
reflectie spectroscopie toonde de hoogste gepoolde sensitiviteit met 93% (95% CI 89-
95) met een specificiteit van 62% (95% CI 47-76). Dynamische spectrale beeldvorming 
toonde de hoogste specificiteit van 83% (95% CI 76-88), met een sensitiviteit van 69% 
(95% CI 48-85). Eerder gepubliceerde data toonde een sensitiviteit van 61% (95% CI 58-
63) en specificiteit van 85% (83-86%) voor conventionele colposcopie. Toepassing van 
alternatieve digitale colposcopie technieken zou dus kunnen leiden tot vergelijkbare 
of verhoogde sensitiviteit en specificiteit. De keuze voor een bepaalde techniek zou 
afhangen van de klinische setting. Er kan echter nog geen aanbeveling voor klinisch 
gebruik gedaan worden, omdat de technieken nog in ontwikkeling zijn en gerandomi-
seerde studies die alternatieve colposcopie technieken vergelijken met conventionele 
technieken ontbreken. 
In deel III van dit proefschrift wordt met twee studies de focus gelegd op de toekom-
stige risico’s van HPV-infecties. 
Het doel van de studie beschreven in hoofdstuk 8 was om de risico’s te onderzoeken 
op het ontwikkelen van hooggradige CIN-laesies en cervixcarcinoom bij jonge vrouwen 
die hrHPV positief zijn voor hun 30e levensjaar. Hiervoor wordt retrospectief gekeken 
hoe hrHPV detectie voor het 30e levensjaar geassocieerd zou kunnen zijn met risico 
op hooggradige CIN-laesies na het 30e levensjaar. Om dit te onderzoeken werd follow-
up data verzameld van een cohortstudie naar HPV-prevalentie in 2,065 niet eerder 
gescreende Nederlandse vrouwen tussen 18-29 jaar, waarbij vrouwen 3-maandelijks 
een zelftest voor hrHPV test afnamen. Vrouwen werden ingedeeld in drie groepen: 
hrHPV negatief, een geklaarde hrHPV infectie, of een persisterende hrHPV infectie. 
Uit de landelijke Nederlandse pathologie registratie (PALGA) werd geanonimiseerde 
follow-up data verkregen van 962 vrouwen. In vrouwen met een persisterende infectie 
op jonge leeftijd was de HSIL-prevalentie 19.3%. Dit was significant hoger (p<0,001) 
dan de HSIL-prevalentie in hrHPV negatieve vrouwen (1.5%) en vrouwen die hun hrHPV 
infectie geklaard hadden (3.1%). Hiermee kan geconcludeerd worden dat vrouwen met 
een persisterende infectie voor het 30e levensjaar een verhoogd risico laten zien op een 
HSIL-laesie na het 30e levensjaar. De voordelen van screening op persisterende hrHPV 
infecties voor het 30e levensjaar zouden overwogen moeten worden om de incidentie 
van cervixcarcinoom bij jonge vrouwen te verlagen. 
In hoofdstuk 9 worden de toekomstige risico’s van hrHPV infecties bij vrouwen met 
een CIN3 laesie bestudeerd, waarbij specifiek gekeken wordt naar het risico op andere 
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hrHPV gerelateerde ernstige premaligniteiten en maligniteiten. Kennis hierover is be-
langrijk om HPV-vaccinatie of intensievere screening op andere hrHPV gerelateerde 
maligniteiten en premaligniteiten te overwegen bij vrouwen met een CIN3. Vrouwen 
met een CIN3 tussen 190 en 2010 werden geïdentificeerd uit de landelijke Nederlandse 
pathologie registratie (PALGA) en gematcht met een controlegroep zonder CIN3. Alle 
hrHPV geassocieerde maligniteiten en hooggradige premaligniteiten van anogenitale 
regio en orofarynx na de inclusiediagnose tussen 1990 en 2015 werden geïdentificeerd 
en incidentie rate ratio’s (IRR) werden berekend. Dit resulteerde in een groep van 
178,036 vrouwen waarvan 89,018 met een CIN3, en 89,018 gematchte controles zonder 
CIN3. Vrouwen met een CIN3 toonden een verhoogd risico op hrHPV-gerelateerde 
maligniteiten en ernstige premaligniteiten met een IRR van 3.85 voor anuscarcinoom 
tot 86.08 voor vaginacarcinoom. Het risico op hrHPV gerelateerde afwijkingen was sig-
nificant verhoogd, zelfs tot 20 jaar na de CIN3 diagnose. Geconcludeerd kan worden dat 
vrouwen met een CIN3 een langdurig verhoogd risico laten zien op HPV-geassocieerde 
maligniteiten en ernstige premaligniteiten van de anogenitale regio en orofarynx. Er is 
aanvullend onderzoek nodig naar methoden als intensieve screening of vaccinatie, die 
dit verhoogd risico eventueel zouden kunnen voorkomen.
In hoofdstuk 10 van dit proefschrift worden bovenstaande onderwerpen in een 
breder perspectief geplaatst. De focus van dit hoofdstuk ligt op verschillende stand-
punten ten aanzien van de aspecten van preventie van cervixcarcinoom besproken in 
dit proefschrift. Ook wordt in dit hoofdstuk het toekomstperspectief voor screening op 
cervixcarcinoom verder uitgelicht.   
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AIN   anal intraepithelial neoplasia
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NA   not available
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NPV   negative predictive value
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NRND   number of referrals needed to diagnose
p16   p16INK4A 
Pap   papanicolaou
PPV   positive predictive value
PRISMA  preferred reporting items for systematic reviews and meta-analyses 
PROHTECT   protection by offering HPV testing on self-sampled cervicovaginal 
specimens trial 
Rb   retinoblastoma
REF  referral rate
RR   risk ratio
siRNA   small interfering RNA
TN  true negative
TOP2A   topoisomerase II-a
TP   true positive
VAIN   vaginal intraepithelial neoplasia
VIN  vulvar intraepithelial neoplasia
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